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Biological Dose Accumulation in Image-guided Radiotherapy
Dose accumulation (DA), the computation of the total delivered 3D dose distribution Da
of a fractionated radiotherapy treatment using daily patient imaging, is getting established
in clinical practice. Although the aim is to estimate the achieved biological outcome of the
treatment, the principles of biological effect estimation are currently not followed consis-
tently in the process. In this thesis, the biological effect accumulation approach and total
biological dose (bEQD) were derived as a biologically consistent DA workflow. Clinical
relevance of bEQD and its dependence on individual workflow aspects were investigated
in data from three patient cohorts. It was found that Da systematically underestimates
the obtained biological effect, which can be avoided by the use of bEQD. Results showed
that this is strongest for late-responding organs at risk (OAR) with low α/β values in
dose gradient regions around the target that are prone to organ motion. bEQD to Da
deviations occurred locally, in so-called hotspots, showing individual cases of high differ-
ence magnitude but only small statistical impact. Hotspots of bEQD − Da deviation
around 4 Gy in bladder and rectum were found in patients treated for prostate carcinoma.
Hypofractionation increased these deviations strongly up to 8 Gy and also showed clini-
cally relevant deviations in dose-volume analysis. Dose-response correlation in standard
fractionation showed only little impact on the DA approaches. Workflow uncertainties are
dominated by those from deformable image registration, which are in the same range as
the difference between bEQD and Da. bEQD should be considered in the application of
treatment adaptation, especially to avoid damage to OARs in individual cases.

Biologische Dosisakkumulation in der bildgeführten Strahlentherapie
Dosisakkumulation, die Berechnung der summierten 3D-Strahlendosisverteilung Da einer
fraktionierten Strahlentherapie Behandlung mittels täglicher Bildgebung, wird derzeit
Teil klinischer Routine. Obwohl das Ziel ist, das biologische Resultat der Behandlung
abzuschätzen, werden mathematische Modelle zur Berechnung des biologischen Effektes
bisher nicht konsistent in der Dosisakkumulation berücksichtigt. In dieser Arbeit wurde
ein Effektakkumulations-Ansatz sowie die gesamtbiologische Dosis (bEQD) eingeführt, um
einen biologisch konsistenten Prozess der Dosisakkumulation zu ermöglichen. Die klinische
Relevanz der bEQD sowie deren Unsicherheiten und Abhängigkeit von einzelnen Workflow
Schritten, wurde anhand von drei Patienten-Kohorten untersucht. Es zeigt sich, dass Da
den biologischen Effekt der Behandlung systematisch unterschätzt, was durch Anwendung
von bEQD vermieden werden kann. Ergebnisse zeigen, dass diese Unterschätzung am
stärksten ist für spät reagierende Gewebe mit kleinem α/β Wert, welche sich in steilen
Dosisgradienten sowie in Regionen regelmäßiger Organbewegung befinden. Abweichun-
gen zwischen bEQD und Da treten lokal auf, in sogenannten Hotspots. Es zeigen sich
Einzelfälle mit starken Abweichungen, jedoch nur geringer statistischer Einfluss. Hotspot
mit 4 Gy Abweichungen in Blase und Rektum wurden in Patienten in Behandlung von
Prostatakarzinomen gefunden. Hypofraktionierung erhöhte diese Abweichung auf bis zu
8 Gy und zeigte zudem klinisch relevante Abweichungen in Dosis-Volumen Untersuchun-
gen. Die Korrelation von Dosis zu Gewebeeffekten im Rektum wurde nur geringfügig
von der Akkumulations-Strategie beeinflusst. Unsicherheiten im Workflow wurden do-
minierten von solchen der deformierbaren Registrierung, welche ähnliche Magnituden wie
der Unterschied zwischen bEQD und Da zeigten. bEQD sollte für die Anwendung in adap-
tiver Strahlentherapie benutzt werden, besonders um Strahlenschäden im Normalgewebe
zu vermeiden.
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I N T RO D U C T I O N
Radiotherapy (RT) aims for accuracy and precision in the delivery of ionizing radia-
tion dose to the tumour and simultaneously sparing of the surrounding organ(s) at
risk (OAR). To achieve this goal, imaging plays an indispensable role in the state-of-
the-art RT workflow. The introduction of computed tomography (CT) in the 1970s
enabled 3D-conformal treatment planning for the first time. The conformality of
the dose delivery was further significantly improved throughout the 1980s and 1990s
with the development of intensity-modulated radiotherapy (IMRT) [9] [6]. With this
technique, isodose-lines could be tailored to the desired target location and shape,
along with steep dose gradients that reduce the dose received by the surrounding
structures.
A RT treatment is delivered in consecutive daily doses. This principle of treatment
fractionation exploits the repair capability of normal tissue between fractions, while
still achieving tumour cell kill. Dose therefore accumulates in the tissue over the
course of therapy. While the initial CT scan prior to the treatment course, is used to
set up the treatment plan, the achieved precision and accuracy of the dose delivery is
strongly impaired by organ motion throughout the course of treatment, both intra-
and interfractional. Due to internal organ movement as well as setup-uncertainties
of the patient, the machine does no longer deliver the planned dose precisely to
the targeted location on each treatment day. In consequence, the accumulating
dose is increasingly washed out which can result in underdosage of the tumour and
overdosage of OARs. To tackle this problem, in recent years image-guidance was es-
tablished such that the setup and anatomy of the day can be monitored. Modalities
used for image-guidance right before dose application are for example CT-imaging
in both the kilo- and megavoltage regime as well as newly established methods
using magnetic resonance imaging. This additional control step prior to RT facili-
tates setup corrections of the patient to ensure that the target receives the desired
dose and that OARs are not being irradiated with a higher than the planned dose.
Furthermore, the daily delivered dose can be estimated at voxel-level, revealing sig-
nificant differences to the planned dose as reported in current literature [41] [28] [26]
[56]. This enables the development of new approaches to improve the outcome of
RT treatments which are a topic of current research: treatment adaptation [71] and
dose-response correlation of the actually delivered dose to the treatment outcome
[63] [70]. Both approaches require the calculation of the dose delivered per day as
well as its computational accumulation in a common frame of reference. With the
estimate of the total delivered dose on a local scale (voxel-wise), clinical decisions
can be made, in case changes of the treatment plan are necessary, e.g. to spare
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OARs that have already received too much dose, re-treatments can be based on
how much dose has already been delivered to the patient before [5], and occurring
side-effects can be correlated to the dose that they were caused by.
Nevertheless, the actual outcome of a RT treatment is not the quantity of total
delivered dose but the biological effect that was achieved in the tissue: the death
of tumour cells and potential damage to healthy tissue. The relationship between
dose and biological effect has been a wide topic of research for a number of decades.
Mathematical models try to describe the effects in tissue usually by estimation of the
cell survival fraction (SF). The most commonly used model introduced in 1972 [36],
which is still standard practice today [49], is the Linear Quadratic Model (LQM).
Within this empirical model, the dose is linked to the SF in an exponential expression
with a linear and a quadratic dose term, including tissue specific radiosensitivity-
parameters.
Dose accumulation, thus, the method of computation of the voxel-wise total dose
delivered to the patient over the course of fractionated treatment, by use of daily
imaging, is entering clinical routine. Nevertheless, it is still discussed as a controver-
sial topic [68] presenting new opportunities as well as challenges. This thesis builds
on the observation that the workflow chain of conventional dose accumulation in
current applications does not take the biological considerations into account in a
consistent way. Within this work, the discussion on the rationale of dose accumula-
tion is extended to the biological level.
This thesis tries to answer two questions: i) How can dose accumulation be per-
formed in a biologically consistent way, i.e. to be in accordance with biological
models and considerations? ii) Is it relevant to consider the accumulated total bio-
logical dose for clinical applications?
To answer the first question, the first aim of this thesis was to set up the methodol-
ogy of a biologically consistent workflow for dose accumulation. Two aspects have
been identified for which a critical rethinking of current applications and recent
postulation is necessary in the context of biological mechanisms and models: the
deformation of dose using deformable image registration (dose mapping), especially
for scenarios where volumes are changing; and with this as a basis, the biological
accumulation of consecutive treatment fraction doses.
Dose mapping describes the deformation of the daily delivered dose to a common
frame of reference to enable voxel-wise dose accumulation. For this, deformable
image registration was used and applied to the daily estimated dose distributions.
The concept of dose mapping, specifically for scenarios of volume change, is a topic
of ongoing debate [90]. Within this work, this process was questioned and investi-
gated critically in a biological context. On the basis of the biologically consistently
obtained voxel-wise daily doses from dose mapping, the main development of this
work was to establish and investigate a biologically consistent way for effect and
dose accumulation. It was found that conventional dose accumulation introduces a
systematic inaccuracy in the prediction of the total biological effect. The introduced
(biological) effect accumulation approach and the concept of the total biological dose
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was developed to avoid this inaccuracy.
The developed methodology was investigated for three patient cohorts treated with
IMRT and daily CT imaging. Each dataset, from the respective cohorts, was used
to tackle certain aspects in the process to obtain the answer to the second question
of this thesis: a data-based conclusion of the clinical relevance and applicability of
biological dose accumulation, especially when considering uncertainties. Daily imag-
ing and delivered dose of a cohort of 9 patients treated for prostate carcinoma at the
German Cancer Research Center (DKFZ), Heidelberg, was investigated in depth to
conclude on how the difference between the total biological dose and conventional
dose accumulation from this data is affected by individual workflow aspects. Fur-
thermore, uncertainties in the respective workflows were estimated. Data from a
larger cohort of 251 prostate carcinoma patients from the VoxTox programme [13],
Cambridge, UK, were used to find a statistical answer on the difference between
both methods. Furthermore, dose-toxicity correlation on the basis of the derived to-
tal biological dose was tested in comparison to the standard approach. In addition,
data from a cohort of 26 cases treated for head and neck cancers from the VoxTox
programme extends the analysis to another body site.
This thesis contains five chapters following this introduction chapter. In chapter 2.1,
selected fundamental concepts of radiotherapy and image-guidance are introduced
as the framework of the thesis. An in depth background on specific methods used
for dose accumulation and radiobiology is given in section 2.2. Materials and meth-
ods are described in chapter 3. In this chapter, the developed methodologies, that
combine the concepts of dose accumulation and radiobiology, are presented: bio-
logically consistent dose mapping, effect accumulation and the total biological dose
(section 3.1). Section 3.2 describes the tools and data used in this thesis, i.e. the
patient data used and the individual dose accumulation workflows. The results of
the patient data analysis of biological effect and dose accumulation are presented in
chapter 4. Chapter 5 discusses the developed methodology and the obtained results
and concludes with the implications for the application of the presented concept
(section 5.3). A short summary is given in chapter 6.
Parts of the content of this thesis have been submitted for publication in Physics
in Medicine and Biology as a note on biological dose mapping [57] and a paper on




P H Y S I C A L A N D C L I N I C A L F R A M E WO R K O F T H E T H E S I S
Cancer therapy searches for therapeutic agents that cause a specific effect on cancer
cells. This means that optimally, the agent is inducing the desired effect in the target
cells (i.e. cell death) while healthy cells remain unaffected. In radiotherapy (RT),
this specific effect is induced by localized deposition of a certain radiation dose in
the target, while the surrounding tissue optimally remains un-irradiated (or realisti-
cally, only receives low dose levels). The therapeutic agent is radiation, specifically
photons in the presented work, and its specifitcity to kill cancer cells relies on the
spatial accuracy and precision of the dose deposition as well as on the amount of
dose and its delivery scheme.
In section 2.1 the physical embedding of this thesis is presented. Detailed back-
ground on the used methodological principles of dose accumulation and radiobiolog-
ical are described in section 2.2.
2.1 physics of image-guided radiotherapy
The protagonist of this section is photon irradiation and its interaction with matter.
Photons are not only used as the therapeutic agent, but also for imaging of the
patient’s anatomy. The latter is necessary to setup treatment plans but also for
image guidance throughout therapy. Within this section, the physics of photon-
radiotherapy and imaging with photons will be presented in section 2.1.1. How
these principle are applied in RT treatment techniques is described in section 2.1.2,
followed by principles of image-guided RT in section 2.1.3.
2.1.1 Photon interaction with matter in imaging and therapy
Physics of photon interaction with matter The attenuation of photons in
matter is proportional to the incoming number of photons (i.e. the intensity I) and
the thickness of the absorber x [66]:
− dI(x) = µI(x)dx (2.1)
Solving the differential equation shows that the attenuation of photons in matter
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Figure 2.1. – Contribution of the photoelectric effect, Compton scattering and pair production to
the total mass attenuation coefficient µ against the photon energy for the example of interaction
in soft tissue (muscle). Highlighted are regions of energy ranges used for standard CT imaging
and for treatment (example for a linac producing a photon energy spectrum with a maximum of
6 MeV). Created using the NIST x-ray attenuation database [29].
with the the linear attenuation coefficient µ of the absorber material which depends
on the photon energy. The mass absorption coefficient is normally reported with
µ/ρ where ρ is the mass density of the absorber material. Note that the above
equation is only valid within a medium of homogeneous absorption properties. In
an inhomogeneous medium, the quantity of µ is dependent on the location within
the absorber, so that the above equation 2.2 should be written as the line integral
along x:
I = I0 · e−
∫
µ(x)dx (2.3)
The attenuation coefficient µ is characterized by the tissue’s anatomical composi-
tion and can be expressed by the electron density ρe times the electron cross sections:
µ = ρe · σe(Eγ, Z), where σe depends on the photon energy and the charge number
of the absorber material.
The manner of photon interaction in matter can be described by mainly three funda-
mental interactions: photoelectric (PE) effect, Compton (or incoherent) scattering
and pair production. The attenuation coefficient can therefore be expressed by the
sum of the individually contributing effects from those three interactions.
µ(Eγ, Z) = τ(Eγ, Z) + σ(Eγ, Z) + κ(Eγ, Z) (2.4)
6
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with the individual energy (Eγ) and material (Z) dependent attenuation coefficients
τ, σ and κ. The contribution of the individual effects on the total absorption co-
efficient is shown in figure 2.1. For imaging, energy ranges between 30 - 150 keV
are utilized which are characterized by an interplay of the PE effect and Compton
scattering, but dominated by the latter. For the therapeutic energy range, energies
in the MeV range are used for which Compton scattering dominates all other effects.
Pair production, although physically possible at energies above 1.022 MeV, only
gains importance for energies above 10 MeV.
Current standard RT is performed using linear accelerators (linear accelerators
(linacs)). Within such a linac, the photon beam is created through bremsstrahlung
of previously accelerated electrons towards a tungsten target. Thus, the resulting
photon beam consists of a spectrum of energies with the maximum defined by the
linacs maximum electron accelerating voltage. In common notation, for example a
6 MV linac produces a photon spectrum with a maximum energy of 6 MeV .
Imaging with photons Photons in matter can either be transmitted through the
medium, be absorbed or reflected (the latter being negligible for the here discussed
energy ranges). For imaging, a delicate balance of transmission and absorption is
to be found. Reasonably high transmission is favourable to achieve a high signal
to noise ration and low dose to the patient. On the other hand, absorption is
necessary to receive information about the traversed material, thus, to gain a higher
contrast to noise ratio. In the energy ranges described above for photon imaging,
both the PE effect and Compton scattering have to be taken into account. For the
Compton effect, only the electron density of the material is affecting the attenuation
(in addition to the dependency on the photon energy) but it is independent of the
charge number Z. Thus, this gives little to no information on differences in soft tissue,
since for those, electron densities are very similar. At lower energy levels, the PE
starts to become more relevant. The attenuation coefficient of the PE effect has an
approximate relationship to the atomic number of the absorber material of τ ≈ Z3−4.
With this, it provides critical information on the tissue composition in imaging but
also leads to increased dose to the patient. Hence, for a good compromise between
dose and contrast, energies between 30 − 150 keV are used.
For imaging with photon, e.g. in computed tomography (CT), the Lambert-Beer-
law as the line integral in equation 2.3 directly describes the intensity I of photon
transmission along the path from the photon source to the detector, characterized
by linear attenuation coefficient µ. Through backprojection of this line integral, µ
can be determined. However, the obtained value will be strongly depend on the
used spectrum of photon energies of the scanner, so that instead, the relative value
to that of water is used. Imaging values in CT imaging are thus given in Hounsfield
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where µW is the attenuation coefficient of water. Per definition, the HU of water
equals 0, while air has -1000 HU. Each HU is therefore equivalent to 0.1% of linear
attenuation in water. Fatty tissue is in the range of -100 to -50 HU and other soft
tissues range between 0 and 100 HU. Bone and other more dense materials range
from 200 to roughly 2000 HU.
Primarily, HUs are dependent on the electron density of the tissue due to the dom-
inating effect of Compton scattering described above. However, due to the impact
of the PE effect, also the atomic charge number affects the HU value of the tissue,
especially for high charged compositions of heavier materials such as bone. This
effect is decreasing when using higher photon energies.
Figure 2.2. – Schematic
depth dose curve of photons
with different energies in wa-
ter. Voltages refer to the
maximum voltage used in
the linac for beam creation,
hence, creating the maximum
of the energy spectrum in keV
or MeV. Recreated from [66].
Treatment with photons The quantity of interest





where dĒ is the mean energy deposited in the mass dm
given in the units of Gray, which equals Joule per kilo-
gram. Energy and mass are both extensive quantities of
the system, resulting in the fact that the dose, as the
ratio, is an intensive quantity, thus independent of the
system size.
In photon RT, the main contribution to dose deposition
is caused by secondary Compton electrons and not di-
rectly by the photon radiation. The absorption of energy
is caused by the Compton electrons through ionization
of the absorber material based on Coulomb interaction
with other electrons. When photons are entering the ab-
sorber material, a cascade of Compton electrons is in-
duced which leads to a build-up effect of absorbed energy.
The energy absorption reaches its maximum at approx-
imately the maximum range of the secondary electrons.
This range depends on the electrons energy which in turn
depends on the energy of the incoming photons. Only
after reaching the equilibrium of Compton electron production and photon absorp-
tion, the exponential decay described by the Lamber-Beer law (Eq. 2.3) is observed.
This is shown in figure 2.2. In this equilibrium, the energy released locally from the
primary uncharged particles can in first approximation be described by the above
mentioned attenuation coefficient µ through the attenuation law:
Ψ(E,~r) = Φ(E,~r)Ee−µ(E,~r) (2.7)
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where Φ is the initial photon fluence and Ψ describes the energy fluence within the
tissue at the interaction point ~r. With this, the Total Energy Released per unit





This quantity is used in dose calculation algorithms described shortly below.
2.1.2 Techniques of photon-radiotherapy
The depth dose curve of photons in matter depicted in figure 2.2 shows that the max-
imum dose deposition is reached already shortly after entering the medium, caused
by the electron build-up effect described above. It is at approximately the range of
the produced secondary electrons, which depends on the initial photon energy. For
the used energies in RT, the range of the secondary electrons is in the order of a few
centimetres. Due to the exponential decrease of the dose deposit distal to the max-
imum, a considerable amount of dose would be delivered also to the healthy tissue,
in case the patient was treated from one direction only. Thus, in order to achieve
the specific effect in the tumour cells, characterized by local deposition of dose and
sparing of the healthy tissue, the principle of crossfire irradiation is exploited in
external beam RT. This means that multiple beams from different directions are
applied in such a way that an overlap is created in the target. In consequence, the
dose to the healthy tissue is kept low in comparison with the dose to the target, by
spreading the dose over a larger volume of healthy tissue.
IMRT and TomoTherapy In cancer therapy, the target volume is often irreg-
ularly shaped and close to adjacent organ(s) at risk (OAR). In consequence, even
with the overlap of beams from several directions, the dose plan cannot cover the
target without significant dose to closely surrounding structures, especially in case
these targets have a concave shape. Collimators are used to shape the beam to fit
the outlines of the target from the respective beam angles, called three-dimensional
(3D)-conformal RT. However, as shown in figure 2.3, this does not necessarily ensure
enough sparing of healthy tissue, especially closely located OARs. To improve the
confromality of the dose deposition to the target, the approach of intensity-modulated
radiotherapy (IMRT) was introduced [9]. The used principle is to modulate not only
the shape, but also the intensity of the incoming photon beam based on the shape
of the tumour. Beamlets (minimum individually controllable areas of a beam) that
traverse through critical structures are reduced in intensity, while the intensity of
beamlets that reach the target, is increased.
This leads to the fact that dose optimization for IMRT treatment planning becomes
an inverse problem. The dose distribution is the given requirement, specified by the
clinician or medical physicist, and parameters on fluence and beam directions need
9
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Figure 2.3. – Schematic illustration of the irradiation of a target volume with a) collimators to
shape the beam according to the target projection and b) intensity modulation (IMRT) to shape
the beam according to the target shape. Adapted from [66].
to be found by the optimizing algorithm. IMRT therefore requires CT imaging the
a basis as well as computer-based dose optimization to create the treatment plan.
Characteristically, IMRT dose plans show steep dose gradients around the target
volume, which is advantageousness to spare the healthy tissue. Large volumes of
surrounding healthy tissue also receive low levels of dose based on the used number
of beam directions.
In current applications, shaping of the beam is achieved by the use of Multi Leaf
Collimators (MLCs), consisting of individually movable (tungsten) leaves. A stan-
dard method of IMRT is the step-and-shoot (a.k.a. fixed-field) technique, where the
linac is moved to the respective beam angle direction step-by-step; at each linac
angle, sequentially different treatment fields are irradiated such that the summed
up intensity of the fields matches the desired intensity modulation. A similar tech-
nique is given by (helical) TomoTherapy, where the irradiation is performed in a
similar manner to CT acquisition (i.e. tomography) performed in a slice-wise rota-
tional manner with a fan-shaped beam. This process can enable a higher number
of beam direction based on the 360◦ rotational delivery which can be used for a
high conformality in target shaping and target dose homogeneity. In turn, this can
result in larger volumes of normal tissue to receive low levels of dose. In comparison,
literature reports better dose homogeneity in the target volume for TomoTherapy
plans, while for standard step-and-shoot IMRT, sparing of OARs was better [45]
[84]. However, it should be noted that the dose distribution strongly depends on the
used dose constraints, prescription dose, the optimizing algorithm and the impact
of the medical physicist.
The mentioned specific effect achieved by RT is only partially based on the spatial
conformality of the delivered dose. Other important factors are the total delivered
dose and the dose delivery scheme. Standard RT is delivered in a fractionated man-
10
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ner, meaning that low doses are delivered in a consecutive fashion of one treatment
per day over a course of several days or weeks. This is based on radiobiological
considerations that will be described in detail in section 2.2.2.
Dose calculation algorithms For treatment planning, the dose needs to be tai-
lored to the structures within the patient. For this it is necessary to compute the
dose absorbed in the irradiated material, conventionally based on a pre-treatment
planning CT scan.
As a short example for dose calculation, the basic principle of kernel-based super-
position is described (i.e. macroscopic descriptions of the physical processes of dose
deposition in tissue) [2]. The computation of kernel-based dose calculation in RT is
based on analytical models and is build up of three components: the primary pho-
ton beam, the absorbed energy, and the dose kernel. The final dose computation is
then given by a superposition, or convolution of these three. The primary photon
beam is the information of the photon spectrum of the linear accelerator, composed
of the photon fluence, the energy spectrum, the photon velocity directions and the
spatial distribution of the photons (for example shaped by collimators or intensity
modulation). This information is necessary to calculate the energy released by the
primary photons in the tissue, i.e. the TERMA, eq. 2.8. However, as described
above, the main dose deposition is caused by the secondary Compton-electrons in
interaction with the electrons of the tissue. This process is computed via so-called
dose kernels, i.e. an energy transfer function of how energy is deposited locally. The
final dose calculation is then given by the superposition of the TERMA and the dose
kernel.
The electron density of the tissue influences both the calcula-
tion of the TERMA (through the path of the photons through
the patient) and the dose kernel computation (absorption rate
is effectively weighted by the electron density relative to that
of water). The HUs described above, derived from imaging, do
however not directly describe the electron density. Furthermore,
the linear attenuation coefficient in the imaging energy range is
different to that of the therapeutic imaging range. Therefore
a calibration is necessary to convert between imaging values in
HU and the necessary information of the electron density from
imaging, thus exploiting the mutual physical dependency on elec-
tron density in both cases, derived experimentally. To obtain the
necessary information, calibration scans of phantoms with known
electron density are performed in current applications. The result
is an empirical curve that links HUs to electron density, so-called
Hounsfield look-up table (HLUT). HLUTs are individually calibrated for each CT
scanner and used image-reconstruction kernel based on a small dependency of the
absolute HU number on both. An example HLUT is shown in figure 2.4.
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Figure 2.4. – HLUT used for treatment planning at the German Cancer Research Center (DKFZ)
to convert from HU to relative electron density. Courtesy of Mona Splinter.
In addition to the kernel-based superposition approach for dose calculation, com-
mon approaches are for example given by a similar kernel-based approach based on
convolution with an initial interaction function (i.e. the pencil-beam approach); the
direct experimental measurement of dose using phantoms and dedicated detectors;
or using Monte-Carlo simulations, thus a stochastic approach to simulate the mi-
croscopic interactions. While the latter provides the highest accuracy, kernel-based
approaches offer a much faster solution which is especially important for treatment
planning in IMRT and in treatment adaptation. For many applications in photon
RT, kernel-based dose calculation offers sufficient accuracy.
Margins Limitations in imaging and dose delivery require the concept of margins
for the target volume [35] [43]. First, the Gross Tumour Volume (GTV) is delineated
by the clinician on the basis of imaging. For this, magnetic resonance imaging (MRI)
is more and more frequently used due to the superior soft tissue contrast in compar-
ison with CT imaging. A margin is applied to account for the microscopic spread
of the tumour to surrounding tissue, which is not yet visible in imaging, forming
the Clinical Target Volume (CTV). To ensure tumour dose coverage, which is the
foremost clinical objective, another margin is added around the CTV to account for
uncertainties in the dose delivery. The thus created Planning Target Volume (PTV)
can therefore even enclose volumes of normal tissue. The extent of these margins
12
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is subject to the treatment optimization conducted by the treating physician and
medical physicist and is usually based on dose-volume constraints (see also 2.2.2.2).
The steep dose gradients in IMRT and TomoTherapy increase the importance of
these margins, as small shifts in the dose field can result in severe underdosage of
the tumour. Margins are therefore not necessarily smaller, but can be reduced in
critical cases of nearby OARs.
2.1.3 Techniques of image-guidance in radiotherapy
3D imaging is the basis for RT as it en-
ables the optimization of the 3D dose field
according to the patient’s anatomy. CT
imaging is up to now the standard method
for image-based treatment planning (section
2.1.2). Though CT imaging does not di-
rectly provide the information on electron
densities, its physical principles are closely
related to the electron density itself and
therefore enable the easy calibration method using HLUTs.
The basic principle of CT imaging is based on two-dimensional (2D) projections of a
photon beam. 360◦ rotational projections in a slice-wise manner (i.e. spiral) around
the to be imaged object then enable the (iterative) backprojection resulting in the
3D image (in HU, section 2.1.1). Current standard CT scanners are constructed
with a single photon source creating a fan-shaped beam which is opposed to a ring
of detectors. The photon source is rotated around the object in a spiral shape so
that 2D projections of the individual slices are projected onto the detectors. The
most commonly used energy range is that of 120keVp, thus, a photon spectrum
with a peak energy of 120keV. Other approaches utilize two separate energies (e.g.
80keVp and 140keVp) which enables the computation of the electron density and the
effective atomic number of the material based on the dependency of µ on the photon
energy. However, for standard photon RT, the HLUT-approach enables sufficient
accuracy and more sophisticated approaches are only needed for RT with protons
or heavy ions.
CT imaging also shows a number of limitations, with the two most important ones
being the limited soft tissue contrast and the dose deposited in the patient. Both
can be eliminated by the use of MRI, which is especially interesting for daily image-
guidance. However, in contrast to CT imaging, imaging signals in MRI do not have
a physical relationship to the required properties necessary for dose calculation (i.e.
electron density). Approaches to compute synthetic CTs from MRI are therefore a
prominent topic of current research, especially in MR-guided RT.
Image-guidance is entering clinical routine. This means that daily images of the
patient are acquired prior to or during treatment in order to guide the treatment
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process. This can be performed in a variety of manners and using different imaging
modalities. Most commonly, image guidance is used for setup corrections. This
means that an image is acquired prior to treatment and in treatment position which
can then be checked to make sure that patient (or the target itself) is positioned
correctly. Especially setup-errors but also to a large degree the motion of organs in-
ternally can impair the accurate delivery of the dose plan. The setup-correction can
be based on different control points, for example: markers on the patient skin, bone
position or direct location of the target. Since relative motion between the target
and markers or bones can occur, the direct target location offers the best possibility
to ensure correct target coverage. However, this is especially problematic using the
low soft-tissue contrast of CT imaging. In case strong organ motion is detected,
sometimes replanning is performed throughout treatment under consideration of a
simple estimation of the summation of the planned dose, without dose accumulation
of the actually delivered dose.
Image guidance using photon-based imag-
ing can generally be separated in two cat-
egories: kV- and MV-based. Daily CT imag-
ing for the presented work was performed
with an in-room CT scanner on rails that
enabled the acquisition of standard kV-CT
scans on the treatment couch. However, of-
ten a CT or an MRI is not available in the
treatment room. Image-guidance is there-
fore mostly based on alternative CT solu-
tion which are available with the respective
treatment setup. Cone beam computed to-
mography (CBCT) imaging, another exam-
ple for kV-CT imaging, is a standard tech-
nique used for image-guidance. In contrast to the classic CT, CBCTs only use a
flat detector array opposing the beam source, which is being rotated around the
patient for about 180◦. The beam shape is that of a cone (hence the name). This
approach results in a fast and dose reduced solution of image-guidance, but shows
strong limitations in imaging contrast, accuracy and the size of the available field
of view. In TomoTherpay, as described above, the treatment delivery is similar
to the acquisition of a CT scan, but using different photon energies and fluences.
However, the same setup can be used to acquire MV-based images (mega voltage
computed tomography (MVCT)) of the patient in treatment position. Based on
the mainly Compton-scattering-based interaction of the photons with matter in the
MV-energy-range (figure 2.1), the signal and contrast to noise ratio is very limited
for MVCT-imaging and shows even lower soft-tissue contrast than standard kV-CT.
Furthermore, patients receive higher dose from imaging so that the resolution as
well as the number of slices is strongly limited in clinical practice.
The daily acquisition of images of the patients anatomy is being studied for the use
14
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in different applications in current research. Besides already commonly used direct
application for setup or organ motion corrections, the aim of using daily imaging
is to estimate the daily delivered dose. On the basis of repeated CT imaging, the
dose estimation is based on dose forward calculation to compute the delivered dose
in the anatomy of the day. For this, the parameters of the treatment plan that
the patient was irradiated with (beam directions, intensities etc.), are used to per-
form the dose calculation on the basis of the image of the day, instead of the initial
planning CT. Depending on the used imaging modality (CT, CBCT, MVCT), the
conversion of HUs to electron densities is different based on the physical differences
in the attenuation coefficient described above. With the information of the daily
delivered dose, the accumulation of the dose can be performed. This information
can be used to estimate the amount of dose that has been delivered to the patient on
a voxel-basisa, details of this will be given in the next section 2.2.1. Applications of
this are for example treatment adaptation - changing the treatment scheme or treat-
ment plan if necessary to ensure target coverage and normal tissue sparing; planning
of re-treatments - in case of an RT treatment is applied after a previous treatment
has already been finished, the dose already delivered to critical structures needs to
be taken into account; and to find correlations of the delivered dose to treatment
outcome - either for tumour control or for toxicities induced in the healthy tissue.
The applications of the daily delivered doses are discussed in more detail with the
application of dose accumulation in RT in section 2.2.1.1.
This work further focusses on dose accumulation on the basis of daily imaging in
RT with photons. The quantity of interest is the delivered dose of the day that is
being transformed to a reference anatomy for the purpose of accumulation of the
local dose in a common frame. The next section will therefore present the details
on the background of specific methods and models used in this work.
avoxel: 3D-volume in a regular grid, equivalent to a pixel in two dimensions
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2.2 methodological background
Embedded in the general context of image-guided RT presented in the previous sec-
tions, this work focusses on two specific aspects: dose accumulation and radiobiology.
The relevant state-of-the-art in both is presented in this section. The here shown
details will be used in the methodological development of this work in section 3.1.
2.2.1 Dose accumulation
This section describes the details of the currently used conventional dose accumula-
tion and the standard workflow. The result of dose accumulation is the voxel-wise
summation of the delivered doses for all fractions of the treatment. Multiple steps
are necessary in this process that will be presented and discussed in this section.
The motivation and conclusion made for the newly gained information, is presented
in section 2.2.1.1 including current literature on the matter. The commonly used
standard workflow that is also used within this work, is explained in section 2.2.1.2,
followed by sections describing the individual steps and applications: image regis-
tration (2.2.1.3), interpolation and mapping (2.2.1.4) and accumulation (2.2.1.5).
2.2.1.1 Motivation and usage of dose accumulation
The impact of organ motion on delivered dose Organ motion, setup uncer-
tainties and change in the tumour volume can cause deviations between planned and
delivered dose. Especially in precise treatment techniques such as IMRT (section
2.1.2), the steep dose gradients within the normal tissue will most likely cause daily
variations of local voxel doses, even if organ motion is at a minimum.
With the increasing use of daily imaging, more studies emerge, that report on the
differences between the planned and delivered doses. A trend that was observed
throughout literature was a generally good tumour coverage despite interfractional
organ motion, indicating sufficiently large treatment margins and recommending the
use of image-guidance (section 2.1.3). On the other hand, significant differences in
the dose to the OARs of bladder and rectum were reported. Kupelian et al. [41] per-
formed an early study in 2006 on the delivered dose in prostate TomoTherapy using
daily MVCT imaging. They found substantial differences in the doses to bladder
and rectum with V2Gy (volume receiving at least 2 Gy) for the rectum varying from
0.1 to 67.3 cc and for bladder from 0.3 to 36.8 cc, while the D95% (dose to 95% of
the structure’s volume, see section 3.2.3) for the prostate only varied between 1.79
and 2.2 Gy. This was also found by Hatton et al. [28] who performed twice weekly
CBCT scans for comparison of the planned to the delivered dose-volume parame-
ters. While CTV coverage shown by the D95% was only marginally impaired, they
found statistically significant difference for the volumes receiving 40 Gy, 60 Gy and
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70 Gy in both bladder and rectum for the majority of observed cases. Godley et
al. [26] similarly found only a maximum of around 3% deviation of the planned to
delivered D95% for the CTV in prostate RT while the V70Gy of bladder and rectum
was found to be up to twice the value of the planned dose distribution. Nassef et
al. [56] measured the mean dose standard deviation to the bladder to be 6.9 Gy
(maximum 18.1 Gy) and rectum to be 2.0 Gy (maximum 4.2 Gy) in prostate IMRT.
Dose differences along various dose-volume measures (V50Gy − V75Gy) varied from
-10% to +7% for the rectum and -4% to +26% for the bladder in 75% of cases.
It should generally be noted that for all these reports, the delivered dose was either
higher or lower than the planned dose without indications on a systematic trend. A
systematic trend was, however, observed by Shelley et al. [70] who found that the
equivalent uniform dose (EUD) (section 2.2.2.2) was systematically lower for deliv-
ered than planned dose to the rectum in prostate TomoTherapy. They concluded
that observed toxicity is therefore linked to smaller than expected dose levels of the
rectum. The dataset used in their analysis comprises a discovery cohort of patients
of the VoxTox programme. Parts of the used data in this thesis were taken from
the same programme, comprising a later acquired cohort with the same treatment
objectives, described in the materials and methods sections 3.2.2 and 3.2.4. Scaife et
al. [65] reported on data from the same study and also found that daily variation of
the rectal dose were considerable even though the median position of the structure
was close to the planning scan position.
For head and neck RT, Nobnop et al. [61] found that parotid doses increased over
the course of therapy by more than 10% for 3/10 patients (range 13-43%) based
on volume shrinkage. Dose to the spinal cord was only marginally increased. Here
again, there was very little impact on the target dose.
Applications of dose accumulation Dose accumulation is now entering clinical
practice to enable different new workflows and investigations. First, the knowledge
of the actually delivered dose allows for treatment adaptation by adapting the
dose plan during the course of therapy, in addition to simple setup corrections. In
case of overdosage of the normal tissue, it might be necessary to change the plan
in order to spare certain areas even more. On the other hand, lower than expected
dose in normal tissues might allow for dose boosts of the tumour volume. This might
also be necessary in case of underdosage of the tumour, though as described above,
good tumour coverage was reported in the majority of publications on delivered
dose. The aim of treatment adaptation is to further improve the clinical outcome
of the treatment in terms of both tumour control and sparing of healthy tissue. It
is therefore especially important to keep in mind the biological impact of dose on
the irradiated tissue even though it is the quantity of the delivered dose itself that
is usually the focus of observations. The rationale for this is tackled in the main
developed method in this work presented in section 3.1.
While treatment adaptation requires the knowledge of the dose of the already deliv-
ered fractions during the treatment course for decisions on the next fraction, the total
17
18CHAPTER 2. PHYSICAL AND CLINICAL FRAMEWORK OF THE THESIS
delivered dose becomes important whenever patients will receive a re-irradiation
after a previously completed treatment. Boman et al. [5] investigated in a recent
study the delivered dose for purpose of re-treatment. They compared the simple
summation of dose based on rigid registration of the images (image registration
techniques see section 2.2.1.3) with a biological summed dose on a simple EQD2-
based rescaling approach (equivalent dose in 2 Gy fractions (EQD2), see section
2.2.2.2) and found differences ranging from -14 Gy to +5 Gy. Here again, the dose
already received by the normal tissue is of high importance for the setup of a new
treatment plan in order to reduce the risk for side effects.
Another field of application of dose accumulation is the estimation of the delivered
dose during treatment with the use of time-resolved imaging. For example Dolde
et al. [19] recently published a study on dose calculation based on four-dimensional
(4D)-MRI (3D + time) for the study of the interplay effect in gated treatment of
pancreatic cancer. This intrafractional dose accumulation is not investigated
in this work. The applicability of the here developed methods (section 3.1) for the
use in intrafractional dose accumulation will, however, be discussed in chapter 5. Its
application is of special importance in lung cancer treatment as well as for strategies
such as gating, investigated in the mentioned publication.
Finally, in order to further improve the understanding of the dose-response relation-
ship in RT, the accumulated delivered dose is being studied for correlation of dose
to outcome. Due to the yet limited number of completed trials that include daily
(or weekly) imaging of the patient and detailed record of the treatment outcome, the
study of delivered dose for this application is yet at an early stage. The Quantita-
tive Analyses of Normal Tissue Effects in the Clinic (QUANTEC) reports from 2010
(specifically Marks et al. [47] and Jaffray et al. [31]) underline the lack of studies
relating delivered dose to outcome for the quality of the reported dose to toxicity
correlations and state that more accurate predictions ”[...] require models that re-
late the true accumulated dose to clinical outcome” [31]. First publications already
predict better dose-to-outcome correlations when using the accumulated delivered
instead of the planned dose. Since dose accumulation facilitates the analysis of the
delivered dose on a voxel-scale, there is a number of studies that report on local dose
deposition investigated with the use of dose surface maps (DSMs) (more informa-
tion on this technique also exploited in parts of this thesis will be given in section
3.2.4). Shelley et al. [70] investigated DSMs of the rectal wall and found stronger
correlations of the delivered dose to rectum toxicity than for planned dose. This
dataset including the used toxicity data will also be analysed in this work. Wortel
et al. [81] found that investigated side effects in prostate RT showed significantly
different dose distributions on delivered DSMs in patients, and they report doses
with differences up to 10 Gy to patients without reported toxicity. Similar results
on DSMs for the bladder were reported by Palorini et al. [63].
The various steps involved in the process of dose accumulation (that will be described
in the next sections) also add to the uncertainty budget of the process. Therefore,
a fundamental question in the rationale of dose accumulation is whether the newly
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gained information is still advantageous when taking into account all uncertainties,
compared with the simple way of only considering the planned dose. This will be
discussed in more detail in section 5.3 on the basis of the results obtained in this
work.
2.2.1.2 Workflow overview
The standard workflow for conventional dose accumulation, which is also used in
this work, is schematically shown in figure 2.5. Section 3.2.3 describes how this
workflow is implemented.
In the planning stage (figure 2.5 a), the patient receives a treatment planning CT
on which dose calculation and plan optimization is based. The physics of dose
calculation on the CT image is explained in more detail in the background section
2.1.2. The dose plan is then created, based on the prescription dose to the tumour
as well as on dose limiting constraints for OARs. The patient will then receive the
dose in a course of daily repeated treatment fractions (number of fractions: n), each
delivering the same dose plan. Image-guidance is nowadays used routinely for setup
corrections or even translational corrections based on the target position. More
information on image-guidance is given in section 2.1.3.
For each of the delivered fractions, the workflow chain required for the ultimate
dose accumulation is performed (figure 2.5 b). In total, four main components are
part of the dose accumulation workflow before the actual summation of the dose can
be performed: repeated imaging (section 2.1.3), dose forward calculation (section
2.1.3), image registration (section 2.2.1.3) and dose mapping (section 2.2.1.4). Based
on this combined information, the daily delivered doses di (where i = 1...n is the
fraction number index) are given on a voxel scale and can be summed up to give
the total (conventionally) accumulated dose Da (section 2.2.1.5). Adaptation of
the treatment might be performed based on the information obtained throughout
the course of therapy given by the respective accumulated dose up to then. As
described above, the total accumulated dose can later be used in case of re-treatment
or correlation of dose to the treatment outcome.
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Figure 2.5. – The standard workflow for conventional dose accumulation from daily imaging and
deformable image registration (DIR). In the planning stage (a), the patient receives a planning CT
on which the treatment plan is based. In stage b, the daily dose is acquired for all n treatment
fractions: daily patient imaging, DIR (to register the daily image to the planning CT), and dose
forward calculation on the daily image based on the treatment plan. Transformations from DIR
and the forward doses are then used to derive the deformed doses di in the reference frame which
are then accumulated to the total dose Da.
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2.2.1.3 Deformable image registration
Image registration is the process of finding
the geometric transformation that describes (via
a deformation vector field (DVF)) the transla-
tion of grid center points in the moving image
(to be deformed) to match the same ones in the
reference frame of the fixed image. Thus, the
information obtained from image registration is
the DVF that results in (ideally) identical posi-
tions of anatomical points in the two registered
images. Registration is performed between pa-
tient images obtained at different time points
here. A good overview of image registration
background and application in image registration can be found in the 2017 review
by Brock et al. [11].
A registration works on a uniform discretized voxel grid of the image. In common
application, the grid center points of the voxels are registered. The voxel value (from
imaging or dose) is thus given as a point measure assigned to the volume of the voxel.
Voxelization therefore is a spatial average of the volume values from imaging or dose
(a discussion on this principle is given in 5.2).
Figure 2.6 illustrates an example registration between two images as the DVF from
the regular fixed image to the new location of these points in the moving image. The
deformed grid (that is also shown in the overview illustrations throughout these chap-
ters) serves the purpose of visualization of the deformation, however, it should be
noted that it is the DVF and not the deformed grid that is the result of deformable
image registration (DIR) and the basis for interpolation explained in the next sec-
tion.
Three types of registration are being distinguished. (A) Rigid registration -
refers to a tranformation that is solely represented by translation and rotation while
preserving the distance between all points. It can therefore only represent transla-
tions and rotations of the entire patient geometry without reflecting internal organ
motion and deformations. (B) Affine registration - in addition to rigid registration,
affine registration includes scaling and shearing which preserves parallels lines in
the grid but not the distance between points. (C) Deformable registration - assigns
individual displacement vectors to each voxel (center point) that can move in all
three dimensions. Point distances are therefore not preserved. For the following,
this work only focusses on DIR which is necessary to map organ motion and defor-
mations. This information is crucial to enable the voxel-wise accumulation of dose
from each treatment fraction.
A registration algorithm contains three main components: A similarity metric,
a transformation model and an optimization algorithm. The details of this are not
used or discussed in this work, but in the following, a few aspects are summarized
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Figure 2.6. – Visualization of DIR between the fixed image (e.g. planning computed tomography
(CT)) and the moving image (e.g. fraction CT). The DVF is the result of the registration and
points from the regular reference grid of the fixed image to the new location of the respective points
after registration. The deformed grid is an illustration of this deformation but does not represent
the information that the algorithm is generating and only the serves the purpose of deformation
illustration. The depicted deformation is a rather strong example. The green enclosed voxel will
be viewed in detail in figure 2.7 when explaining the interpolation step for value mapping.
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for further understanding of methods and results:
One of the main components of a registration algorithm is the similarity metric, a
measure for the similarity between the two images. The registration algorithm tries
to maximize or minimize this metric in order to best map the two source images (op-
timization step). A metric is either geometry- or intensity-based. A geometry-based
metric tries to match positions of specific points identified on both images (point
matching) or maximize the overlap of two structure contours (surface matching).
Manually setting landmarks or contours is labour-intensive but ensures that defor-
mations are anatomically realistic. Furthermore, this technique is more robust to
imaging noise and using different modalities. Deformation in landmark-free regions
are extrapolated making these regions error prone. Furthermore the manual inter-
action of setting landmarks is subject to uncertainties. Biomechanical modelling
would be required in landmark-free regions which is not commonly implemented in
currently used software. On the other hand, intensity-based metrics measure the
similarity between the two images based on the grayscale voxel value information.
Thus, no manual work in setting landmarks is required but there is also no guaran-
tee that the deformation is anatomically realistic. For the sake of completion but
without further details, commonly the following intensity-based similarity metrics
are used: sum of squared differences (SSD), mean squared difference (MSD), cor-
relation coefficient (CC) or mutual information (MI). In short, all of these metrics
assume a relation between the voxel values in both images, from equivalent (SSD,
MSD), over linear (CC) to statistical (MI). Improving the outcome of intensity-based
algorithms for example requires quality control of the images, e.g. by intensity cor-
rections.
Usually, applications are either intensity- or geometry-based, but some solutions
combine both approaches as the here used ANACONDA algorithm ([77], section
3.2.3).
The minimization or maximization of the metric is performed iteratively by an opti-
mizer. Commonly, a registration contains several stages, each of which is iteratively
optimized and going from low to fine voxel resolutions. In addition, the optimizing
algorithm is often given constraints and regularizations to ensure that the resulting
transformation is anatomically realistic. Smoothness constraints are often utilized
to avoid high frequencies, vortices or singularities in the deformation. This, however,
can wrongly represent sliding organ surfaces.
In this work, different transformations are used in the DIR process that are be-
ing compared in their results for dose accumulation. More information on the used
software is given in section 3.2.3 where the above mentioned components of the
used registration algorithms are described shortly. Additionally to clinically applied
standard software, two transformations were performed based on the demons and
b-spline algorithm, respectively. The b-spline algorithm is point-based and uses
polynomials (bases functions) to connect weighted control points in the grid. This
description offers a smooth deformation solution. The demons algorithm works on
intensity gradients, optimization is here based on a gradient descent method and
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additional smoothing is achieved via a Gaussian smoothing approach.
Deformable image registration is necessary whenever the voxel-wise dose informa-
tion of the day needs to be mapped to the reference frame in order to enable dose
accumulation and its further applications described above. Another application of
DIR is the propagation of contours to reduce the labour intense tasks of contour-
ing in clinics. Furthermore, DIR is used to create synthetic CT images from other
modalities such as magnetic resonance imaging (MRI) or cone beam computed to-
mography (CBCT). An approach to do this is for example described by Kraus et al.
[40], where the planning CT is deformably registered to daily MRI scans to create
the electron density map of the day for dose calculation (see section 2.1.3).
DIR is implemented to register two images with essentially the same geometry but
with deformations. However, it is often the case that organ motion also includes
volume changes (i.e. growth or shrinkage of a structure). For example by tumour
growth or shrinkage, bladder or rectal filling changes, lung motion etc. In these cases
new material is added to the system or material leaves the system. The problem is
then ill-posed for the registration algorithm. While the algorithm might eventually
come up with a geometric solution that can be satisfactory, its underlying mecha-
nism, especially when it comes to the biological basis, needs to be addressed and
implemented in a way to be in accordance with biology. This topic will be handled
in detail in section 3.1.1 for structures undergoing volume changes based on different
causes.
Volume changes will be visible in the deformed grid or DVF as areas of higher grid
point density (shrinkage) or lower grid point density (expansion). A measure for the
voxel-wise change in volume, based on the DVF is the determinant of the Jacobian
matrix of the DVF. This parameter can also be used for quality assurance of the
DIR. A Jacobian larger than 1 refers to volume growth, while a number below 1
refers to shrinkage. Negative values indicate areas where the registration is fold-
ing in on itself and is therefore physically and anatomically unrealistic. While this
parameter can be an indicator for registration quality, it is no guarantee that the
transformation is correct.
Quality assurance (QA) of DIR is a topic of ongoing research and debate. While
other metrics exist in addition to the Jacobian determinant, this field is highly lim-
ited by the missing knowledge of the underlying ground truth of the voxel-wise
deformation in a patient setup. Qualitative registration QA is recommended and
usually performed by clinicians on the deformed data set. Quantitative approaches,
for example, measure the alignment of specific points in the images. For this, the
target registration error (the average residual between the points) can be calculated.
There will, however, always be an underlying uncertainty in the identification of the
two respective points and this metric has only limited informative value for areas in
between points. Similarly, organ contours can serve for purpose of control of the reg-
istration quality. The Dice similarity coefficient or the mean distance to agreement
can be used to quantify the amount of overlap of the structures. It should be noted
that whenever one of these metrics is used to guide the registration process (in for
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example geometry-based algorithms), it is not reasonable to use the same metric for
purpose of QA.
Nevertheless, a quantification of the registration uncertainty for the individ-
ual voxels is not possible with either of these metrics. There are several approaches
proposed in literature for quantification of uncertainties that require model-based
approaches of error sampling. This will be discussed in section 5.2 along with the
obtained results on the accuracy of registration and accumulation.
The registration and resulting DVF are only the basis to create the deformed
(mapped) images. In addition, strategies are required to transform one image to
another based on the information from the DVF. For this, interpolation is necessary
which is being addressed in the next section.
2.2.1.4 Interpolation and mapping
Transformation and interpolation are essentially
two parts of the registration process. The as-
pects described in this section are therefore still
a part of the overall DIR process to derive the
final deformed image.
Registration provides the information on where
points in the grid have moved to at another time
point. Mapping extracts the new voxels values
in the fixed frame based on the information of
the location in the moving frame. In the deformed grid, the displaced grid center
points do not necessarily directly match voxel center points of the regular uniform
grid of the undeformed original (moving) image. Therefore, interpolation is required
to obtain the value of the respective grid center points (i.e. voxels).
The result of the registration is a DVF that contains the information where points
from the fixed image have moved to in the moving image. The deformed grid (as
a visualization) therefore shows how the information from the first to the second
timepoint has taken place. Interpolation is used to derive the values of the individ-
ual voxels in the reference frame at this second time point. Different interpolation
strategies are proposed in literature which will be discussed below as well as in sec-
tion 5.2. Once the point value is computed, it is ”pulled-back” to the regular grid of
the reference frame, i.e. the value is assigned to the respective voxel (center point)
that it is linked to via the DVF. Figure 2.7 illustrates this process as a follow up on
registration shown in figure 2.6.
This method is commonly referred to as ”value-pulling”. There are essentially two
directions for interpolation, thus ”value pulling” or ”value pushing”. The second one
requires computations on the basis of the unregular deformed grid which is much
less time and memory efficient than the first method. ”Value pulling” is used to
deform the image to a common reference frame (i.e. the planning CT). Commonly,
”value pushing” is used when the information from the planning scan (grey values
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or dose) is transformed into the anatomy of the day (e.g. generation of synthetic
CTs). An example of the application of both methods in different aspects of the
same workflow is given by Glitzner et al. [25]. In this work, only the first option is
required to compute the daily deformed doses in the same frame of reference.
Figure 2.7. – Illustration of the mapping process on the basis of DIR shown in figure 2.6. The
regular grid (a) of the fixed image is linked to the moving image via the DVF (b). c) deformed
grid voxel overlayed on moving image grid (for visualization). d) Interpolation computes the value
of the mapped voxel as a weighted average of the neighbouring voxel values in the moving image
which is then assigned to the volume and location of the voxel it is linked to in the fixed image
(”value pulling”) (e). Deformation grid only for visualization: Size and shape of the deformed voxel
will be backprojected to the regular voxel shape (e), resulting in a volume shrinkage in this case,
while the value of the voxel is conserved in the process. Detailed analysis in section 3.1.1.
A standard method for interpolation that is also used in this work is trilinear inter-
polation. For this, the nearest neighbouring voxels in the grid of the undeformed
moving image are identified to retrieve the value of the respective points in the de-
formed grid (see figure 2.7). The point value is calculated as a weighted mean of
the values of the neighbour points where weighting is based on the distance to the
point of interest. It can be shown mathematically that this process is essentially
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a volume-weighted average of the regular voxels of the undeformed grid that con-
tribute to the deformed voxel. In figure 2.7 c), in the deformed voxel overlayed onto
the gray values of the moving image (highlighted in green), averaging of the gray
values included in this voxel can be interpreted accordingly.
Rosu et al. [64] have shown that for areas of large volume changes, this basic
trilinear interpolation method is not sufficient to map the volumes correctly since
voxel values might be neglected that still contribute to the voxel of interest. They
base their analysis mainly on lung tissue, where this problem has increased impor-
tance. In their solution, they propose sub-voxelization of the grids in order to push
the problem back to scenarios with less strong volume changes. Before mapping,
the voxel are sub-divided into smaller voxels that are being used for interpolation.
The interpolation of these sub-voxels in then again the standard trilinear interpola-
tion. After interpolation, the corresponding sub-voxel are merged again to respective
larger voxel. According to Rosu et al., this method can impact the outcome of the
interpolation mainly in dose gradient regions. This method is also shortly studied
in this work.
Interpolation can be performed on the gray values of the image (in Hounsfield Units
(HU)) to obtain the deformed anatomical representation, but also based on the
voxel-wise dose information. For the following, the latter will be referred to as dose
mapping (also known as dose warping or dose deformation). Dose mapping is essen-
tial for dose accumulation to compute the daily deformed doses.
The mapping of dose can either be based on the dose value or the deposited energy.
Within this work, the used implementations are dose-based. The reasoning and
implications of this will be discussed later in section 5.2. Moreover, dose mapping
can be performed in a way to conserve the voxel value of the irregularly deformed
voxel when being pulled back to the reference grid (which may include a change in
volume) as depicted in figure 2.7 e). It can also be implemented in such a way as
to scale the voxel value according to the change in volume. The question of how
the interpolation should be implemented comes back to the biological basis of the
deformation, especially when volumes are changing. This is a field of ongoing debate
which will be tackled in this work in detail in section 3.1.1 by supplementing the
debate with the underlying biology.
2.2.1.5 Accumulation
Once the daily deformed doses di are obtained from
DIR (transformation + interpolation, i.e. mapping),
the calculation of the conventionally accumulated dose





with i denoting the fraction number and n the total number of fractions. This is pos-
sible since all daily dose distributions are based on the same reference grid through
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registration and voxels ideally link to the same locations in the patient’s anatomy.
However, uncertainties in the dose mapping process will naturally be forwarded to
the accumulated dose. From error propagation, the (voxel-wise) uncertainty of Da






For the success of a radiotherapy (RT) treatment, the fractionation concept needs
to be based on the biological response to radiation. Specifically, the interplay be-
tween the total dose and dose per fraction for tumour as well as for normal tissue.
Since the early beginnings of RT, various models to describe the biological radiation
response mathematically have been proposed. An overview of these models can for
example be found in the 2016 review by Bodgi et al. [4] and in the 2019 review by
McMahon [49].
Radiation response is usually reported as the (cell) survival fraction (SF) based on
experimental observations. For these experimental approaches, the quantification
of the SF with respect to dose is assessed in clonogenic cell assays. A cell is con-
sidered ”dead” when it looses its ability to form colonies (therefore, the cell should
rather be called ”sterile” than dead in strict terms). In a simple clonogenic assay
setup, an initial number of cells N(0) is irradiated with a dose d. The number of
colonies that are formed after irradiation gives the number of initial cells that have
not been killed (i.e. sterilized) by the radiation, N(d). The cell survival fraction is
thus given by SF(d) = N(d)/N(0). It was generally observed that the SF follows
an exponential decrease with dose while details of this decrease are described by
different approaches. The most common and robust approach is the descripton of
the SF by a linear-quadratic relationship to dose within the exponential, the Lin-
ear Quadratic Model (LQM). As the basic model used up to date and within this
work, it is explained in more detail in section 2.2.2.1 below. In the following, the
development and hypothesis behind other biological models described in literature
are shortly described to be related to the LQM.
The target theory as a concept was already hypothesised in the early radiobiolog-
ical experiments in the 1920s. The basis of this theory is that exposure to radiation
is essentially seen as hitting the cells (targets) with random projectiles. The prob-
ability density function to hit the target was described by a Poisson distribution,
with the number of hits being directly proportional to the applied dose. In order for
radiation induced cell death to occur, it was hypothesised that “[...] it is necessary
that its [the cell’s] sensitive zone absorbs a minimal number s of quantas” by Curie
[16] (referred to as quantum radiobiology), so that cell kill was described by a simple
exponential function: SF(D) = e−D/D0 (with D0 being the mean dose that leads to
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one hit per target). However, advances in experimental radiobiology later revealed
a shouldered exponential response curve. The target theory was therefore further
adapted through the following decades from the initial single-hit, single-target model
to a single-hit, multi-target model. In this approach, a certain number of targets m
within one cell need to be hit in order to induce cell kill [20]:
SF(D) = 1− (1− e−D/D0)m (2.11)
Cell survival is therefore linked to a lack of hits in the sensitive region. Nevertheless,
experimental observations showed discrepancies to the curves provided by the above
model, especially in low and high dose regions.
Follwing the target theory, the LQM was introduced by Kellerer and Rossi in 1972
[36]. The description via a linear and a quadratic term linked to dose showed much
better agreement to the observed SF curves.
Opposing one basic assumption of the target theory is the actual number of hits that
cells receive during irradiation: For a dose of 1 Gy in photon therapy, an estimated 40
double strand breaks (DBS) in the DNA occur, accompanied by around 1000 single
strand breaks (SSB) and 10 000 base damages. Thus, the cell must be capable of
DNA repair that results in radioresistance and subsequent survival rather than
the simple approach of a lack of hits. Therefore, later approaches in the 1980s
tried to include the repair capability and different radiosensitivities of cells in the
concept and interpretation of the LQM - for example the Repair–MisRepair-, the
Lethal-Potentially-Lethal-, and the saturated-repair-models. However, there is a
number of contradictory findings against these models including the nature of DNA
repair kinetics and consequences in cells as well as the basics of direct and indirect
radiation damage to DNA.
2.2.2.1 The linear quadratic model and its variations
”The Linear-Quadratic (LQ) model, which is to date the most frequently used model
in radiobiology and RT, dominates all the other models by its robustness and sim-
plicity.” [4]
The linear-quadratic approach first proposed by Kellerer and Rossi [36] provides
a good fit to experimental data for the commonly used dose regimes. Figure 2.8
shows a comparison of the above mentioned models based on the target theory with
the LQM-based survival fraction.
The survival fraction for a single fraction of dose d is given by:
SFLQM(d) = e
(−αd−βd2) (2.12)
The parameters α and β represent tissue specific quantities. The shoulder region
of the survival curve (on a semi-logarithmic scale) is represented by the linear dose
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term and the according α value while the linear region is characterized by the β
term.
For consecutive fractions, it was shown that fractions of equal dose d are isoef-
fective, so that the LQM for fractionated treatment is given by a power-to-n law
[27]:
SFLQM(d, n) = e
(−αd−βd2)n = e(−αnd−βnd
2) = e(−αD−βdD) (2.13)
with n being the number of fractions and D = nd being the total treatment dose.
This is based on the fact that after sufficient time (6-8 hours), DNA repair is com-
pleted and cells are either dead (repair was not possible) or can be treated as fully
repaired cells without dose memory.
Figure 2.8. – SF curve comparison for the different de-
scribed models. Exemplary values taken from [49]. For
the single-target and the multi-target model, D0 was set
to 2 Gy. For the multi-target model, m was set to 2. For
the LQM: α = 0.2, α/β = 6. It can be seen that the
multi-target, single-hit model and the LQM are very simi-
lar for the chosen parameters, underlying that both models
can provide good empirical fits to the data. However, in
detailed analysis the multi-target model failed to represent
the SF curve of experiments especially in the low and high
dose regions.
While the LQM provides a
simple application (due to the
low number of variables) and
good representation of experi-
mental findings, it needs to be
noted that it is still an empiri-
cal model and its biologically
based interpretation remains
unsolved. It was initially set
up by Kellerer and Rossi based
on the assumption of a two-
level cell kill (or inactivation)
process: either due to a single
particle hit (α term) or com-
ing from a first damage to a
second one resulting in kill (β
term). In later explanations,
this was interpreted as a death
following either an unrepairable
double strand break, or the suc-
cession of single strand breaks.
A mathematical explanation on
the other hand follows the as-
sumption that any type of re-
sponse can in principle be mod-
elled using polynomials from a
Tailor expansion. The LQM in
this sense only shows that the
response of cells to ionizing ra-
diation might be already adequately characterized by the linear and quadratic terms.
With the nature of radiation response with respect to the LQM still unknown, its
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use and interpretation needs to be treated with caution. This is especially valid
for the underlying tissue-dependent α and β parameters. Conventionally, the
α/β [Gy] value is used and reported for clinical applications instead of the indi-
vidual parameters. Its determination is usually based on cell culture experiments
of the above described clonogenic assays. This involves a number of uncertainties
since the tissue structure and environment also plays a role in term of its radiosen-
sitivity. The estimation of the α/β value in patient analysis on the other hand is
endpoint-specific and includes a range of assumptions on the tissue and including
uncertainties in the overall process. Therefore, reported α/β values often show a
wide range, especially when derived from patient data (see also table 3.2 in section
3.2.3 for the applied ranges in this thesis). For example Williams et al. [78] investi-
gated on the α/β value of prostate cancer. They found that for the 95% confidence
interval, the results of α/β ranged from 3.7 Gy to infinity. By increasing the range
of included dose per fraction schemes (including boost therapy) this interval shrunk
to a range from 0.9 to 4.8. They concluded that the spatial and temporal variance
of the delivered dose between patients that could not be accounted for, had a large
impact on the resulting uncertainty range. It should be noted that also the patient
variability (genetics and way-of-life background) impacts the radiosensitivity of tis-
sue substantially. Thus, the α/β value for the same tissue type can vary between
patients. Furthermore, organs can show substructures which can potentially have
different α/β values which is not reflected in the common approach to assign one
value for the whole organ. In summary, this means that there is possibly a natural
range of α/β values for the same tissue type.
It should be noted that the underlying individual α and β values play an important
role in the description of the LQM curve, as shown in figure 2.9 a). The impact on
the results in this work are discussed in section 5.2.
Despite the missing biological explanations, the LQM provides a good basis for clin-
ical applications and interpretations of fractionated treatment. Fractionation is
based on the concept that tissue can be spared from damage when using consecutive
low doses. While this is true for both the tumour and normal tissue, the difference
in repair capability, which is higher in normal tissue, results in the effect that normal
tissue benefits from fractionation to a larger extent than tumour tissue (dependent
on the choice of the fractionation scheme as outlined below). The α/β dependency
and the impact of the fractionation scheme is shown in figure 2.9 b).
Within the LQM, the α/β reflects the tissues response to radiation. Tissues with
a low α/β (1-5 Gy) are known as late responding tissues due to a low proliferation
rate (like kidneys, heart or the rectum). On the other hand, a larger α/β value
refers to early or acute responding tissue (like skin and bone marrow). Figure 2.9 a)
illustrates the LQM-based SF curves for different α/β values. It can be seen that
the cell kill per unit dose is increased for lower α/β values based on the increased
impact of the β term and its quadratic relation to dose. Based on this, figure 2.9
b) shows that tissues with low α/β values benefit more from fractionation with a
high number of fractions and low dose per fraction because the high dose regime is
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Figure 2.9. – The cell SF according to the LQM for a) different underlying α and α/β values and
b) the fractionation dependency. a) shows that the cell kill per unit dose is increased for lower
α/β (and same α). The underlying α value determines the bending of the curve (extent of the
shoulder). b) Visualization of the fractionation principle (green: α = 0.1, violet: α = 0.19), n =
number of consecutive fractions. For n=1 and n=2, the curve with higher α/β value shows a higher
SF, showing that a low number of high dose fractions is advantageous for normal tissue with high
α/β while achieving higher cell kill in tumours with lower α/β (principle of hypofractionation).
However, in case the tumour (as conventionally expected) has a higher α/β values than the normal
tissue, a higher number of low dose fractions is advantageous: for n = 5, the upper curve now is
based on the lower α/β value, using the advantage of lower cell kill for lower doses due to the
shoulder region, justifying standard fractionation schemes.
cut while for tissue with a high α/β, the SF curve is almost linear to the dose per
fraction and therefore benefits less from decreasing the fraction dose.
It was conventionally assumed, that due to the interpretation of cancer being a
volume of fast and uncontrolled cell proliferation, tumours have a high α/β value
(commonly applied tumour α/β = 10 Gy). On the other hand, slow proliferating
normal tissues shows lower values (around 3 Gy). This is the basis for standard
fractionation in usually 34-37 fraction of around 2 Gy that optimized normal tissue
sparing based on its recovery and the total treatment time.
However, different strategies should be applied for cases where the α/β value of the
tumour is lower than that of the surrounding normal tissue. In the case of prostate
RT, recent works pointed out that the α/β value of prostate carcinoma might be low
compared to the common standard (e.g.: [1], [10], [53], [78]). Miralbell et al. [53] for
example suggest α/β = 1.4 Gy. For these cases, hypofractionation is proposed, thus
lowering the number of fractions while increasing the fraction dose. The beneficial
impact of this can be seen in figure 2.9 b) where for higher doses per fraction, the
tissue with higher α/β value (in this case the normal tissue) will be spared more
(higher survival). Details on how to convert different fractionation schemes are given
below in the next section.
32
2.2. METHODOLOGICAL BACKGROUND 33
The recommended dose range for using the LQM is between 1 to 5 Gy per
fraction [34] while some other recommendation go up to 10 Gy. Experimental ob-
servations indicate that the LQM might not be appropriate outside of this range,
underlining the missing biological interpretation of the model. For high dose re-
gions, while the LQM shows continuous bending, experimental observation indicate
a rather straight line. Different approaches are suggesting how to account for the
observed discrepancies, each including at least one more tissue dependent parameter.
The derivation of three instead of two parameters from the limited information in
experimental setups (especially in the high dose region where the SF decreased to
below 10%) provides a big challenge up to the point that these models did not find
clinical applications up to date. One of these is the linear-quadratic-cubic model
that compliments the LQM with an additional cubic parameter and the tissue spe-
cific constant γ.
On the other side of the scale, some experimental observations [48] indicated a low-
dose hypersensitivity for doses below 1 Gy. It was found for some mammalian cell
lines, that the region below about 10 cGy shows a much steeper SF slope than the
LQ-fits for higher doses suggest. This slope is followed by an increased resistance
again. An explanation for this is a sort of repair-inducing dose threshold at about
10 cGy that only then causes certain repair mechanisms to take action. For the low
dose region, another modification of the LQM was therefore suggested, called the In-
duced Repair model. Essentially, the Induced Repair Model combines two versions
of the standard LQM: for low doses, it represents the LQM with parameters αs and
β and for high doses the LQM with αr and β. αs therefore indicated the steeper
slope at lower doses. The low-dose hypersensitivity might become important for
treatments that irradiate large volumes of the patients anatomy with relatively low
doses. This is for example the case for intensity-modulated radiotherapy (IMRT)
where large volumes of normal tissue is irradiated with doses below 1 Gy. However,
this topic is still in debate with only very limited experimental proof.
The basic form of the LQM does not consider time-linked parameters. In case of
consecutive fractions where fractions are delivered before cell repair is completed
(multiple fractions per day or continuous irradiation), more factors need to be con-
sidered in the use of the LQM. However, this will not be relevant within this work.
Furthermore, for fast proliferation (of e.g. tumours), the significant increase in cell
number also needs to be taken into account. This can for example be done by includ-
ing another term in the exponential expression representing proliferation according
to the specific tumour type [23]. For the analysis in this work, this factor is not
considered.
2.2.2.2 Radiobiology in clinical practice
When planning a RT treatment, it is necessary to know which dose magnitudes can
and should be applied to the human tissue. In case of tumour tissue, it needs to
be known how much dose is necessary, in order to achieve local control: complete
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inactivation of all cancer stem cells within the tumour, so that no further regrowth
after therapy is possible. For normal tissue, constraints need to be applied to the
planned dose field, in order to avoid normal tissue toxicities as consequences of radi-
ation damage. Based on these numbers combined, the treatment plan is optimized
to fulfil dose prescription to the tumour (usually described by dose coverage at a
certain prescription dose level like the D95%, the dose that 95% of the structure
receives) and the normal tissue constraints, usually defined by the volume V that is
allowed to receive a certain dose level x, referred to as Vx%/Gyb.
Conversion of fractionation schemes It is often desired to change the fraction-
ation scheme (number of fractions and dose per fraction) without changing the bio-
logical effect (isoeffective approach) that proved good clinical applicability. Mainly,
it is the conversion from normal fractionation (standard approach of 2 Gy per frac-
tion) to hypofractionation (lower number of fractions with doses above 2 Gy) that
needs to be calculated as outlined above in section 2.2.2.1. The isoeffective conver-
sion of fractionation schemes is a direct application of the linear-quadratic approach
in clinical practice by using the LQ description of the relationship of dose to biolog-
ical effect.
The equivalent dose in 2 Gy fractions (EQD2) refers to the total dose of a
treatment with a fraction dose of 2 Gy that is biologically equivalent (isoeffective)
to a treatment delivered with fraction dose d and total dose D = nd with n being





In clinical practice, 2 Gy per fraction is the commonly applied dose and therefore
serves as a good value for comparing the new treatment scheme to the standard ap-
proach and experience. However, in principle any other number can be applied for
conversion. The EQD2 is derived from setting the effect based on the LQ approach
from two different treatments to be identical, i.e. being isoeffective. This principle
will be used later in the derivation of the total biological dose bEQD (see section
3.1.3).
There are other concepts in literature for the same purpose which are also math-
ematically and biologically equivalent and will therefore not be explained in more
detail here: the biologically effective dose (BED), the extrapolated tolerance dose
(ETD) or the normalized total dose (NTD).
TCP, NTCP and volume effects The interpretation of the SF in clinical prac-
tice is not straightforward since the quantification of cell survival can often not
bNote that two conventions exist: V50Gy refers to the volume that receives at least 50 Gy while
V50% is the volume that receives at least 50% of the tumour prescription dose. This will be
noted accordingly in the following.
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directly be linked to treatment outcome due to a number of reasons outlined be-
low, especially in normal tissue. Therefore, models are proposed that describe the
relationship of dose to treatment outcome. Fundamentally, one has to distinguish
between tumour and normal tissue in the description of dose response.
For the irradiation of tumours, the aim is to achieve local control as described be-
fore, which means in the classic interpretation that optimally, all cancer cells are
inactivated. This is reflected in clinical terms with the tumour control proba-
bility (TCP) that is directly used as a tool for treatment planning in comparing
different treatment strategies. The concept is based on the hypothesis that every
single cancer cell can in principle generate a tumour, thus, for the success of an RT
treatment, all cancer cells need to be eliminated. This is also why tumour coverage
with a certain dose level is often prioritized over the risk of occurring side effects.
The standard TCP approach is based on the expression given by the LQM in first
approximation that in fractionated RT, the α term alone defines the slope effectively.
The initial absolute cell number is approximated by tumour volume and clonogenic
cell density. The probability of cell death is approximated with Poisson statistics to
derive the final TCP formula.
However, TCP is also criticized for two reasons mainly: the estimation of cell kill
is model based and cannot be measured directly and secondly, not in all cases, it is
necessary to inactivate all tumour cells to achieve cure (but for example only cancer
stem cells [18]). Zaider and Hanin [86] propose that it is rather the ”probability of
cure” of the patient that should be aimed for rather than a certain TCP value.
The situation in normal tissue is even more complex. For example, the quantifi-
cation of toxicity is often difficult. For many endpoints, patient reported outcome
is given via a questionnaire in which the assessment is naturally subjective, thus
the direct correlation of toxicity to SF is unsuitable. Furthermore, the relationship
between SF and induced toxicity is not necessarily straight forward but depends on
the functional structure of the organ and so called volume effects.
The response of normal tissue to radiation is described in so called normal tissue
complication probability (NTCP) models. Several approaches exist. An early and
widely used model was presented by Lyman in 1985 [46]. The model includes two
variables, given by the dose and the volume, and is described by three model pa-
rameters: D50, a uniform dose to the structure that when received by the entire
volume results in a 50% probability of the certain endpoint to occur; an exponent to
the volume variable, n, that describes the volume effect (see below); m, a parameter
describing the steepness of the dose-response curve. This model is purely empirical.
A huge challenge in NTCP modelling is the complex architecture of normal tis-
sue that requires the description of volumetric effects. This is also a problem in
the Lyman model, since it is only valid for uniformly irradiated structures, which
does not occur in actual clinical practice. A further developed form of the Lyman
model was presented by Kutcher and Burman in 1989 [42] who tried to tackle this
limitation by introducing the effective volume method (resulting in the so called
Lyman-Kutcher-Burman (LKB) model). In their approach, the dose-volume distri-
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bution (dose-volume histogram, description see section 3.2.3), is summarized into a
single dose metric, the equivalent fraction volume that receives the maximum dose,
which is then used within the Lyman model. This is based on the assumption that
each volume fraction follows the Lyman model in the same way as the entire struc-
ture.
NTCPs are up until now a field of research and do not provide enough clinical
evidence or experience to be used for treatment decision making. Moreover, the de-
scription of volume effects in and outside of NTCP modelling is a wide field of current
research. The volume that receives a certain dose often determines its dose tolerance
and therefore the necessary clinical tolerance dose constraints. For treatment
planning, therefore often dose constraints to certain volumes are used as a simpler,
and more robust approach instead of NTCPs. They are, for normal tissue, mostly
given in the form of Vx, the volume receiving at least x Gy, as mentioned before. In
many cases, clinical decisions are based on the 1991 recommendations by Emami et
al. [21]. However, these are not necessarily based on clinical or experimental evi-
dence, but rather opinion- and experience-based. In 2010, the Quantitative Analyses
of Normal Tissue Effects in the Clinic (QUANTEC) reports [47] summarized the
given published evidence-based experience for normal-dose constraints and provide
the up to date standard. However, the reported toxicities are related to planned
doses which might vary substantially from the delivered doses (see section 2.2.1.1).
Furthermore, most data is based on three-dimensional (3D)-conformal treatment
plans (see section 2.1.2) and not using IMRT which show substantially different
dose distributions. Hypofractionation is also not covered. These problem are impor-
tant aspects in current research and were also investigated in this work (discussion
see section 5). Results obtained in this work were compared to the QUANTEC
constraints for the planned dose and the two strategies to obtain the accumulated
dose.
To tackle the volume effect question, Withers et al. [80] first introduced the concept
of functional sub-units (FSUs). The definition of FSUs is tolerance dose based
and defines the largest volume of a structure that can be regenerated from a single
clonogenic cell and on the other hand represent subunits that are independently
sterilized by irradiation. The varying forms of radiosensitivity of entire organs is
described by the architectural arrangement of FSUs. The physiological function of
an organ is only then impaired, if either a critical number of FSUs is damaged or a
FSU was exposed to a certain threshold dose. This then defines the volume of the
organ that may receive certain dose thresholds without inducing organ damage.
Two types of an organ’s architecture can be distinguished: serial or parallel. For
serial type organs, the damage of single FSUs (or maybe even just one) may in-
duce organ toxicity . This means that in clinical practice, this organ is prone to
side-effects when exposed to local high doses, even in small volumes, so called ”hot
spots”. The dose distribution to the entire organ (e.g. mean dose) plays a minor role.
A classical example of a serial type organ is the spinal cord or the intestines. On the
other hand, parallel type organs are susceptible to radiation-induced side-effects in
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cases large volumes (a certain number of FSUs) of the organ receive a certain dose
level. The dose distribution within the organ becomes relevant. Lung or liver are
examples for more parallel type organs. It needs to be noted that organs are never
organized in a purely parallel or serial manner. It may be that for example an organ
contains regions that are serial-type organized, introducing a serial-component in
an otherwise parallel organ.
For the above described LKB model, the volume exponent n describes the volume
effect within this NTCP model. For n close to 1, the volume effect is large, which
means that the tolerance dose increases strongly with decreasing volume (more par-
allel), while n close to 0 describes a small volume effect given for more serial type
organs. This principle was extended by the introduction of the relative seriality
model [39] that includes an extra parameter s to describe the tissue architecture in
this manner.
The volume effect is also used when converting an inhomogeneous dose distribu-
tion to a homogeneous dose distribution resulting in the same SF: The equivalent
uniform dose (EUD) is defined as a generalized meanc used to summarize hetero-
geneous organ doses [59]. It is defined as a weighted mean, where the weighting is








vi denotes the volume of the structure with absorbed dose Di. For the exponent a,
the general recommendations are rare and usually based on empirical fits, a prob-
lem that is also valid for the discussed NTCP models before. The International
Commission on Radiation Units & Measurements (ICRU) report 83 [50] generally
suggests: ”serial-like tissues have large positive values of a, and values are close to
1 for parallel-like structures”. With a close to 1, the EUD converges to the mean of
the dose. Some works use the inverse of the exponent a, referred to with n = 1/a
also described above for the LKB-model. It should be noted that EUD is therefore
as well a model-based quantity.




M AT E R I A L S & M E T H O D S
3.1 methodology of biological dose accumulation
This work builds on the observation that conventional dose accumulation is not be-
ing used consistently with regard to radiobiological models and considerations. To
overcome this inconsistency, a methodology of the accumulation of the biological
effect and dose was developed in this work. This chapter builds up on the method-
ological background given in section 2.2 and brings together both aspects of dose
accumulation and radiobiology.
As the basis for accumulation, the post-processing chain of the dose data from daily
imaging (dose mapping) needs to be in accordance with biological mechanisms. Sec-
tion 3.1.1 supplements current debates in literature about the rationale of dose
mapping by discussing this problem based on biological considerations. The result
of this section is a conclusion on how the mapping algorithm should be implemented
in order to give a biologically meaningful transformation of the tissue and the dose.
Based on this, biologically consistent dose accumulation is presented. This is twofold:
first, the effect accumulation approach is described - the consistent use of the biolog-
ical model in order to retrieve the cell survival fraction after fractionated treatment
(section 3.1.2). Second, the concept of the total biological dose bEQD is presented
- the total dose of the treatment that represents the mathematically correct (cell)
survival fraction (SF) according to the effect accumulation approach (section 3.1.3).
The chapter is summarized in section 3.1.4 to present the complete workflow of
biologically consistent dose accumulation.
3.1.1 The biological rationale of dose mapping
The content of this section was submitted for publication in August 2019 to Physics
in Medicine and Biology as a Technical Note as it is presented here [57].
In the previous sections, the workflow for conventional dose accumulation was pre-
sented (section 2.2.1.2). The basis of any sort of dose accumulation is the fractional
delivered dose values that need to be transformed into the grid and geometry of
a common frame of reference, the deformed doses the di. Thus, the fundamental
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prerequisite of dose accumulation is dose mapping which is based on deformable im-
age registration. This section presents the methodological analysis of dose mapping
under consideration of biological mechanisms. This serves the purpose of building
the basis for the following dose accumulation. This chapter is based on a thought ex-
periment and will hold no further data based results in the following chapters. The
result of this chapter is the conclusion on how dose mapping needs to be performed
in order to be biologically consistent.
The underlying principles and assumptions involved in this dose mapping procedure
are the topic of an ongoing debate [31] [90] [68], especially for cases where anatom-
ical structures change in volume over the course of treatment. Dose mapping and
accumulation has uncertainties [74] [56] associated with the use of deformable im-
age registration (DIR) as also outlined above. Two distinct cases can be identified:
(i) The images to be registered represent the exact same anatomy containing only
tissue deformation; (ii) the two images include changes in anatomy, for example due
to tumour growth or shrinkage, changing organ fillings, or weight loss in normal
tissue. While the registration problem of (i) is well-defined and, at least in princi-
ple, has an unambiguous solution, case (ii), requires the registration of two different
objects and is therefore an ill-posed problem. In the following, this work focusses
on the latter case. The DIR will produce a solution, which may be satisfying from a
geometrical standpoint. For the biological assessment of dose mapping, however, it
is necessary to consider also the biological target receiving the dose, and how doses
at different time points can be added in a biologically consistent way.
Most bio-effect models are observational in nature, derived to fit time dose and frac-
tionation dependencies of the observed responses as discussed in detail in section
2.2.2. They are by nature approximate models making certain assumptions. Bi-
ological understanding of cell organisation has been integrated into these models,
and demonstrated to have clinical relevance [67] [60]. Current clinical imaging tech-
niques do not provide a resolution at the level of individual cells nor to distinguish
between viable and sterile/killed cells. We can therefore base our implementation
of bio-effect models and conclusion only on the results on a voxel level which will
always suffer from discretization effects (further discussed also in section 5.2).
Dose mapping based on DIR can be implemented so as to conserve dose, or so as to
conserve delivered energy [90]. In a recent review on adaptive radiotherapy (RT) by
Sonke et al. [71] it was stated that, in the case of volume changes of the structure
”As a consequence, however, when transforming scans and daily doses back to the
planning computed tomography (CT), mass and energy are not conserved. While
corrections can be applied to enforce mass and energy in such transformations yield-
ing ”physically” more correct representations, it is debatable if such corrections are
also biologically more relevant.”. Here, the two existing approaches are discussed by
extending the debate to include considerations at the biological level. The conclu-
sions here are based on the basic postulation that the mapped dose and subsequent
accumulation has to be in accordance with the observed biological response of tu-
mour and normal tissues. It will be shown here, that the dose conserving approach
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facilitates a biologically consistent interpretation of the relation of the accumulated
dose and the biological effect. On this basis, the different effects causing volume
change (for both growth and shrinkage) are analysed for DIR on a biological level
and its implication for the dose mapping implementation are discussed.
Biological considerations For incompressible soft tissues, it is assumed that
physical density remains constant over time. In biomechanics, soft tissue organ
architecture is defined by cellularity, architecture of the extracellular stroma, and
extracellular water content. The extracellular stromal content is the most highly
conserved of these three properties. Across a wide range of physiological and patho-
logical processes, intracellular and extracellular compartments both approximate to
water density. Thus, changes in organ volume are caused by a change in voidage
(cellular packing) due to reciprocal gain or loss of water and cells. Changes in organ
volume are therefore directly proportional to mass [24] while the cell density can
change without change in physical density. The following analysis is mainly based
on this type of tissue. For lung tissue on the other hand, it is necessary to look at
intrafractional motion. In this case, though volume changes, the mass of the object
is constant while physical density changes. This scenario will be discussed briefly at
the end.
Ultimately, treatment outcome is a combination of the treatment parameters as well
as radiobiological parameters of the tumour and normal tissue of the patient. The
argument is based on the Linear Quadratic Model (LQM) for the prediction of the
biological effect given as the SF. For simplicity, the biological effect discussed here
only considers cell survival as the endpoint and it does not consider changes in organ
function of normal tissue which depends on more complex cellular architectures [60]
[67].
In the following, both dose mapping approaches are briefly analysed with regard to
the resulting mapped dose. Afterwards, the biological implications from the derived
mapped doses are analysed in detail. Furthermore, the discussion of biologically
consistent dose mapping is extended to four different biological causes of volume
change in tissue.
Dose- vs. energy-conserving dose mapping: a thought experiment To
perform dose mapping in case of mass loss or gain, two approaches can be consid-
ered: conserving the delivered dose or conserving the deposited energy. The two
approaches are analysed based on a thought experiment of a structure made up of
uniformly-sized volume elements (voxels). The example situation of the thought
experiment, where the structure reduces in volume and mass and receives a homoge-
neous dose, is shown in figure 3.1, along with the transformation back to its initial
state.
Conservation of dose in the context of dose mapping means that the deformation vec-
tor field (DVF) and interpolation is applied to the dose distribution, analogously to
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grey values in a CT image. In this implementation, when the volume of a uniformly
irradiated structure is changing (figure 3.1, a) (the smallest of which is a voxel), the
dose to this volume will still be the same after the mapping process (figure 3.1, b)
(the same principle as visualized before in figure 2.7). Recent works promoted the
concept of energy conservation [90] [15] [89] [91] [14] for structures that change in
volume. In this approach, the same transformation and interpolation is applied to
the energy delivered to the structure, instead of the dose (figure 3.1, c).
For the analysis of the dose mapping processes, the following thought experiment is
considered in figure 3.1: The starting point is a volume at timepoint T1 (figure 3.1, a)
that shrinks to 1/4th of its initial volume at timepoint T2. Uniform shrinkage is as-
sumed so that each initial voxel will also shrink to 1/4th of its volume when looking
at the corresponding sub-unit at T2. The whole structure receives a homogeneous
dose of a delivered dose of 2 Gy at T2 that is then being mapped back to timepoint
T1 for the purpose of dose accumulation in the reference frame. By applying the
DVF obtained from DIR between the fixed image from T1 to the moving image in
T2, to the structure in T2, the result is a structure of the same size as in T1 (after
applying the DVF: T ′2). We assume an anatomically correct transformation to solely
focus on the underlying principles, so that for the volumes: V ′2 = V1 = 4V2.
From T1 to T2, volume and therefore mass is reduced by a factor 4 and then virtually
increased again by a factor of 4 in the mapping to T ′2. This is the direct result of
biologically consistent mapping by assigning water equivalent density at all stages.
A direct mapping of the structure to its initial volume and location is a prerequisite
for accumulation on a voxel scale in the reference frame represented by timepoint
T1.
For the dose conserving mapping approach shown in figure 3.1 b, the dose in the
entire volume in T ′2 remains the same as in T2. Since mass was virtually increased
in the mapping, the delivered energy is also (virtually) increased by a factor 4, since
energy, in contrast to dose, is an extensive quantity of the system. In contrast, when
conserving the delivered energy (figure 3.1 c), the total energy after mapping is the
same as in the structure at T1, so E ′2 = E2. Since dose is defined as energy per unit
mass, the dose within the structure is reduced to 1/4th of its initial value.
Biological implications of dose- and energy-conserving dose mapping The
biological effect as predicted by the LQM is solely linked to dose, not to delivered
energy. Dose is an intensive quantity of the system and is therefore the same for
each mass element (i.e. cell) in one voxel within the limits of discretization. For the
presented scenario in figure 3.1, all cells in the highlighted yellow region receive 2 Gy
at timepoint T2. Thus, the cell survival fraction resulting from the irradiation at T2
is given by the LQM for d2 = 2 Gy. When conserving the dose (figure 3.1, b), the
survival fraction within the mapped volume is the same for both the original cells
from T2 and virtually added volume (water or cells) in T ′2. In the energy conserving
approach (figure 3.1, c), the dose is decreased by the factor increase in mass. There-
fore, also the dose to each cell is decreased and the SF within the mapped volume
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Figure 3.1. – Example case of a structure shrinking to 1/4th of its initial volume from timepoint
T1 to T2. Density is assumed to be approximately water equivalent (ρW) at all times, therefore
volume is directly proportional to mass. a) Deformation and resulting mapped structure (T ′2). b)
Dose conservation within the entire structure that receives homogeneous dose. Deposited energy
is scaled according to the factor change in mass. c) Energy conservation implies that the dose for
the entire structure is reduced to 1/4th of its initial value according to the increase in mass. For
cases of volume increase, the calculation can be performed analogously.
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will be that of the LQM for 1/2 Gy:
SF(T2) = LQM(2 Gy);
SF(T ′2)dose−conserved = LQM(2 Gy);
SF(T ′2)energy−conserved = LQM(1/2 Gy)
In summary, the dose conserving approach conserves the SF at timepoint T2 in
the mapping process while altering the deposited energy to the overall structure.
Conserving the energy that was delivered by the treatment device, on the other
hand, results in altering the biological effect imposed at timepoint T2 by reducing
the dose received by the individual cells.
A requirement for biologically consistent dose mapping is to conserve the survival
probability of cells in fraction x. This is to conserve the biological impact of the
irradiation of each fraction and enable to calculate the overall survival fraction of
the treatment schedule in the reference frame. As the process of DIR along with
dose mapping is not a physical process, but a mathematical projection of one state
to another, this work suggests to adjust and interpret the implementation of this
process with our knowledge about the biological system. The structure change
between T1 and T2 is a physical process that results in a mass change. Thus, the
structures in T1 and T2 do not represent the same physical system. In the attempt
to map the structure from T2 to T1, a non-closed biological system is simulated,
so the implementation should not try to conserve a closed system in the process.
Whenever volume (i.e. mass) changes, so does the absorbed energy. In this sense,
the aim of dose mapping should not be to conserve what energy has been delivered
by the treatment device to one of these systems but rather which effect has been
obtained in the biological tissue. Thus, the question needs to be answered, what
energy would have been needed to be deliver to the structure in the reference frame,
in order to cause the same biological effect as was obtained in the structure at
fraction x. This is achieved by mapping the dose that was delivered to the structure
in T2 in a dose conserving-manner, while the energy of the system is scaled with
the change in volume induced by the mapping process. Thus, one must not demand
energy conservation but equality of the ratio of change in energy and mass which is
given by the conservation of dose.
Recently, Zhong and Chetty [90] published an opinion piece in which they state
that energy conservation is violated in the process of dose mapping for scenarios
where structures undergo volume changes. In their conclusion, they propose energy
conservation for dose mapping. In this thesis, it is agreed that delivered energy is
not conserved in this process as presented above, but disagreed with the conclusion,
and argued that energy conservation is not legitimate in instances where volumes
are changing while the physical density is conserved. This is in accordance with a
short reply by Hugo et al. [30] to the mentioned opinion statement above. Two
different states of an imaged patient’s anatomy along with the delivered dose do not
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Figure 3.2. – Scenarios of volume change in biological (un-compressible) soft tissue. In the top
row, the physical implementation is depicted analogously to figure 3.1, referring to tissue shrinkage
and growth. In the bottom row, possible biological mechanisms of the individual cases are shown.
Both cells and extracellular space have approximately water equivalent density so that a change in
cell density does not induce a change in physical density. For the cases of change in cell number,
the result of the mapping process is that cells are virtually added or removed, while a change in cell
density is given by a virtual increase/decrease in water content. In tissue, the depicted scenarios
usually occur in a mixed manner.
represent the same closed physical system. The very fact that volumes change (loss
or gain of mass) underlines this. This is in-line with the above conclusion that it
is dose, not energy that needs to be conserved during the mapping process for a
volume of homogeneous dose even if this volume changes in size.
Biological consistency of the dose-conserving mapping method in differ-
ent scenarios There are four main processes that drive volume change in soft,
non-compressible tissue, presented in figure 3.2. Using dose conservation in the map-
ping process, a consistent relation between mapped dose and biological effect can
be achieved. This will be discussed separately for the four cases that are depicted
as well as for the case of lung tissue:
Scenario 1 - Volume decrease due to decreasing cell number (radiation induced
cell kill and resorption): Cells that are killed and resorbed from T1 to T2 will be
virtually added in the projection from T2 to T ′2 (V ′2 = V1) and assigned with the dose
of the voxel they contribute/ are shifted to. This ensures that the dose delivered to
the original vital cells present in T2 is not diluted and the SF of the cell cohort at
T2 is conserved within the volume V ′2. It needs to be noted that all virtually added
cells represent dead cells (since they were resorbed as such from T1 to T2). In the
accumulation process, this SF needs to be taken into account as will be discussed in
detail in section 3.1.2. Thus the dose conserving dose mapping approach conserves
the SF at each fraction as well as the absolute number of surviving cells for accumu-
lated doses. It has to be noted that this argument is also valid, in case not all cells
that were killed in the first fraction are resorbed prior to the subsequent fraction,
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but remain in the volume as sterile cells.
Scenario 2 - Volume decrease due to increasing cell density (reduction of cell vol-
ume or vanishing of an oedema): The dose to a cell within a voxel of x Gy is also
x Gy, independent of the absolute number of cells within that voxel (cell density).
The increase of volume from T2 to T ′2 causes a decrease of cell density back to its
original value (as in T1) by virtually adding water to the system. Whether the vir-
tually added mass is made up of dead cells (first case above) or water that receives
the delivered dose (i.e. additional virtually delivered energy) is irrelevant as long
as in the accumulation process, the survival fractions from previous fractions are
considered analogously to the argument above. Dose conservation ensures that dose
to individual cells is not diluted.
Scenario 3 - Volume increase due to increasing cell number (proliferation): In
the projection of T2 to T ′2, volume is decreased again, virtually removing cells from
previous proliferation. When applying the LQM, we assume that repair has been
finished before the next treatment fraction is delivered (for standard fractionation
of one fraction per day). Thus, cells can be considered being either sterilized/killed
or completely repaired and therefore without dose memory and in the latter case,
will behave like un-irradiated cells. Thus, it is not necessary to distinguish previ-
ously irradiated and newly proliferated cells in the volume decreasing step, which
would not be possible on the basis of the imaging data. By conserving the dose,
the SF of the cell cohort is conserved accordingly. Note that here again, for the
consistent accumulation of the biological effect, the survival fraction from previous
fractions needs to be considered. Regarding the absolute cell number, the increase
by proliferation between the two fractions has to be considered. This can be done
by adding a proliferation term in the LQM as explained before. It needs to be ques-
tioned whether dose (or effect) accumulation on the initial volume is still reasonable
for scenarios where volume increases over the course of therapy due to proliferation
since additional tissue that might be present at the end of the treatment compared
with the initial state is being neglected in the analysis of the accumulated delivered
dose in the reference frame.
Scenario 4 - Volume increase due to decreasing cell density (e.g. increase in water
content due to oedema): In this case the volume at T2 is increased compared with
T1 and is mapped back to the initial volume by the mapping process. Virtually,
water is removed from the system and the same argument applies as in the previous
case that conservation of dose also conserves the SF of the cells within the volume
decreased in the mapping process.
Scenario 5 - Volume change due to physical density change (intrafractional lung
motion, not illustrated in the figure): This case is different to the four cases discussed
above since physical density changes and the motion occurs on a small time scale.
For the overall structure of the lung, mass is conserved in this case. This holds true
as long as the entire structure is being observed and mapped (no migration of lung
tissue outside the field of view that is being mapped). In this case, both energy-
and dose-conserved mapping are equivalent.
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In conclusion, in all scenarios of tissue shrinkage and growth, the dose conserving
mapping approach facilitates a consistent implementation of the biological effect
in terms of SF as well as absolute cell number, independent of the cause of volume
change. In biological tissue, volume change is caused by various processes happening
simultaneously that could for example be described by combinations of the described
scenarios. Since all discussed causes of volume change can be treated in the same
way in the mapping process, combinations of these are also permissible.
In conclusion of this analysis, dose mapping should be performed in a dose con-
serving manner. This way of implementation is used throughout the workflow of
this thesis and will not be further analysed but used as a given standard. A short
discussion on implementation consideration is presented in section 5.2 .
3.1.2 The effect accumulation approach
Fractionation is a key principle in RT to open the therapeutic window, i.e. to achieve
higher differences between the cell kill in tumour and normal tissues. The basis of
this principle is the non-linear relationship between dose and biological effect. As
described above in section 2.2.2, the LQM represents a good empirical model to
describe this biological effect by an exponential decrease in the cell survival frac-
tion with dose. As given in equation 2.12, within the exponential expression, the
biological effect is linked to a linear and a quadratic dose term. With this, the de-
scribed shoulder-shape of the cell survival curve over dose offers the chance to take
advantage of the difference in radiosensitivities of tumours and normal tissues by
fractionation.
The advantages achieved by fractionation are, however, reduced by fact that between
fractions, organs will move. As described in section 2.2.1.1 this can strongly impair
the delivered dose per fraction and lead to underdosage of the tumour or overdosage
of normal tissues. On a local scale, the dose within each voxel will change from
day to day, even for small organ motion amplitudes. Above, the principle of dose
mapping and accumulation is discussed to retrieve the total delivered dose of the
treatment course that includes these daily variations on a voxel scale (section 3.1.1).
Even though the daily dose variations are in fact summarized in the total conven-
tionally accumulated dose Da (equation 2.9), in this process, the information on the
daily dose variations is lost. Instead, this information is reduced to the mean dose
per fraction d = Da/n.
As stated above, the relationship of dose and biological effect is non-linear, mani-
fested in the β-term in the exponential expression, which is quadratic to dose. Thus,
using the averaged fraction dose d in the LQM equation 2.12 will lead to a different
SF outcome than using the individual fraction doses di. Thus, a mathematical flaw
is introduced by neglecting the non-linear relationship by first performing a linear
operation on the dose information.
The effect of this inaccuracy is visualized in figure 3.3 that shows cell survival curves
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according to the LQM for three consecutive treatment fractions. Each colour rep-
resents the same total dose but build up of different fraction doses that will in
consequence each result in a different SF at the end of the three fractions. The blue
curve shows three equal fraction doses. As can be seen, this leads to the highest cell
survival fraction in total. Thus, the total biological effect of the treatment does not
only depend on the total dose, but on each delivered fraction dose throughout the
treatment.
Figure 3.3. – SF according to the LQM for three consecutive fractions. Each colour shows the SF
for the same total dose, but delivered in different fraction doses. It can be seen that the total SF
depends on the individual fraction doses which shows the inaccuracy in using the conventionally
accumulated dose for biological effect prediction in case of varying fraction doses. Reprinted from
[58].
To overcome this inaccuracy, the steps of effect prediction and accumulation need to
be interchanged. In the following, the principle of mathematically correct effect and
dose accumulation is derived and compared to conventional dose accumulation and
effect prediction. The following derivations along with parts of the results presented
in chapter 4 were submitted for publication in Physics in Medicine and Biology [58].
The magnitude of the difference between the shown exemplary curves in figure 3.3
is topic of the results of this work in chapter 4.
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In section 2.2.2, the biological effect after n fractions of dose d and total dose Da
was described, which is obtained from the LQM by a power-to-n-law resulting in the
total SF of n fractions of:
SF(d) = e(−αDa−βnd
2) (3.1)
In the following SF(d) will denote the SF of n fractions of dose d, called the dose
accumulation approach (the conventional workflow).
The flaw in this principle for use in actual treatment scenarios is the fact that the
dose d is changing in each fraction. However, the power-to-n-law is only valid to
use for a constant fraction dose d. This law is applied in common practice by
using d = Da/n for all fractions, thus the average of the daily dose d derived from
conventional dose accumulation.
In order to retrieve the mathematically correct total survival fraction, it is necessary
to calculate the biological effect of each fraction dose prior to accumulation.
The effect of a single fraction dose di is given by equation 2.12. When accumulating
the effects of multiple fractions (i=1...n), then the accumulated effect is given by









A visualization of the two approaches to estimate the final SF of the treatment are
depicted in figure 3.4, following up figure 2.5 of the conventional dose accumulation
workflow. The workflow principles follow the same path until after the transforma-
tion from DIR is applied to the forward calculated daily doses (the steps until this
point are discussed in section 3.1.1). Thus, both approaches build up on the same
transformation and use the same deformed doses di.
Comparing SF(d), called the dose accumulation approach representing the conven-
tional workflow, with SF(di), the effect accumulation approach postulated in this
work, the difference between both is given solely for the β-term. In other words: by
performing dose accumulation, the amount of cell kill due to the radiation of previ-
ous fractions is not adequately taken into account and for all following fractions, the
accumulation of any further fractions is based on a wrong number for cell survival.
Using Jensen’s inequality for a convex function [33], both approaches can be directly








where λi is a non-negative parameter with
∑n
i=1 λi = 1. This is given when using λ
as a normalizer for the number of fractions n, so that all λi = 1/n. The definition
of the effect is given by the expression within the exponential of the LQM, which
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Figure 3.4. – The dose accumulation and effect accumulation workflows in comparison, following
up on figure 2.5.
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This can be rearranged to:
αDa + βnd











Comparing to equations 3.1 and 3.2, the above expression directly compares the
survival fractions resulting from either the dose or the effect accumulation approach.
It can be seen that when using conventional dose accumulation, the survival fraction
of the total treatment is systematically overestimated:
SF(d) > SF(di) (3.7)
Going back to figure 3.3, indeed the delivery of equal fraction doses (as assumed
when using the conventional dose accumulation approach) will always lead to a
higher survival rate than any delivery of varying doses with the same total dose.
This might become especially important for normal tissues, since the survival rate
after dose accumulation is assumed to be higher than what is actually predicted by
the biological model. Therefore, this work will focus on the impact of the inaccuracy
in biological effect estimation in normal tissue.
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3.1.3 The total biological dose bEQD
For interpretation and clinical applications, the SF is an inconvenient quantity. Thus,
following up on the previous chapter the question is, what would be the total dose
delivered to the tissue that represents the mathematically correct cell survival frac-
tion of the treatment? With the estimate of a total dose that consistently considers
the LQM, common comparisons of dose constraints and prescription doses for the
total dose of the treatment can be based on a biologically consistent workflow.
In order to answer this question, the total achieved biological effect needs to be
conserved in the conversion process. For this purpose, the concept of the equivalent
dose (described in section 2.2.2.2) was adapted to convert from a treatment of con-
stant dose d, to a treatment with varying fraction doses di while being biologically
isoeffective (instead of conversion between fractionation schemes). For this, the esti-
mates of the fraction doses di are used, to find a total dose that results in the same
biological outcome.






Here, the total biological dose (bEQD) is the total dose of a treatment with constant
fraction doses d that results in the total biological effect Ed. This effect is now to
be equal to the total effect after application of the effect accumulation approach

















To resolve the question for bEQD, Ed and Edi have to be equal, so that the total









This total biological dose bEQD is an alternative to conventional dose accumulation
(Da) that is in contrast in accordance with the underlying biological model by tak-
ing into account the varying fraction doses as well as the tissue radiosensitivity. In
the following work, bEQD will be compared to the conventionally accumulated dose
Da. For a direct comparison, the constant fraction dose d in equation 3.10 is set
to be the same as the mean fraction dose of the treatment, given by: d = Da/n.
This way, the difference between both parameters will directly reflect the systematic
inaccuracy caused by the method of conventional dose accumulation in contrast to
effect accumulation.
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A visualization of the principle of the bEQD embedded in the workflows described
above can be seen in figure 3.5, following up on figures 2.5 and 3.4. As for the effect
accumulation approach, it uses the deformed doses di. Applying the LQM on the
total biological dose will result in the same SF as given by the effect accumulation
approach (note that the change in number of fractions needs to be taken into ac-
count).
Comparing bEQD and Da can be performed analogously to the above derivation
of the difference between the effect from dose accumulation and effect accumulation
using Jensen’s inequality (equation 3.3). From this, it follows that the total biolog-
ical dose bEQD is systematically higher than the conventionally accumulated dose
Da:
bEQD > Da (3.11)
which is in accordance to the fact that the effect accumulation approach results in
a systematically lower SF (equations 3.6 and 3.7).
Figure 3.5. – Illustration of the effect accumulation workflow (top) in comparison with the biolog-
ically equivalent bEQD workflow (bottom row), following up on figure 3.4.
Uncertainties from dose mapping are also inherited by the bEQD. The uncertainty
of bEQD with respect to the uncertainties in the respective di and with constant
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3.1.4 Summary: the biological workflow
Figure 3.6 summarizes the complete biologically consistent workflow aspects of dose
mapping and accumulation, derived in this work. For correct dose mapping, com-
putation should be based on the dose, instead of energy (to be biologically correct)
nor the mapping of the SF directly (to reduce uncertainties). For the accumulation,
however, computations need to be based on the SF directly by following the effect
accumulation approach to derive the mathematically correct survival fraction; or by
calculation of the total biological dose bEQD.
Within this work, biologically consistent dose mapping is treated as an already given
requirement. This is because common applications, like the ones used here, are im-
plemented in a way to conserve the gray value of the voxel, given as dose in case
dose distributions are being mapped. Thus, the common approach of dose mapping
is implemented in a dose-conserving manner, though these implementation were not
based on biological considerations. A change in this concept was recently postulated
and is being used more commonly by now. However, in this work, a conclusion was
assessed on a biological level and it was derived that the commonly used approach
needs to be utilized, instead of changing it to energy-conservation. Therefore, the
following chapters do not focus on the dose mapping aspect but on the dose accumu-
lation approaches of bEQD and Da. In contrast to dose mapping, the application of
conventional dose accumulation is commonly performed in the described biologically
systematically wrong manner. The magnitude of the deviation between bEQD and
Da is the focus of this work in theoretical analysis as well as in patient data. The
impact of different aspects of effect accumulation (e.g. fractionation scheme, α/β,
uncertainty assessment) were analysed in detail as well as statistical a assessment of
the total dose deviation and dose-toxicity correlation based on bEQD.
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Figure 3.6. – Summary of the biologically consistent dose accumulation using either the effect
accumulation approach or bEQD. In the first part of the data-post-processing, dose mapping,
computations should be based on dose (not energy). For accumulation, computations have to take
into account the non-linear relation of dose to the biological effect.
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3.2 data & workflows
This section describes the tools and data used for analysis in this work. Systematic
investigations were based on a theoretical analysis of the dependency between dose
variation magnitude and its impact on the different dose accumulation strategies
(total biological dose (bEQD) and Da), described in section 3.2.1. An overview of
the used patient data is given in section 3.2.2. Sections 3.2.3 and 3.2.4 describe
the analysed patient cohorts and the details on how the methodologies presented in
section 3.1 are implemented for the respective workflows along with all tools and
methods used in this process.
3.2.1 Theoretical analysis
The first part of investigation of biological dose accumulation was performed on a
theoretical fictional voxel undergoing certain magnitudes of daily dose variations
(as also submitted for publication [58]). This analysis was performed to be able to
conclude on the magnitude of impact from effect accumulation and bEQD in com-
parison to conventional dose accumulation to assess resulting difference magnitudes
and focus points of further investigations. All computations were performed in Ra.
Results on the theoretical analysis are presented in section 4.1.
The simulated fractionation scheme was chosen analogously to the used German
Cancer Research Center (DKFZ) patient data (see next section 3.2.3): standard
fractionation of 76.5 Gy in 2.25 Gy per fraction; moderate hypofractionation with
63 Gy in 3.0 Gy per fraction (equivalent dose to 75.9 Gy with an α/β-value of 1.4
Gy). Four different scenarios were chosen: a voxel in a high and in a medium dose
region, for standard and for hypofractionation, respectively, giving the following fic-
tional voxel mean doses: standard high = 2.25 Gy x 34 fractions, standard medium:
1.5 Gy x 34 fraction, hypo high: 3.0 Gy x 21 fractions, hypo medium: 2.25 Gy x 21
fractions. The investigations focused on the dependencies of the deviation between
bEQD and Da (see section 3.1.3) on the magnitude of dose variations, the assigned
α/β-value, mean dose and the fractionation scheme. Fractional voxel doses were
chosen manually to guarantee the desired mean dose and dose variation magnitude.
The dose variation magnitudes, given as the standard deviation are chosen to be
0%, 12.5%, 25% and 50% with respect to the mean dose, where bEQD with 0% dose
standard variation is equal to the conventionally accumulated dose Da.
aR Development Core Team (2008). R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, http://www.
R-project.org. It is used in this work for statistical computation and generation of graphics
and plots. Version 3.3.1 was utilized, scripts were written using RStudio Version 0.99.903.
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3.2.2 Patient data overview
Three different patient cohorts are investigated: two cohorts of patients treated for
prostate carcinoma (one acquired at DKFZ, one acquired for the VoxTox programme,
Cambridge, UK) and one dataset of patients treated for head and neck (H&N) can-
cers (VoxTox programme). While the DKFZ pelvis cohort and VoxTox H&N cohort
were given as three-dimensional (3D) data, for the VoxTox rectum data, dose surface
map (DSM) of the rectum alone were available and analysed. An overview of the
used cohorts and their focus within this work is shown in table 3.1 along with the
data source. The main focus is set on the pelvic data. The pelvic region is prone
to sudden and undirected motion caused by gas in the intestine that can potentially
impair the planned dose distribution significantly.
Each cohort is used in this work to focus on specific aspects in the investigations
of biological dose accumulation. The DKFZ pelvis data (section 3.2.3) was used for
an in-depth analysis of the used strategies and workflows for the individual cases:
detailed comparison to planned dose (γ-index analysis, dose-volume analysis, com-
parison to current dose-constraint recommendations), treatment schemes (normal
vs. hypofractionation), uncertainties (deformable image registration (DIR), α/β-
value and interpolation) and volumetric analysis (local vs. dose-volume histogram
(DVH), whole organ volumes vs. organ walls). The VoxTox rectum cohort (section
3.2.4) constitutes a larger dataset and was therefore used to conclude on statistical
outcome. Based on the rare toxicity data available from this cohort, dose-toxicity
correlation was performed in comparison to published analysis on this data that was
using conventional dose accumulation. The VoxTox H&N data (section 3.2.4) were
used to compare the results from the pelvis region with another body site show-
ing different motion patterns. It also serves for comparison between daily imaging
strategies.
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Table 3.1. – Overview of the analysed patient data cohorts and their focus in this work. 1: DKFZ,
Heidelberg. Ethics approval S-380/2017 by the Ethics Committee of the Medical Faculty of Hei-
delberg, Germany; 2: Cambridge University Hospital NHS Foundation Trust, UK, Ethics approval
East of England - Essex Health Research Committee (13/EE). Intensity-modulated radiotherapy
(IMRT); computed tomography (CT); mega voltage computed tomography (MVCT)
Cohort DKFZ pelvis VoxTox Rectum VoxTox H&N
Site Prostate carcinoma Prostate carcinoma Various H&Ncancers
Data












modality In-room kV-CT MVCT MVCT
Treatment














local vs. volume: 4.2.3;
diff. to plan: 4.2.4;
uncertainties - DIR, α/β,
interpolation: 4.2.5




3.2.3 The DKFZ data and workflow
An overview of all workflow steps and acquired results is given in figure 3.7. The
results from the ”DKFZ pelvis” cohort are presented in section 4.2.
The investigation on biologically consistent dose accumulation with the DKFZ pelvis
cohort were based on data from a clinical study by Bostel et al. [8] (Ethics approval
S-380/2017 by the Ethics Committee of the Medical Faculty of Heidelberg). The
data had been acquired previous to this work. Within this thesis, the post-processing
of the data for conventional and biological dose accumulation was set up, in parts
in a collaboration with the department of Medical Image Computing at DKFZ,
described below. Additional analysis regarding fractionation, volumetric analysis
and uncertainties was performed.
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Figure 3.7. – Workflow followed for data acquisition, post-processing and analysis with the DKFZ
pelvis cohort. Boxes framed black represent data in the reference geometry of the planning CT.
Boxes framed yellow are final results that are being presented in the results section 4.2.
Patient cohort ”DKFZ pelvis” The cohort analysed in this work consists of
nine patient cases that were treated for prostate carcinoma at DKFZ. Acquisition of
the data was done prior to this work for analysis of the daily delivered dose and focus
on re-treatment strategies. A first analysis of this cohort was recently published by
Bostel et al. [8]. In cooperation with the clinicians in charge of the study, the
patient data were retrospectively used for analysis of biological dose accumulation
in this work. The study was approved by the Independent Ethics Committee of the
Medical Faculty of the University of Heidelberg, Germany (S-380/2017).
Patients were scored with intermediate-risk prostate cancer stage T1c to T2b. 6 MV
IMRT step-and-shoot treatment (background see section 2.1.2) was performed with 9
coplanar fields (Art́ıste linear accelerator, Siemens, Erlangen, Germany). Treatment
plans were created using the RayStationb treatment planning system (TPS). The
Clinical Target Volume (CTV) was defined by the prostate gland with an additional
7 mm margin for the Planning Target Volume (PTV). For standard fractionation,
bThe RayStation® is a treatment planning system by RaySearch Laboratories (Stockholm, Swe-
den). Version 6.1.1.2 was utilized for computations in this work.
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a prescription dose of 76.5 Gy was chosen, delivered in 34 fractions of 2.25 Gy.
Three of the nine patients were treated for the prostatic fossa after surgery with 34
fractions of 2 Gy. Dose constraints followed the Quantitative Analyses of Normal
Tissue Effects in the Clinic (QUANTEC) recommendations [51].
Data acquisition Daily CT-imaging with an in-room CT scanner (Primatom;
Siemens OCS, Malvern, USA) was performed in diagnostic quality in treatment
position prior to each treatment session (background on imaging can be found in
section 2.1.3). The CT-scanner itself is approved for treatment planning scans.
For each fraction, the target and organ(s) at risks (OARs) were delineated by board-
certified radiation oncologists. For analysis of the dose to the OARs, the whole
organs of bladder and rectum was used in the standard workflow. Further analysis
for this work was performed for the bladder and rectum walls. Based on the former
delineated organs, the organ wall contours were created in an approximate manner
by an isotropic subtraction of a 3 mm smaller organ delineation to obtain organ wall
contours (performed in RayStation).
Computation of the daily deformed doses For computation of the treatment
plan as well as forward calculated of the daily doses (see section 2.1.1), the CT scans
were imported in the RayStation TPS. An in-house Hounsfield look-up table (HLUT)
(DKFZ-HLUT) was used for dose calculations on the basis of CT Hounsfield Units
(HU) (see also section 2.1.1).
The RayStation TPS was used to perform all basic computations on the acquired
data to compute the daily deformed doses di and the conventionally accumulated
dose Da. The following steps were performed after data acquisition during patient
treatment: dose forward calculation on the basis of the daily image using the dose
plan, DIR, dose deformation and dose summation.
For DIR, the hybrid intensity and structure based option was chosen which is based
on the ANACONDA (anatomically constrained deformation algorithm) algorithm
[77]. The algorithm is both intensity-based and additionally geometry-based by the
organ contours (region of interests (ROIs)) in the target and moving image (called
controlling ROIs). The objective function to this algorithm consists of four metrics
in a linear combination that is to be minimized: image similarity (measured with a
correlation coefficient), smoothness of the grid (grid regularization), a shape based
regularization and a penalty term (the latter two referring to the controlling ROIs
in the images). Background information on DIR can be found in section 2.2.1.3.
For all patients and fractions, the contours of the bladder, the rectum and the PTV
were selected as controlling ROIs. DIR was performed with the planning CT as the
target image which is then used as basis for dose accumulation (reference frame).
Computation of α/β-maps Both variations to compute the total biological
effect ((cell) survival fraction (SF)) require the underlying information of the α/β-
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value of the individual tissues. For this, α/β-maps were created based on the delin-
eated organ structures in the reference frame of the planning CT. From the contours
contained in the structure-sets, binary maps for the individual organs were created
using the in-house developed VoxelizerTool, an implementation in the RTToolbox
[88]. In this tool, voxels within the delineated contour are assigned a value of 1,
while everything else is set to 0. The binary organ maps were then imported into
3D Slicerc and by using the built-in Python framework, α/β-maps were created
containing the values for the CTV, bladder and rectum as well as all other tissue in
one map in the geometry of the reference frame.
Table 3.2. – α/β-values used for the
respective tissues for computation of
SF(d), SF(di) and bEQD, based on lit-
erature reported values (section 2.2.2.1).
Bold: clinical standard values
CTV 1.4, 10
rectum 2, 3, 4, 5
bladder 5, 10
all else 3
Since the α/β-values of the individual organs
show a range of uncertainty, the impact of this
uncertainty is studied for the result of the to-
tal biological effect and the total biological dose.
This was done by assigning a range of different
values to the tissues based on reported ranges in
literature. Details on the α/β-value and litera-
ture references can be found in section 2.2.2.1.
For the ROIs used in this work, the range of
studied values is shown in table 3.2. Clinical
standard valuesd shown in bold are used as standard values assigned in all cases
expect for analysis with focus on α/β-variation. α was set to the constant value of
0.1 Gy−1 and the variation in α/β was achieved by only changing β. To study the
dependency on α, results were also compared to those given from α = 0.2 Gy−1
with the same α/β ratios.
Accumulation Conventional dose accumulation was performed in the RaySta-
tion system. Da and the individual di were exported from the RayStation anonymized
for further processing. Calculation of the total survival fraction from conventional
dose accumulation and from effect accumulation were performed using the AVIDe
framework. Within this work, the AVID framework was extended to calculate the
survival fractions from the two respective approaches as described in section 3.1.2.
The biological effect based on the accumulated dose Da is using equation 3.1. The
total effect from effect accumulation based on the individual di is obtained using
equation 3.2. The required data were: the deformed doses di as output from the
RayStation and the computed α/β-maps.
c3D Slicer: an open source software platform for medical image informatics, image processing,
and three-dimensional visualization. Version 4.5.0-1 was used [22] along with the SlicerRT
extension Version 0.17.1.; https://www.slicer.org/
dpersonal communication with PD Dr. Juliane Hörner-Rieber, radiation oncologist at the Uni-
versity Hospital Heidelberg
eAVID: Analysis of Variations in Interfractional RaDiotherapy. An automated software frame-
work to allow handling of large datasets, in-house development at DKFZ.
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bEQD as described in section 3.1.3 was computed using the same di and α/β-maps.
Calculations of bEQD were performed in R. bEQD was then compared to the con-
ventionally accumulated dose Da as output from the RayStation.
Hypofractionation The same patient cohort was used to restrospectively cal-
culate hypofractionated treatment plans. Two hypofractionation strategies were
chosenf. First, the in-house standard approach for moderate hypofractionation was
used, given by 3 Gy per fraction. Using an α/β-value of 1.4 Gy for the prostate
(to be consistent with further analysis), the standard equivalent dose in 2 Gy frac-
tions (EQD2)-based conversion was performed (section 2.2.2.2). This resulted in a
treatment scheme of 21 fractions of 3 Gy (total dose 63 Gy, equivalent to 75.9 Gy).
For patients treated for the prostatic fossa, 21 fractions of 2.7 Gy were chosen. For
strong hypofractionation, a number of five treatment fractions was fixed. Using the
same conversion principle, this resulted in a treatment scheme of 6.8 Gy per fraction
(6.1 Gy for the fossa) over five fractions, giving a total of 34 Gy (equivalent to 76.4
Gy).
Dose-volume histograms (DVH):
In a cumulative DVH, all voxels that re-
ceive at least a certain dose x correspond
the according percentage volume on the











For example, the point on the DVH-curve
at an x-value of 50 Gy represents the vol-
ume including all voxels that received at
least 50 Gy. This point would be re-
ferred to as V50Gy. Analogously, D95%
describes the dose to 95 % of the volume.
D95% therefore describes the dose cover-
age of the structure while D5% describes
the high dose areas within the volume. It
should be noted that spatial information
is lost in the computation of a DVH and
all dose-volume parameters are reduced to
a volumetric summary.
Hypofractionated plans were calcu-
lated by rescaling of the initial stan-
dard fractionated dose plans, per-
formed in R. Dose constraints to the
OARs were converted according to
EQD2 with the respective α/β val-
ues. For all plans, the desired con-
straints were fulfilled after rescal-
ing. Rescaling of the dose for fur-
ther analysis was performed on the
deformed doses D − i after export
from the RayStation.
In order to simulate realistic treat-
ment conditions, the first 5 and
21 fractions, respectively, for each
patient were rescaled and anal-
ysed. Optimization of new treat-
ment plans with hypofractionation
doses was not performed since this
would potentially impair compara-
bility of the results, as will be dis-
cussed later. The workflow and
analysis using the rescaled deformed
doses was performed analogously to the described standard workflow.
fafter personal communication with PD Dr. Juliane Hörner-Rieber, radiation oncologist at the
University Hospital Heidelberg
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Analysis The survival fraction after dose and effect accumulation were compared
as the absolute and relative cell survival differences. Analogously, the absolute dose
difference between bEQD and Da was analysed. The differences were investigated
on a voxel-scale. All computations were performed in R. Visualization of the results
was realized using MITKg
γ-index analysis: This method was
initially described by Winiecki et al. [79].
It analyses dose difference as well as spatial
displacement between two points, usually
given for a voxel in a reference frame
compared with another dose distribution.










with the distance between the analysed
points given by |~rc,~rm|, the dose differ-
ence by |D(~rc) − D(~rm)| and DTA (dis-
tance to agreement) and ∆D (dose differ-
ence) representing scaling factors chosen as
the ∆D/DTA criterion. The final γ(~rc)-
value is given by the minimum of γ(~rc,~rm).
The γ-criterion is passed for values below
1. In common practice, a γ-passing rate is
reported, represented by the percentage of
volume with γ < 1. Clinical standard for a
passed γ-analysis is a γ-passing rate of 95%.
In addition to this local analysis,
Dose-volume-histograms and dose-
volume (DV)-parameters were com-
pared between planned dose, con-
ventionally accumulated and biolog-
ically accumulated dose. Cumula-
tive dose-volume histograms were
created in R (see box for more infor-
mation on DVHs). DV-parameters
were computed: for the CTV the
D2%, D5%, D95% and D98%; for
bladder and rectum the V30Gy-
V75Gy (standard fractionation). For
moderate and strong hypofraction-
ation, the respective VxGy were
converted using the EQD2 with
α/β = 5 Gy for the bladder
and α/β = 3 Gy for the rec-
tum. Dose constraints for bladder
[75] and rectum [51], given by the
QUANTEC reports, were analysed
for the planned and the accumulate
doses. These constraints were also
converted to hypofractionation for
comparison but it should be noted
that these are not recommended for use. The analysis was based on the organ vol-
umes defined by the contours in the reference frame. Additionally, the analysis of
the whole organ volumes of bladder and rectum were compared with the dose values
to bladder- and rectal-wall alone.
Parts of the results are presented in the form of Boxplots which show: the median
dose as the central thick line, the interquartile ranges given by the coloured box,
the minimum/maximum values ±1.5 times the interquartile range as error bars and
outliers as circles. Boxplots were created in R.
Comparison of bEQD and Da with the planned dose, respectively, was performed in
a γ-Index analysis (see box for more information). Passing rates for a 3%/3 mm
gMITK: The Medical Imaging Interaction Toolkit. An open source software for medical image
processing [62]; Version: ITK 4.7.1, VTK 6.2.0, QT 5.4.1. www.mitk.org.
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criterion were investigated. A lower dose cutoff threshold was set to 10%. γ-analysis
was performed in 3DSlicer using the SlicerRT extension. Plots for visualization were
created in MITK. In contrast to the standard process, the analysis was adjusted in
two ways: 1) Usually, the analysis is given for the entire imaged volume of the pa-
tient. Hot spots of a failed γ-criterion in smaller volumes can be hidden in the large
analysed volume. Therefore, the γ-analysis was performed for the individual OARs
of bladder and rectum in this work. 2) The γ-value does not report on the direction
in which the dose in the compared voxels differ. While for OARs, lower doses than
planned are advantageous, a γ-value above 1 can be obtained which reduces the
passing rate nevertheless. Therefore, in this work for all voxels with lower delivered
than planned dose in the OARs, the γ-value was multiplied by −1. All voxels with
γ < 1, including negative values are rated as passed.
DIR Uncertainties The analysis of uncertainties in conventional and biological
dose accumulation inherited from uncertainties in DIR was performed in two ways:
(I) In section 3.1.3, it is described how errors from DIR propagate mathematically
to Da and bEQD respectively. Since a direct quantification of errors in DIR is a not
yet solved problem, as described in detail in section 2.2.1.3, a simplified approach
was tested. A 3 mm error in DIR was assumed to each single voxel in the image.
The value was chosen according to reported values in literature [3]. Within this 3
mm distance from each voxel, the highest dose difference to the center voxel was
computed. This represents a worst case estimate for an error in the mapped voxel
dose. This value was then used in the calculation of the respective uncertainties of
Da and bEQD as described before. Calculations were performed in R.
(II) A direct comparison of the outcome of biological dose accumulation for different
registration algorithms was performed. For this purpose, DIR and dose mapping was
integrated into the above mentioned AVID workflow using the plastimatchh DIR
algorithm. The demons as well as the b-spline algorithms were used, respectively.
The registrations are based on a three- and four-staged parameter file, respectively
that can be found in the appendices B. No further guidance of the registration was
performed (no landmarks or structure contours guidance).
Interpolation of dose values for dose mapping was based on trilinear interpolation.
Background on DIR and interpolation is described in sections 2.2.1.3 and 2.2.1.4.
For comparison, the sub-voxelization interpolation method by Rosu et al. [64] was
investigated which is implemented in the AVID framework. Additional data required
for the computation in AVID were the planning CT, the daily CTs and the forward
calculated doses that are to be deformed. The results for Da and bEQD were
compared to those following the standard RayStation based workflow.
hplastimatch: an open source software for image computation with focus on image registration,
Version 1.6.4. www.plastimatch.org
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3.2.4 The VoxTox programme
The VoxTox programme was initiated to test the hypothesis ”that delivered dose
provides a better predictor of toxicity than planned dose” [13] by Neil Burnet and
colleagues at the University of Cambridge (Cambridge University Hospital NHS
Foundation Trust, UK, Ethics approval East of England - Essex Health Research
Committee (13/EE)). Daily MVCT scans within the TomoTherapy unit used for
treatment were acquired for the purpose of patient positioning guidance in the stan-
dard treatment workflow. These daily acquired scans were then used within the
VoxTox programme to calculate the delivered dose of the day, perform conventional
dose accumulation and correlate the result to the collected patient-reported toxicity.
The objective of the collaboration project was to implement the derived biological
dose accumulation (as described in section 3.1.3) within the workflow pipeline of
the VoxTox programme for both pelvis DSM analysis and H&N cases. Statisti-
cal conclusions on the magnitude of difference between conventional and biological
dose accumulation were aimed for. The impact of biological dose accumulation in
comparison with conventional dose accumulation and planned dose in dose-toxicity
correlation for the rectum was investigated.
Based on the large amount of data, one objective of VoxTox programme was to fa-
cilitate an automated workflow of data post processing for the correlation of dose to
treatment outcome. Implementation and automation of steps included data transfer,
auto-contouring (of the rectum), dose re-calculation on the MVCTs, conventional
dose accumulation and dose-volume reporting, including automated control of the
entirely pipeline.
The acquired data had three main advantages compared with the DKFZ cohort
described above: a much larger number of cases is available; data exist for two dif-
ferent entities: prostate and H&N radiotherapy (RT); toxicity reports are available
(minimum of 2 years follow up time, 4 year median for prostate cases). Together
with the colleagues from Cambridge, a cooperation was initiated within this work
to exploit the potential of this highly valuable dataset also for purposes of biological
dose accumulation.
Patient cohort ”VoxTox rectum” The cohort used for analysis in this work
comprised of 251 prostate cancer cases from the study consolidation cohort for which
daily dose data in the form of dose-surface maps (DSMs) was made available. A
previous study by Shelley et al. [70] was based on 109 cases as a discovery cohort
(different cohort) and more details on the data and the post-processing workflow can
be found in the given publication. The workflow steps and choice of investigated dose
measures was based on this work in order to compare the results of the bEQD analy-
sis to the existing conclusions. Patients were treated with TomoTherapy (see section
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2.1.2) in either 37 fractions with a total dose of 74 Gy (136/251) or with moderate
hypofractionation of 20 fraction with a total dose 60 Gy (115/251)i. For analysis of
the hypofractionated cases, the dose was rescaled to the equivalent of 37 fractions
with the standard biologically effective dose (BED) approach (see section 2.2.2.2).
Table 3.3. – Available rectum toxicity data analysed in
this work. G1 and G2 refer to grade 1 and grade 2 toxicity





proctitis (G1) 17.7 136
proctitis (G2) 13.2 136
rectal bleeding (G1) 33.1 136
rectal bleeding (G2) 11.8 136
bowel bother (G4) 39.1 138
Daily imaging was performed
using MVCT. Calculation of
the daily doses followed a Cam-
bridge in-house developed ray-
tracing algorithm [72] (more in-
formation on dose calculation is
given in the background section
2.1.1). The contours of the rec-
tum were generated automati-
cally (due to the large amount
of data) on all daily MVCT
scans and manually on the plan-
ning CT scans. MVCT scans
did not cover the same volume in all fractions but were sometimes shifted towards
head or feet direction. Follow-up toxicity data were not available for all 251 cases
for all endpoints. An overview of the available toxicity data and incidence rates is
given in table 3.3. The total biological dose (bEQD) approach was implemented into
the VoxTox workflow to compare the results for the conventionally and the biolog-
ically accumulated doses. The workflow was implemented in Matlabj. Figure 3.8
illustrates the workflow and where it was complimented for purpose of this work.
The provided workflow contained the following: automated segmentation of the
rectum contours; generation of dose-surface maps (dose surface maps (DSMs)) of
the rectal wall along with conventional dose accumulation; extraction of dosimetric
features. DSM generation was based on algorithms described in literature by
Buettner et al. [12] and Murray et al. [55]. A DSM is a two-dimensional unfolding
of a structure, in this case the rectum, considered as a cylinder. For this, the rectum
wall was virtually cut on the posterior side of the center of mass and represented
as a two-dimensional (2D)-image. The height is in this case defined by the num-
ber of slices (3 mm thickness on the planning DSM and 6 mm on the daily mega
voltage computed tomography (MVCT) DSMs) and the width was scaled to equal
the height. Daily MVCT scans were restricted in length (number of slices) and did
not necessarily match the planning DSM height. In these cases, missing data were
substituted with planned DSM data. As a dose summarizing measure, the equiv-
alent uniform dose (EUD) was calculated for the planned and both accumulated
dose versions with a = 11.11 (assuming a serial-type structure of the rectum, see
iRecruitment details for the used data from the CHHiP trial can be found here: https:
//www.icr.ac.uk/our-research/centres-and-collaborations/centres-at-the-icr/
clinical-trials-and-statistics-unit/clinical-trials/chhip
jMatlab: Release R2016a, The MathWorks, Inc., Natick, Massachusetts, United States
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Figure 3.8. – Workflow of the analysis of the VoxTox rectum DSM data. Blue boxes show workflow
and data provided by the VoxTox group, green boxes indicate complimentary steps added for bEQD
analysis within this work. For calculation of the bEQD, α/β-values of 2 Gy, 3 Gy and 4 Gy were
used for the rectum, analogously to the investigations for the DKFZ pelvis cohort, and results were
compared respectively. 3D data from prostate TomoTherapy (planning CT and daily MVCTs) was
used. MVCT rectum contours were generated automatically. Daily DSMs were used to generate
the accumulated DSM dose Da and additionally the code was adapted to calculate the bEQD on
the same basis. No image registration was performed to map the images on a voxel scale, this is
solely based on the contouring of the rectal wall on the daily scans. The equivalent uniform dose
(EUD) and dose widths were computed for all DSMs. Results were analysed statistically and using
receiver operator characteristics (ROC) analysis to investigate correlations of dose to toxicity.
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equation 2.15 and details in section 2.2.2.2). Furthermore, the ’dose-width’ was
fitted to the DSMs based on the method reported by Buettner et al. [12]. For this,
an ellipsoidal-fit was performed based on a certain iso-dose line. Dose data were
therefore transformed to binary maps for certain dose thresholds and an ellipse was
fitted to the largest central cluster. The maximum lateral extend relative to the
total DSM width of certain iso-dose levels was used as the respective dose-width.
The dose-width was calculated for iso-dose levels of 30, 40, 50, 60, 65 and 70 Gy.
ROC curve analysis: The Receiver operator
characteristics (ROC) curve was calculated to de-
termine correlations between dose and treatment
outcome. The ROC curve itself is a measure
for separability between classes. Here, the two
classes being compared are the ones reporting the
certain toxicity, and the ones without. The ROC
curve is plotted as sensitivity vs. 1-specificity.
The sensitivity is a synonym for ”true positive
rate” given by: true positives / (true positives
+ false negatives). 1-specificity is given by the
false positive rate: false positive / (true negative
+ false positive).
The measure reported to quantify magnitude of
correlation is the area under the curve (AUC),
which is given as a number between 0 and 1. For
an AUC of 0.5, the correlation of input and out-
put is deemed to be purely by chance, thus, there
is no correlation. AUC values differing by greater
or lesser amounts from 0.5 can provide stronger
of weaker evidence for correlation.
The VoxTox rectum DSM co-
hort allowed for statistical
conclusions on the impact
of biological dose accumulation
due to the 251 analysed pa-
tient cases in contrast to the
low number of cases from the
German Cancer Research Cen-
ter (DKFZ) pelvis cohort. As
described above in section 3.1.3,
the difference between bEQD
and Da is systematic and both
accumulated doses built up on
the same daily deformed dose
data. Therefore, statistical
tests for significant difference
between these results is neither
valid nor expedient. The com-
parison between both methods
was thus done by descriptive
statistics of dose measures com-
puted in R.
Correlation of rectum toxicity to delivered dose (Da and bEQD) was done by
performing a ROC-curve analysis. The result of this is to assess whether individ-
ual dose-volume parameters can be predictors for different reported toxicities. This
analysis was performed for comparability to the already published results from this
VoxTox cohort by Shelley et al. [70]. The analysis was performed in SigmaPlotk.
Patient cohort ”VoxTox H&N” Within this thesis, the investigation of the
head and neck (H&N) cases serve the purpose of comparing results in the pelvis
region to another body site to be able to estimate the impact of biological dose accu-
kSigmaPlot is a scientific data analysis and statistics software (Version 12.0), Systat Software,
Inc., San Jose California USA, www.systatsoftware.com.
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mulation in radiotherapy (RT) in a more generalized way. Additionally, the dataset
enabled investigations of three-dimensional (3D) data, like for the DKFZ data, but
using different applications in the workflow. Therefore, this section is not part of
the central analysis of this work but for complimentary analysis and conclusions.
For the H&N cohort, about 200 cases where available that were treated for various
cancer sites in the head and neck region. However, for more detailed analysis, the
focus of investigations was put to dose to brainstem and spinal cord. As will be
discussed later (section 5.2), this is because of the rather serial than parallel nature
of these organs for which the bEQD is more relevant. Therefore, a test sub-cohort
of patients with dose plans that might indicate increased doses in the respective
regions was studied, resulting in 26 cases for investigation (6 cases of potentially
increased brainstem dose, 23 cases for spinal cord).
The workflow followed for dose accumulation in the H&N data is essentially the
same as presented in section 2.2.1.2 for conventional dose accumulation and de-
scribed above for the DKFZ cohort. Patients were treated with TomoTherapy and
underwent daily image-guidance. In comparison with the methods described for the
DKFZ workflow, main differences were: a) the used modality for daily imaging and
b) the registration algorithm. For a), MVCT imaging was used on a daily basis to
estimate the daily delivered doses. As described for the DSM data, dimensions of the
MVCT were restricted in length (number of slices) compared with the planning scan
and might have varied from day to day. Due to the use of MVCT, dose-recalculation
on the daily images was required using the same algorithms as described above [72].
For b), the used image registration algorithm is based on the Elastixl software pack-
age [38][69]. Within the Elastix implementation, mutual information between the
moving and fixed image are maximized, using stochastic gradient descent methods.
A first affine registration was followed by a cubic-bspline transform (background
on deformable image registration (DIR) see section 2.2.1.3). More details in the
appendix B.
The provided workflow pipeline worked on the already deformed daily doses (DIR
+ interpolation) and using the manually generated organ structure sets containing
the contours. The data post processing pipeline within the VoxTox programme was
set up in Python. The provided dose accumulation pipeline was complimented by
integrating the effect accumulation and bEQD formalism for this work. The as-
signed α/β values for the respective tissues were: spinal cord - 2 Gy, parotids - 3
Gy, brainstem - 2.5 Gy, brain - 2.5 Gy, Clinical Target Volume (CTV) - 10 Gy, all
else - 3 Gy ([34] and values as used within the clinical workflows of the VoxTox pro-
gramme). Analysis was performed on the 3D data and for volumetric parameters of
the structures of interest using the organ contours.





R E S U LT S
This chapter is organised by the analysed data: theoretical fictional voxel analysis
(section 4.1), the DKFZ pelvis cohort (section 4.2), the VoxTox rectum dose surface
map (DSM) cohort (section 4.3) and the VoxTox head and neck (H&N) cohort
(section 4.4). An overview of the data can be found in the materials & methods
chapter in table 3.1. The results are partially submitted for publication as indicated
in the respective sections [58].
4.1 theoretical predictions
The results as presented in this section are partially submitted for publication [58].
The impact of the dose per fraction and the assigned α/β value on the survival
fraction is shown in figure 4.1 for a fictional voxel receiving conventional and hy-
pofractionated irradiation dose with different daily dose variation magnitudes. It
can be seen that the absolute (cell) survival fraction (SF) decreases strongly for
lower α/β. Lines that correspond to a higher underlying α and β but for the same
ratio α/β show lower SF . The differently dotted lines indicate the impact of the
fractional dose variation as the dose standard deviation (std). The higher the dose
variation magnitude, the lower the survival fraction according to the effect accu-
mulation approach. For the conventional dose accumulation approach, there is no
difference since only the mean dose is considered (d = Da/n), which is the same in
all cases. The absolute difference between the effect accumulation approach SF(di)
and the conventional approach SF(d) is higher for higher α/β, while the relative
difference increases strongly for lower α/β. For 12.5% std, the relative SF difference
is low (below 10% difference) for α/β above 3 Gy, but can reach values up to 20%
for α/β below 3 Gy. At 25% std, these values already increase to 20-80% and even
higher for 50% std where the relative difference can reach 100%. In case of hypofrac-
tionation (figure 4.1, right side), the SF curve is steeper and tissue with higher α/β
is less affected (note the different axis but that at 1.4 Gy, both curves show the same
SF). However, the relative SF difference is very similar and only slightly increased
compared with the standard fractionation case.
Figure 4.2 shows the results on total biological dose (bEQD) for the analysis of
the same fictional voxel calculations as above. The emphasis here is put more onto
the impact of the delivered dose and fractionation scheme involved. Again, three
dependencies of bEQD can be seen: bEQD changing with the dose variation magni-
tude, given as the dose standard deviation (std), the underlying α/β-value and the
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Figure 4.1. – Theoretical analysis of the SF based on the effect accumulation approach SF(di)
(Eq. 3.10) (top row) and the relative SF difference to conventional accumulation (SF(d), Eq.2.9),
bottom row, for a fictional voxel receiving standard (left) or hypofractionated (right) irradiation
with different magnitudes of dose variation. Both fractionation schemes are biologically equivalent
at 1.4 Gy (equivalent dose in 2 Gy fractions (EQD2) -based conversion, section 2.2.2.2). The dose
variation magnitude is given as the standard deviation of the fractional doses di in percent with
respect to the mean dose d. Note that the SF(di) with std(di) = 0% is the same as SF(d). Light
green curves are calculated with α = 0.05 Gy−1, dark green curves with α = 0.1 Gy−1.
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fractionation scheme (number of fractions and the mean delivered dose d). The dif-
ference to the base line referring to a std of 0%, so that bEQD andDa are equivalent,
visualizes the total dose difference between both approaches. The difference between
Figure 4.2. – Biologically accumulated dose bEQD for a fictional voxel receiving standard (left) or
hypofractionated (right) irradiation with different magnitudes of dose variation. The dose variation
magnitude is given as the standard deviation of the fractional doses di in percent with respect to
the mean dose d. Note that bEQD with std(di) = 0% equals Da. Black curves represent the voxel
in the respective high dose regions of 2.25 Gy (34 fractions) and 3.0 Gy (21 fractions) that are
biologically equivalent at 1.4 Gy (EQD2 -based conversion, section 2.2.2.2). Blue lines represent
voxels in the respective fractionated treatment in a medium dose regime of 1.5 Gy or 2.25 Gy.
Numbers in the plot are given to show dose difference to the 0 % dose variation case (Da). For
less than 12.5 % dose variation, the difference remains below 1 Gy.
bEQD and Da strongly depends on the dose variation magnitude. At a standard
deviation below 12.5% of the mean physical dose, the difference between bEQD and
Da remains below 1 Gy. For high dose variation magnitudes of 50% with respect to
the mean physical dose, the difference between the two accumulation methods can
reach values of up to 12.9 Gy.
It can also be seen that the lower the α/β-value used in bEQD, the higher the differ-
ence between bEQD and Da. For example the highest impact in the given example
can be seen for a standard fractionated treatment in the high dose regime with the
highest dose variation magnitude where the difference of bEQD (α/β = 1 Gy) to
bEQD (α/β = 10 Gy) is 9.5 Gy. This dependency induces an uncertainty in the
calculation of bEQD based on the uncertainty of the α/β-value which is analysed
in the patient data results.
The curves in figure 4.2 show that for the same number of fractions, the higher
the mean dose, the higher the difference between bEQD and Da. Generally, the
absolute differences are higher for the standard fractionated case. This is because
the difference between Da and bEQD accumulates over the course of treatment and
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scales with the total delivered dose. Furthermore, it also scales with the dose per
fraction d. Therefore, the difference between Da and bEQD relative to the total
delivered dose is higher for the hypofractionated case for the respective high and low
dose regimes (e.g. 2.25 Gy x 34 fractions compared with 3.0 Gy x 21 fractions).
4.2 cohort dkfz pelvis
The results for the DKFZ pelvis cohort show the analysis of three-dimensional (3D)
data sets. Details on data and acquisition are given in section 3.2.2. Parts of the
results as presented in this section are submitted for publication [58] and further
complimented with additional details and analyses.
The first part of the analysis in section 4.2.1 focusses on the deviations found in
the 3D data for the SF and total dose between conventional and biologically consis-
tent accumulation. The impact of the choice of the fractionation scheme (standard
fractionation, moderate and strong hypofraction) on the difference between both
methods to accumulate the total delivered dose is shown in section 4.2.2. Section
4.2.3 investigates the dose to volume relation, given by condensing the 3D results
into commonly used dose-volume parameters as well as by analysing the dose to
organ walls (bladder and rectum) rather than total organs. A comparison of bEQD
and Da to the planned dose is shown in section 4.2.4. Finally, section 4.2.5 shows
the results for uncertainty assessment in the accumulation process from deformable
image registration, the assigned α/β values and the use of different interpolation
algorithms.
4.2.1 Survival fraction and total dose difference in 3D data
Figure 4.3 shows the results of the comparison of the survival fraction from the
dose and the effect accumulation approach for the nine analysed patient cases. As
shown theoretically, the SF from effect accumulation is systematically lower than
the results after conventional dose accumulation. Largest deviation were found in
all cases in the gradient regions around the target. The magnitude is between 35 -
40% in 6/9 cases and reaches 50.7% for case 6) in a distinct hot spot. Areas of SF
deviation are mainly located in the organ(s) at risk (OAR) in bladder and rectum
and the space between those, while within the Clinical Target Volume (CTV), the
difference remains marginal.
The analysis of the nine patient cases analysed with respect to their bEQD-Da
difference are shown in figure 4.4. As shown theoretically, bEQD is systematically
higher than Da. In all cases, larger areas with pronounced deviations in total dose
between bEQD and Da were found in the dose gradient regions around the target
volume with values around 1-3 Gy, analogously to the SF difference. More distinct
deviation hot spots could be found for 6 out of 9 patients within the bladder and
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Figure 4.3. – Relative SF difference as calculated from the dose accumulation approach SF(d)
and the effect accumulation approach SF(di). Presented as (SF(d) − SF(di))/SF(d) in [%] for the
nine analysed patient cases calculated with α = 0.1 1/Gy for all tissues and an α/β-map with
CTV = 1.4 Gy, rectum = 3 Gy, bladder = 5 Gy, all other tissue = 3 Gy, assigned by changing
the according β value. As mathematically predicted, SF(di) was systematically lower than SF(d).
Each picture shows the sagittal slice with the highest SF deviation of the respective patient. Cases
1)-6) represent patients treated for prostate carcinoma with the whole prostate marked as CTV ;
cases 7) - 9) show cases of the prostatic fossa with a slightly lower prescription dose of 2.0 instead
of 2.25 Gy per fraction. All cases were treated and imaged for 34 fractions. For seven of the nine
cases (except cases 4) and 7)), deviations were 34.8 – 50.7 % in distinct hot spots with maximum
difference of 50.7% in case 6). Only case 4) showed deviations below 18% in the entire volume.
the rectum with maximum deviations around 3.3 – 4.9 Gy in regions of high motion
amplitudes. The maximum difference was given in case 6 with 4.9 Gy. For only one
patient (case 4), the deviations were below 1.4 Gy in the entire monitored volume. A
region of repetitive high deviation amplitude could be found for all patients between
the delineated organs above the apex of the CTV, often coinciding with the rectal
and bladder wall.
Naturally, total SF deviation hot spots shown in figure 4.3 coincided with hot spots of
total dose difference shown in figure 4.4. Both figures are qualitatively very similar
with only little differences. The magnitudes of these deviations depended on the
total dose delivered in the respective voxel along with the dose variation magnitude.
Table 4.1 summarizes the maximum deviations for both the SF approaches and
the dose accumulation approaches. It can be seen that both magnitudes scale very
similarly from 0 - 5 Gy and from 0 - 50%, respectively. Areas of higher deviation
are a little broader for the SF comparison.
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Figure 4.4. – Total dose deviation of the biologically accumulated dose and the conventionally
accumulated dose: bEQD – Da [Gy], same cases and slices as shown in figure 4.3. As mathemati-
cally predicted, bEQD was systematically higher than Da. For six of the nine cases (1), 3), 5), 6),
8), 9)), deviations were 3.3 – 4.9 Gy in distinct hot spots with maximum difference of 4.9 Gy in
case 6). Only case 4) showed deviations below 1.4 Gy in the entire volume.
Table 4.1. – Maximum deviations between the effect and the dose based methods: SF: (SF(d) −
SF(di))/SF(d) in [%]; dose: bEQD−Da [Gy], for the 9 cases shown in figures 4.3 and 4.4.
case: 1 2 3 4 5 6 7 8 9
SF [%]: 36.5 39.4 35.3 17.9 35.8 50.7 26.5 34.8 35.2
dose [Gy] : 3.3 2.5 3.9 1.4 3.4 4.9 2.2 3.5 3.4
4.2.2 The impact of fractionation schemes
Figure 4.5 gives an overview of all 9 patient cases for all 3 fractionation schemes for
the analysed total dose difference. Difference magnitudes strongly increased when
increasing the dose per fraction while lowering the number of fractions. Highest
differences were found for strong hypofractionation in 5 fractions where 7 of 9 cases
show difference hot spots above 4.3 Gy with a maximum of 8.4 Gy (case 9). The
difference was above 8 Gy in 3 cases. Highest difference hot spot for the 21-fraction
scheme was 6.8 Gy for case 6) with 5 cases showing difference hot spots above 5
Gy. For comparison, at 34 fractions (see section 4.2.1) the maximum hot spot was
at 4.9 Gy. Hot spot areas are broader for the 21-fraction scheme in 7 cases and
decreasing in size but for most cases increasing in magnitude, when reducing the
fraction number to 5. In one case, the magnitude of difference decreased when going
from 34 to 21 fractions and for two cases when going from 21 to 5 fractions.
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Figure 4.5. – Total dose de-
viation (bEQD – Da [Gy])
for the nine analysed patient
cases (same as in figure 4.4)
using different fractionation
schemes: 34 fractions of 2.25
Gy / 2.0 Gy as used for treat-
ment, 21 fractions of 3.0 Gy
/ 2.7 Gy (moderate hypofrac-
tionation), 5 fractions of 6.8
Gy / 6.1 Gy (strong hypofrac-
tionation). The lower 3 cases
show patients treated for the
prostate fossa. Schemes were
converted using the standard
EQD formalism with prostate
α/β = 1.4 Gy to be biolog-
ically equivalent. Note that
the dose difference color scal-
ing is different to previous
figures (0 – 8 Gy). Differ-
ences were generally increas-
ing when going to higher
fraction doses for the ma-
jority of cases as predicted
in figure 4.2. Differences
were highest for 7/9 cases
for strong hypofractionation
(above 4.3 Gy) with a maxi-
mum of 8.4 Gy (case 9). At 21
fractions, case 6) showed the
highest difference hot spot
with 6.8 Gy.
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4.2.3 Local vs. volumetric analysis
DVH analysis Dose comparison using dose-volume histograms (DVHs) revealed
only small differences between the two accumulation methods for standard fraction-
ation although distinctive hot spots of increased total dose difference are visible for
all patient cases in the 3D data (figure 4.4). The DVHs of cases 3) and 9) are shown
in figure 4.6. For case 3), in comparison to figure 4.4, the distinct hot spot within
the volume of the rectum is visible as only a slight difference in the DVH of the
rectum. There is no difference of Da and bEQD for the bladder or the CTV , al-
though for the bladder there was a higher difference to the planned dose. The visible
difference between the DVH curves of Da and bEQD for the rectum were similar to
the depicted case 3) for two other cases, while 6 cases showed lower difference. For
Figure 4.6. – Cumulative DVHs of case 3) and 9) (see figures 4.4, 4.5 and 4.8), showing the planned
dose, Da and bEQD for the three investigated fractionation schemes. For case 3) the distinct hot
spot difference between bEQD and Da is visible only as a small difference in the curves for the
rectum in the DVH in the mid dose region, while no clear difference can be seen for CTV and
bladder. Black arrow: dose regime where bEQD increases the overdosage between planned and
delivered dose further, as also shown by the black arrow in figure 4.8. Blue arrow: The increase in
the delivered dose calculation by bEQD is still below the planned dose (seen also figure 4.8). For
case 9) the strong difference hot spot in the rectum is also visible as a stronger difference in the
DVH for hypofractionation with 5 fractions (fx).
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hypofractionation, differences were slightly more distinct for case 3) based on the
overall higher difference reported in the previous section. For case 9), the difference
hot spot in the rectum for strong hypofractionation also shows a stronger difference
in the DVH . The DVHs for the bladder showed generally lower differences between
the two accumulation methods than those for the rectum. For both bladder and
rectum, there was a distinct difference to the planned dose, similar to the depicted
case in a total of three cases while the other 6 cases showed only small differences.
For all cases, the dose coverage of the tumour was similar as in the depicted DVH.
More information and analysis on the difference between planned and delivered dose
is given in the next section.
DVH metrics An overview of the comparison of dose-volume (DV) parameter as
the difference of these as DV(bEQD) - DV(Da) for all patients is given in figure 4.7
(standard fractionation) for: D2%, D5%, D95%, D98% of the tumour (CTV ), V30Gy
- V75Gy for bladder and rectum, and mean dose and equivalent uniform dose (EUD)
for all. The results are shown for the entire organs of bladder and rectum, as well
as for bladder and rectal wall.
The systematic difference between bEQD and Da can also be seen for all dose
metrics. The median difference (thick black line) is however close to 0 in all cases,
while the range differs. Generally, the organs walls of bladder and rectum showed
lower differences compared with results for the whole organs.
For both bladder and rectum the difference in mean dose is around 0.2 to 0.3 Gy
(median) with a range of about 1 Gy. The EUD is lower in comparison, only around
0.1 Gy difference, along with a smaller range of about 0.2 - 0.3 Gy. For the bladder,
all VxGy metrics show differences below 0.5% volume, decreasing with increasing
dose threshold, with the exception of a few outliers, along with a small range of
0.5%. These are slightly higher for the rectum where the median is round 0.5%.
V50Gy shows a higher range compared with the other metrics of about 1.5%. The
difference is increasing for the mid dose range and decreasing again for higher dose
thresholds. The CTV shows generally very low differences below 0.2 Gy for mean
dose and EUD and below 1 Gy for D98% and D95%. The difference in D5% and D2%
is negligible.
Generally, the differences in the DV-metrics were increased for moderate and strong
hypofractionation. The analogue figures to 4.7 can be found in appendix B, figures
B.1 and B.2. The above described trends can be seen analogously for the other
fractionation schemes: for the bladder, the VxGy-differences are decreasing with
increasing dose threshold. For the rectum, the mid dose regimes show the highest
differences with a median close to 1% for moderate and strong hypofractionation,
with a range of ±2%. In one case, a difference of 7% in V21Gy for the rectum in
strong hypofractionation was found and 4% for the bladder in V23Gy. More details
will be given in section 4.2.4 for comparison to the planned dose.
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Figure 4.7. – Comparison of DV parameters for standard fractionation as the difference between
DV(bEQD) and DV(Da) of the structures of interest of bladder, bladder wall, rectum, rectal wall
and tumour (CTV ) for various dose metrics. A comparison to the planned dose will be given in
figure 4.9 for the same dose metrics. The results for hypofractionation can be found in appendix
B.
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4.2.4 Comparison to the planned dose
Gamma-analysis In the Gamma-analysis for the 3mm/3% criterion, the passing
rate was lowered for all cases and all volumes when using bEQD instead of Da by
an average of 1.0% for the bladder and 1.6% for the rectum with a maximum of
3.0%. The passing rate was below 95% for the rectum in all cases and in 5/9 cases
for the bladder. The gamma analysis is shown for three cases in figure 4.8. The
main influence of bEQD compared with Da was pronounced as an increase of the
γ value in regions of already failed γ criterion, as shown for the maximum values
in figure 4.8 (red). The deviation hotspots between bEQD and Da coincided with
increased γ values in regions of already failed γ criterion (γ > 1), indicating a more
severe deviation to the plan than calculated with Da (black arrows) in four cases in
the bladder volume and in five cases in the rectum volume. However, regions of high
deviation between bEQD and Da (figure 4.8 left) did not necessarily coincide with
overdosed regions (red) in the γ analysis (figure 4.8 right). For example, in case
3) the strongest total dose deviation hot spot coincided with an underdosed region
(blue in γ analysis), effectively only lowering the magnitude of the underdosage (blue
arrows) but not adding to the failing rate. A similar scenario is observed in a total
of two bladder and two rectum volumes.
DVH metrics Figure 4.9 shows the same dose volume metrics for standard frac-
tionation as before in the comparison between both accumulation schemes, now for
the comparison to those derived from the planned dose (for both bEQD and Da).
The same analysis for hypofraction can be found in appendix B in figures B.3 and
B.4. More information and analysis on the difference between planned and delivered
dose for conventional dose accumulation can be found in a preceding study [8]. The
median difference to the planned dose is close to 0 Gy in all cases. The range shows
much higher magnitudes than the difference between both accumulation strategies.
For the majority of cases, it can be seen that the computed dose metrics for the
organ walls are smaller than that of the entire organs. This can either mean that
they are closer to 0 Gy difference to the planned dose or show a higher negative
difference.
The range of difference is around 10 - 12 Gy for the bladder for the mean dose and
the EUD . While the mean dose is mostly higher for the accumulated results than
the planned dose, the EUD is very close to or lower than planned. For the VxGy
dose-volume metrics of the bladder, the ranges generally tend to shift towards neg-
ative values for higher dose thresholds, especially for the bladder wall. The ranges
are higher for the whole bladder (12 - 22% absolute range) than the bladder wall (8
- 12 % absolute range).
For the rectum, difference of the mean dose for the whole organ is at 1.5 Gy (median)
but shifted towards 0 Gy (median) when only considering the rectum wall. The EUD
varies uniformly around 0 Gy difference to the plan. For the VxGy metrics, the range
and median are similar for all with an increase in outliers in both directions towards
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Figure 4.8. – γ-analysis for three cases (3, 8 and 9). Left: bEQD −Da as depicted in figure 4.4.
Center and right: γ-analysis of the conventional accumulated dose (Da, center) and the biological
dose (bEQD, right) compared to the planned dose Dp, respectively (for standard fractionated
treatment). Percent γ passing rates for a 3 mm/3% criterion for bladder and rectum are given.
Failed γ-criterion is marked in orange and red colors and separated by a black line. Black arrows
highlight regions of failed γ-criterion, enhanced in the case of using bEQD compared with Da.
These regions coincide with total dose deviation hot spots shown on the left. Blue arrows in case
3) show an area where the total dose deviation hotspot coincided with a negative γ-value region,
thus increasing γ (less negative) without changing the passing rate outcome.
higher dose thresholds. Again, the difference between whole organ and organ wall is
more pronounced than for the bladder. This is also true for the difference between
bEQD and Da. In comparison to the bladder results, for the mid dose thresholds
deviations between the bEQD and Da based differences can be seen.
The CTV dose difference range of the mean dose is limited to ±1 Gy and a lit-
tle more towards negative values for the EUD. The range of the investigated Dx
is strongly decreasing for the metrics of low volume (referring to the highest dose
regions), while those for large volumes (referring to dose homogeneity) show abso-
lute ranges of about 10%. D98% was lower by 1 Gy (median) for Da and bEQD
compared with the planned dose.
Especially for the rectum, the impact of the fractionation scheme in the difference
to the planned dose was clearly visible. As a summary of figures 4.9, B.3 and B.4,
figure 4.10 shows the DV-difference between the accumulation methods as well as
the difference of the respective DV to the planned dose for the rectum for all fraction-
ation schemes. It can be seen that the median as well as range of DV-difference is
increasing for hypofractionation. It needs to be noted that based on the conversion,
the high dose thresholds for hypofractionation are already above the CTV planning
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Figure 4.9. – Comparison of DV parameters as the difference between either DV(bEQD) or
DV(Da) to DV(Dplan), respectively. Shown for the structures of interest of bladder(B), bladder
wall (BW), rectum (R), rectal wall (RW) and tumour (CTV ) for various dose metrics. The absolute
difference between the same parameters derived from bEQD and Da is furthermore shown in figure
4.7.
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Figure 4.10. – Overview of the DV-analysis in the rectum for all investigated fractionation schemes.
Top row: absolute difference in the respective DV-metric between bEQD and Da. Bottom row:
respective difference to the planned dose. Complementing figures 4.7 and 4.9.
dose. The bottom row depicts the respective differences to the planned dose. As
can be seen, this is especially increased for strong hypofractionation. Furthermore,
an increasing difference between bEQD and Da can be observed, especially for the
median dose differences.
For an evaluation of the derived total doses with current dose constraint recommen-
dations found in the Quantitative Analyses of Normal Tissue Effects in the Clinic
(QUANTEC) reports, figure 4.11 shows the planned dose, bEQD and Da for all
cases and VxGy metrics along with the recommended constraints. As noted before,
the dose conversion for hypofractionation works in favour of the normal tissues that
are assigned with a higher α/β than the tumour, so that the highest dose threshold
values in normal tissue are above the CTV planned dose. It can be seen, that espe-
cially for the rectum, dose constraints are violated for 1 - 2 cases for the high dose
thresholds. The violation is already given for Da, the effect is slightly increased
in all cases for bEQD. In appendix B, figure B.5, the same results are shown for
V25%, V50%, V75% and V100% (volume receiving x% of the planning dose) for a bet-
ter comparison of the fractionation schemes. As can be seen there, the trends are
equal in all cases but the difference between bEQD and Da is generally increased
for hypofractionation.
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Figure 4.11. – VxGx comparison between planned (Dp), accumulated (Da) and biological accumu-
lation dose (bEQD) with respect to QUANTEC dose constraint recommendation for rectum and
bladder. The respective VxGy and dose constraints were converted for hypofractionation according
to the EQD2 approach.
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4.2.5 Uncertainty assessment
Worst case DIR error estimation Image registration is required in order to
perform either strategy of dose accumulation (bEQD and Da). The impact of a
faulty registration on the daily dose was estimated as the highest dose difference
to that of each respective voxel within a 3 mm distance. This daily dose error
was propagated to Da (eq. 2.10) and bEQD (eq. 3.12), respectively. Figure 4.12
depicts the resulting error estimation for cases 1-3). Generally it can be seen that the
magnitude of uncertainty is higher for ∆bEQD than ∆Da. Furthermore, the volume
showing differences above 1 Gy is higher for the dose mapping error estimation than
the difference between the two dose accumulation methods (left). In the analysis of
all patients, ∆bEQD showed maximum values around 9 Gy while the maximum of
∆Da was at 5 Gy. Uncertainties are located in the gradient regions resulting from
the neighbouring voxel deviation estimation. The magnitude of ∆Da is similar to
that of (bEQD − Da), while that for ∆bEQD is higher. Regions of highest dose
mapping error estimations coincide for ∆Da and ∆bEQD but do not coincide with
strongest hot spots in (bEQD−Da).
Figure 4.12. – Worst case dose mapping error estimation for cases 1-3). A 3 mm deformable image
registration (DIR) registration is assumed for each voxel, the maximum dose difference within that
range to the voxel of interest is calculated as the error. Error propagation on bEQD and Da
is calculated, respectively. Left - Total dose difference bEQD − Da as shown in figure 4.4 for
comparison; center - ∆Da, eq. 2.10; right - ∆bEQD, eq. 3.12.
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Different DIR implementations For the main analysis of this work, registra-
tion was performed in the RayStation system which uses the ANACONDA algo-
rithm and is guided by the structure contours. For comparison, plastimatch was
used within the AVID workflow, either based on the b-splines or the demons algo-
rithm, respectively, but without landmark or contour guidance. For information
on DIR algorithms, see section 2.2.1.3. Figure 4.13 shows the results of the total
dose difference bEQD −Da based on the three different DIR approaches for three
example cases. As can be seen, the results differ substantially, especially for the b-
spline-based registration. The magnitude of difference is similar for the RayStation
and the demons based DIR with larger volumes of high difference in the RayStation
examples. The b-spline-based results show both higher difference magnitude and
larger volumes of higher difference. In all cases, high differences are located mainly
in the dose gradient regions.
Figure 4.13. – Example comparison of cases 1-3) for the total dose difference bEQD−Da [Gy] for
three different underlying DIR implementations: left - RayStation ANACONDA algorithm; center
- plastimatch using b-splines; right - plastimacth using demons. Note that the scale is changed
compared with previous figures. Case 1) is highlighted in detail in figure 4.14.
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For case 1), b-spline DIR , the difference within the CTV is unexpectedly high.
Therefore, this case was investigated in more detail in figure 4.14. Here, the total
dose differences are again shown in the upper row for the demons- and the b-spline-
based results along with the planning computed tomography (CT), which serves as
the reference frame (fixed image). For the example fraction CTs, it can be seen that
both the bladder and the rectum volume increased. While the bladder volume is
similar in all fraction CTs, the rectal volume is especially increased in fractions 1 and
22. The mapped CTs show in all cases that the bladder volume was not correctly
mapped in the upper region. B-splines shows generally large deformations while
those for the demons algorithm are small. In fractions 1 and 22, b-splines shows
that the grid is folding in on itself. This can also be seen on the right periphery of
the demons registration which is folding in voxels from outside the dose field. In
fraction 22, the b-splines algorithm clearly failed to find an anatomically plausible
deformation field, resulting in the fact that the CTV dose was entirely mapped
out of the CTV contours, which results in the deviation in this area in the total
dose difference. For fraction 21, both the b-spline and the demons algorithm show
anatomically realistic deformations on the deformaed CTs and qualitative assessment
of the DIR would not reveal any substantial differences. Nevertheless, the two
resulting mapped dose distributions are substantially different in the bladder and
upper rectum volume.
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Figure 4.14. – Three ex-
ample fractions of registered
CT and mapped dose of
case 1), using b-splines and
demons registration, respec-
tively. Top left: planning
CT and contours for refer-
ence; Top center and right:
Total dose difference bEQD−
Da (as shown in figure 4.13),
as the result of the below
shown DIR-based dose map-
ping for b-splines and demons
registration, respectively. Be-
low - Left: fraction CTs and
contours along with the for-
ward calculated doses. Cen-
ter: b-spline registration re-
sults for the mapped CTs
(deformation grid correspond-
ing to deformed voxels of the
fixed image that are being
pulled back to the regular
grid, thus enclosing the imag-
ing/dose values they ”pull
back”, structures show the
reference structures of the
planning CT), along with
the resulting mapped doses.
Right: results from demons
registration, same as for cen-
ter. The anatomically un-
realistic deformation of frac-
tion 22, b-splines, is the rea-
son for the unexpected to-
tal dose difference within the
CTV shown in the top row.
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Uncertainties from α/β In contrast to conventional dose accumulation, bio-
logical dose accumulation depends additionally on the assigned α/β-values of the
respective tissues. Generally, as reported above, the lower the α/β-value of the
tissue, the higher is bEQD. Since α/β-values for tissues suffer from an uncertainty
of their own, this will be passed on to the uncertainty in the calculation of bEQD.
Based on the range of recommended values in literature (see table 3.2 materials &
methods section 3.2.3), bEQD was calculated for the patient cases with different
underlying α/β-maps. As an example, figure 4.15 shows the impact of changes
Figure 4.15. – Impact on bEQD of assigning different underlying α/β values to the respective
structures according to ranges of recommendations in literature. Analysis shown for case 3), sepa-
rately for the respective structures in comparison to the reference results in the upper left.
in α/β-values for case 3) for the individual structures. Highest difference between
bEQD computed with different α/β-maps coincided with regions of highest differ-
ences to Da. Changing the α/β-value for the rectum from 3 to 4 Gy resulted in
a maximum decrease of 0.6 Gy (0.2 – 1.3 Gy) in bEQD averaged over all patients.
Lowering α/β from 3 to 2 Gy led to a maximum increase in bEQD of on average 1.0
Gy (0.4 – 1.3 Gy). For the bladder, the difference between the lowest recommended
α/β-value of 5 Gy to the highest of 10 Gy resulted in a maximum difference of 0.9
Gy (0.3 – 1.5 Gy) on average. In the CTV, changes were generally lower due to
the overall lower dose variation magnitude. Assigning the standard α/β-value for
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tumours of 10 Gy instead of the more recently promoted low α/β-value of around
1.4 Gy changed bEQD by a maximum of 0.7 Gy (0.0 – 1.7 Gy) on average.
The bEQD solely depends on the ratio α/β, so that the individual values do not
affect the outcome, when looking at the same ratio. This is different for the SF itself.
Figure 4.16 shows the impact of changing the individual α and β, while keeping the
same ratio. It can be seen that the magnitude of absolute dose difference between
the dose and the effect accumulation approach is not affected by the choice of α.
However, the region of high difference is shifted towards the outer dose field for
higher α (figure 4.16, a). The relative SF difference is decreased by approximately a
factor 1/2 for assigning the half as high α values (figure 4.16, b). As for the absolute
difference, the difference in the individual accumulation approaches is similar (figure
4.16, c). The magnitude is high in the regions of low dose (up to 25%) and becomes
very small for higher doses as well as for regions where the dose goes to 0 Gy.
Figure 4.16. – Assessment of the impact of the choice of the individual α and β on the resulting
SF from SF(d) and SF(di), respectively. Example for case 3). a) absolute SF difference between
the dose and the effect accumulation approach, based on either α = 0.11/Gy (used standard) or
α = 0.051/Gy. β was changed accordingly to keep the same ratio of α/β in both. b) relative SF
difference for the same parameters. c) SF difference for the individual SF(di) and SF(d).
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Uncertainties from interpolation As a comparison to standard trilinear in-
terpolation of the dose, the sub-voxelization method of Rosu et al. [64] (see also
section 2.2.1.4) was applied within the AVID framework. Figure 4.17 shows the
results for the difference between both interpolation methods for case 3). The range
of difference is the same for both bEQD and Da. Larger differences can generally
be seen for the demons based registration in this case while the total dose difference
of bEQD −Da was lower than for the b-splines-based DIR in this case. Difference
are not systematic but can be positive or negative in magnitude, ranging between -2
to +4.4 Gy. Highest absolute difference are located in the gradient regions around
the target but also at the beam penumbra.
Figure 4.17. – Comparison of the mapped dose using different underlying interpolation algorithms:
classic trilinear interpolation and the sub-voxelization method introduced by Rosu et al. [64].
Shown for case 3) for both b-splines- and demons-based DIR . Left - Total dose difference bEQD−
Da [Gy] for reference with the same colour scale (same results as in figure 4.13). Center - difference
of the bEQD results between the Rosu-interpolation and trilinear interpolation. Right - Same
difference for Da.
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4.3 cohort voxtox rectum
The VoxTox rectum cohort compliments the above investigation of the German
Cancer Research Center (DKFZ) pelvis cohort by i) local dose analysis based on
DSMs of the rectal wall; ii) allowing for statistical conclusions based on the much
higher number of 251 cases (section 4.3.1); iii) dose-toxicity correlation based on the
available patient-reported outcome data (section 4.3.2).
Since the data and workflow was made available through a cooperation with the
VoxTox group in Cambridge, UK, the bEQD approach was implemented into the
existing workflow. Investigation of the individual workflow steps, as done for the
DKFZ pelvis cohort, was not feasible within this work.
4.3.1 Total dose deviations on DSM
The results of the dose calculated on the rectum surface as DSMs were computed for
conventional dose accumulation Da and biological dose accumulation bEQD, analo-
gously to the analysis of the DKFZ pelvis cohort. Figure 4.18 a) shows the difference
bEQD−Da for the maximum and the mean dose deviation for all 251 investigated
cases. bEQD was calculated with different underlying α/β values to investigate the
impact on the total dose deviation. The systematic deviation between bEQD and
Da was also confirmed for this cohort, with bEQD being systematically higher than
Da. The magnitude of maximum dose difference ranges from 0 - 3.3 Gy with the ma-
jority of cases below 1.5 Gy. For the mean dose difference, values reach a maximum
of 0.3 Gy with the majority of cases below 0.15 Gy. A trend can be observed that for
higher maximum dose difference, the mean dose difference is higher as well. As was
also shown theoretically and for the DKFZ data, the lower the α/β, the higher the
dose difference (highest difference for the calculations based on α/β = 2 Gy). Using
the same α/β of 3 Gy as for the DKFZ pelvis cohort, magnitudes decreased to 2.5
Gy (max. difference) with an average of 0.74 Gy and 0.25 Gy (mean difference) with
an average of 0.08 Gy. Figure 4.18 a) shows the boxplot statistics for this case as
well. For an α/β of 4 Gy, the difference decreased to below 2 Gy (max. difference)
and 0.2 Gy (mean difference).
Figure 4.18 b) shows the same data as in a) as the respective difference to the
planned dose (Dp). For the maximum dose difference, a range from 0 - 37 Gy can
be seen. The mean dose difference ranges from 0 - 3.5 Gy. Again, the impact of the
assigned α/β value can be seen with a generally higher impact on the points located
at higher maximum and mean dose difference. Da and bEQD show systematically
higher mean values than the planned mean dose. In comparison to the difference to
the planned dose, the difference between the accumulation methods is small. Nev-
ertheless, the additional difference to the mean planned dose induced by the use of
bEQD (instead of Da) is clearly visible in figure 4.18 b) and it reaches up to 25 %.
A histogram of the additional shift in mean dose by bEQD compared with Da is
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Figure 4.18. – Overview of the mean and the maximum dose difference in the DSM data between
a) the two accumulation methods as bEQD−Da (boxplots shown for difference with and α/β =
3 Gy) b) the individual Da and bEQD and the planned dose Dp. The results from all 251 patient
cases are shown. bEQD calculation is depicted for different underlying α/β values of the rectum
as indicated by the colours. Highlighted cases 1) and 2) refer to the highest maximum (3.3 Gy)
and highest mean (0.3 Gy) dose difference, respectively, shown in detail in figure 4.20.
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shown in figure 4.19. A peak around an additional 6% can be seen and a substantial
amount of cases above 10%.
Figure 4.19. – Additional mean dose difference relative to
the planned dose induced by the difference in bEQD to Da
in [%].
As an example, the two cases
showing the highest maximum
dose difference (1) 3.3 Gy) and
the highest mean dose differ-
ence(2) 0.3 Gy), respectively,
are visualized in figure 4.20,
as indicated as well in figure
4.18. Mainly, the highest dif-
ferences between both accumu-
lation methods as well as high-
est differences to the planned
dose are located in the periph-
eral superior dose region. Case
1), showing the highest maxi-
mum dose difference, is char-
acterized by the distinct differ-
ence hotspot of about 3.3 Gy,
while in the rest of the area,
the difference remains marginal.
This is similar for the difference to the planned dose. For case 2), which shows the
highest mean dose difference, the area of difference between Da and bEQD above 1
Gy is larger than in case 1) but located as well in the peripheral superior mid dose
regions and again similarly located as highest differences to the planned dose.
In the following, the DSM data were analysed with respect to the work published
on this data by Shelley et al. [70]. Within this prior work, the results on the con-
ventionally accumulated dose were investigated with respect to the planned dose.
The EUD and the dose width was computed on the planned dose and the conven-
tionally accumulated dose for a (different) discovery cohort of 109 patients. Figure
4.21 shows the results acquired in the here presented work for the statistics on dose
width and EUD from the Da as well as bEQD, compared with the planned dose, for
all available 251 cases of the consolidation cohort. It can be seen that the higher
the dose threshold for the dose width fit, the lower the median dose difference to
the planned dose. While this is very close to 0 for a dose threshold of 30 Gy, it
monotonically decreases to - 3 (relative lateral extend) at 70 Gy threshold. Along
with the median dose difference shift, the range of values also tends to lower differ-
ence with increasing dose threshold. The range is generally large between ±12 (50
Gy) to (−35) − 5 (70 Gy). The difference between both accumulation methods is
small in comparison to the difference to the planned dose. However, it can again be
seen also for the dose width that the extent is smaller for Da than for bEQD with a
difference of about 1 - 2. EUD calculated from bEQD and Da was lower than that
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Figure 4.20. – Example cases for DSM of the case showing 1) the highest maximum dose difference
of 3.3 Gy and 2) the highest mean difference of 0.3 Gy, indicated in the overview in figure 4.18, for
α/β = 2 Gy. Note the different scales on the colour bars. Sup: superior, inf: inferior, P: posterior,
lat: lateral, A: anterior. Dp: planned dose.
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Figure 4.21. – DSM Boxplot statistics of the dose metric differences between bEQD- or Da-based
calculation and the planned dose, respectively: dose width fits based on several dose thresholds
from 30 to 70 Gy; and the EUD.
based on the planned dose for the vast majority of cases by about 1 Gy (median)
(note that as shown above, the mean dose was higher for the accumulated doses in
all cases). The results from bEQD and Da are only marginally different with EUD
(Da) lower by about 0.1 Gy. The same dose metrics (EUD and dose width) will be
correlated to the reported toxicity in the next section.
4.3.2 Dose-toxicity correlation
For the correlation of dose to outcome, the above presented dose metrics of the
EUD and the dose width were related to the patient-reported outcome. In section
3.2.4, the endpoints and incidence rates were reported with rectal bleeding grade 2
showing the lowest incidence of 11.8% and the highest for bowel bother grade 4 with
39.1%. For rectal bleeding grade 1, the incidence was strongly increased compared
to grade 2 with an incidence rate of 33.1%. The incidence rates are shown again
in figure 4.22 along with the results of the receiver operator characteristics (ROC)
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analysis for the area under the curve (AUC) .
Figure 4.22. – All AUC results for the investigated endpoints: RB: rectal bleeding; Proc: Proc-
titis; BB: Bowel Bother; G1/2: grade 1/2. Shown for the planned dose Dp, the conventionally
accumulated dose Da and the biologically accumulated dose bEQD. Cases marked with a yellow
star highlight those where AUC for the accumulated doses (bEQD and/or Da) is higher or equal
to that of the planned dose. The green star highlights the case with highest impact of using bEQD.
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Figure 4.23. – Three example ROC curves
for rectal bleeding (RB) G2. a) high AUC
with that of Da and bEQD being higher
than Dp, b) AUC from Dp higher than Da
and bEQD. c) Highest difference in AUC be-
tween bEQD and Da.
For the correlation of dose to toxicity, the
same analysis was performed as reported by
Shelley at al. [70] on a subcohort of the here
used data. In the performed ROC analysis
(see section 3.2.4) generally small differences
between the planned dose and the accumu-
lated doses bEQD and Da can be observed.
An overview of all AUC results for all in-
vestigated endpoints can be seen in figure
4.22 for the planned dose, bEQD and Da.
For the majority of cases, the AUC is close
to 0.6 and shows only very little difference
for the different dose metrics. Only for rec-
tal bleeding grade 2 (RB G2), the AUC re-
sults reach values up to 0.79 with highest
correlation found for the mid to high dose
thresholds between 50 - 65 Gy. Cases for
which the AUC is higher for the Da and/or
bEQD than for the planned dose are high-
lighted with a yellow star. It can be seen
that for the majority of cases, actually the
ROC analysis for the planned dose resulted
in a higher AUC. bEQD and Da showed a
higher correlation mainly for the high dose
thresholds and, for all endpoints except for
proctitis grade 1, for the EUD. Three exam-
ple ROC curves are shown in figure 4.23 for
RB G2, dose widths with a threshold of 55
Gy and of 65 Gy which correspond to curves
of high AUC, as well for 70 Gy, which shows
the highest difference for the bEQD-based re-
sult, but generally lower AUC . There was no
notable difference for the bEQD-based AUC
results when using different underlying α/β
values. Comparing the outcome of the AUC
of bEQD and Da, only very little difference
can be seen which is much smaller than the
already small difference to the AUC from the
planned dose. The strongest difference be-
tween AUC from bEQD and Da is shown
for RB G2 (figure 4.22 and figure 4.23 c))
for a dose width threshold of 70 Gy, where
the difference is at 0.03.
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4.4 cohort voxtox h&n
The VoxTox H&N data analysis investigates the difference between bEQD and Da
in 3D data for a different body site than the up until here analysed pelvis cases.
The data is also part of the VoxTox programme so that the here proposed bEQD
approach was implemented in the already existing workflow to accumulate the total
dose.
In total 26 H&N cases were studied in more detail that were chosen due to an in-
creased risk of overdosage in the brainstem and spinal cord. The brainstem was
contoured in 6 cases, the spinal cord in 23 cases. Left and right parotids as well as
the CTV were also studied which were contoured in all patients.
In general, in the overall imaged patient volumes the observed total dose differences
were smaller than those found in the pelvic region, though the highest deviations
found reached up to 8 Gy locally and even around 5 Gy locally in the spinal cord,
which is higher than for standard fractionation in the pelvis regions. However, high
differences were mostly localized in smaller volumes and in the peripheral superior-
inferior positions of the imaged volume.
Example cases of the planning CT, a fraction mega voltage computed tomography
(MVCT) and the dose difference map are depicted in figure 4.24. For all cases, the
daily MVCT scans imaged smaller volumes than the planning CT scan. In the
superior-inferior position, the location of these scans was not identical on all days.
The difference between both accumulation methods was especially increased in the
superior and posterior regions. Figure 4.25 shows two examples for the difference
Figure 4.24. – Examples of the imaging data for two different H&N cases (planning CT, pCT,
and daily MVCT ) and resulting dose difference location (just qualitatively, with white showing
high difference regions). Main volumes of higher dose differences were located in the superior and
inferior periphery of the imaged volume. Location of the MVCT scans was not identical in all
imaging fractions but shifted towards head or feet direction.
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between bEQD and Da with high differences in the regions of interest. Figure 4.26
shows the boxplot statistics of the volumes that show a dose difference higher than
1 Gy in the respective regions of interest.
Figure 4.25. – Two examples cases of the difference
bEQD−Da in Gy for the investigated VoxTox H&N cases.
For the brainstem, in all 6 cases,
the local dose difference was
higher than 1 Gy, observed in
an average of 22±10% of voxels
of the brainstem volume (me-
dian of 17% with a range from
0-39% in figure 4.26). For case
1) in figure 4.25, a difference of 7
Gy locally within the brainstem
can be seen. In 4 of 6 cases, the
mean dose was higher than 1 Gy
- by 1.6 Gy, 3.2 Gy, 1.5 Gy and
1.5 Gy, respectively.
In 21 of the 23 spinal cord cases,
the local dose difference was
higher than 1 Gy. This magni-
tude was seen in an average of
4.0±1.9% of voxels of the spinal
cord thus very locally. This can
also be seen in the statistics in
figure 4.26 where the range of difference is below 10% with a median of 4%. In both
cases in figure 4.25, local maximum dose differences of 5 Gy can be seen, however
in very small volumes and fast decreasing to a region of difference between 0.5 and
2 Gy. The mean dose of the spinal cord was never higher than 1 Gy. D2% and D5%
were not different in the range of accuracy when comparing bEQD and Da.
Examples of high dose difference in the parotids can also be seen in the examples in
figure 4.25. For 10 and 5 out of 26 cases of the right and left parotids, respectively,
the local difference was higher than 1 Gy. The range was similar in both cases from
0 - 23 Gy. Mean doses were higher than 1 Gy in non of the cases in the parotids.
In the CTV, in 4 of the 26 investigated cases local differences above 1 Gy were
found. Figure 4.25 shows an example of 8 Gy difference. Dose differences, as shown
in figure 4.26 above 1 Gy where found in 5.3, 10.9, 3.5 and 14.9 % of the volumes
for the 4 cases. The mean CTV dose was increased by more than 1 Gy in two cases
by 1.7 Gy and 2.8 Gy, respectively.
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Figure 4.26. – Boxplot statistics of the volume showing a local dose difference above 1 Gy for




D I S C U S S I O N & C O N C L U S I O N
Dose accumulation is getting established in clinical practice to estimate the success
of radiotherapy (RT) treatments. Ultimately, however, it is the biological effect de-
livered in the tissue that needs to guide treatment adaptation and re-treatment and
is the relevant parameter in response estimations. Section 3.1 presented the method-
ological workflow of biological dose accumulation that was derived within this
work to achieve consistency of the links of individual steps to obtain a total biologi-
cal effect estimation.
Two aspects have been isolated and investigated in this work, for which in current
applications and research the biological effect is not adequately addressed or needs
to be questioned:
i) Dose mapping as the basis for the computational accumulation of the total
dose, needs to be implemented in a way to conserve the obtained biological effect
within the tissue, as it is proposed in this work in section 3.1.1. Conventional dose
mapping implementations conserve the gray value of the voxel, so that when map-
ping is performed on the dose distribution, a dose-conserving mapping is applied
automatically. Recent postulations called for conserving the deposited energy in the
mapping process, instead of the dose, in case volumes change in size [90]. In the
here presented analysis of both the energy and the dose conserving approach, it was
found that energy conservation violates the conservation of the obtained biological
effect. It was shown here that conservation of dose is necessary for a biologically
consistent dose mapping. Furthermore, this is independent of the mechanisms and
direction of volume changes in the biological tissue. Remarks on implementation
details are discussed in section 5.2.
ii) Conventional dose accumulation was found to be mathematically inconsistent
with radiobiological models. It was shown that averaging of the daily delivered
doses performed by using conventional dose accumulation introduces a systematic
overestimation of the (cell) survival fraction (SF) and therefore an underestima-
tion of the total dose with respect to the resulting biological effect. To overcome
this inconsistency, the concept of effect accumulation and the total biological dose
(bEQD) was introduced (sections 3.1.2 and 3.1.3). For effect accumulation, the steps
of accumulation and effect prediction need to be interchanged. The concept of the
total biological dose bEQD was derived that represents the total dose which yields
the SF as obtained from the effect accumulation approach. Due to the systematic
overestimation of the SF and the underestimation of the total dose by conventional
dose accumulation, this effect becomes especially important for healthy tissue since
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the radiation-induced effects are stronger than what was expected from the conven-
tional approach. Thus, adaptation might become necessary at an earlier stage in
order to spare the normal tissue; re-treatments would need to be optimized for lower
doses in the organ(s) at risks (OARs); and in dose response-modelling, higher than
expected doses would be correlated to toxicity, and side-effects might occur earlier
than what conventional dose accumulation would suggest. For tumour tissue, on the
other hand, the deviation between the effect- and the dose-based approaches are less
important because of two reasons: as will be discussed later, the deviation between
the approaches scales with the daily dose variation magnitude which is expected to
be small to negligible within the clinical target region; and second, because achiev-
ing a higher cell kill than expected is advantageous for the tumour in contrast to
normal tissue. Therefore, in the following, the analysis focusses on the deviations
found in OARs. The investigation of the magnitude of the differences between the
effect- and the dose-based approaches is the second aim of this thesis based on daily
patient imaging data.
The discussion will continue with a general assessment of the introduced concept
and derived magnitudes in comparison of the results from theory with those in the
individual patient cohorts and with reports in literature in section 5.1. Afterwards,
the individual investigations and workflow aspects are discussed in more detail in
section 5.2. Concluding, the question of whether it is actually advantageous to per-
form biological dose accumulation is discussed based on the combined results and
discussions with a focus on the overall uncertainty budget and possible applications
of the derived approaches (section 5.3). Aspects of the here presented discussion
have been submitted for publication [57] [58].
5.1 concepts, magnitudes and trends
The effect accumulation approach is a simple and straightforward biologically
consistent application of the Linear Quadratic Model (LQM) within the workflow
of dose accumulation (introduced in section 3.1.2). Effect accumulation is based on
the same data as the conventional approach and without any additional computa-
tional cost. In contrast to conventional dose accumulation, however, the value of
the daily dose information does not become degraded in the process of averaging. In
theoretical analysis it was found that, for strong daily dose variations, the relative
SF differences between the effect accumulation approach and effect estimation after
conventional dose accumulation can reach 100% relative SF difference. In patient
data, relative differences around 35% were found in large volumes for the majority
of investigated cases. In a single case, a hot spot of 50% SF difference was observed.
These investigations were based on standard fractionation and found in tissues as-
signed with an α/β between 3 and 5 Gy. As will be discussed in detail in the next
section, even higher deviations are to be expected for hypofractionation and lower
α/β-values.
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For the SF difference, the relative difference was reported while the absolute dif-
ference was studied only theoretically. Two cases have to be distinguished for the
interpretation of absolute and relative differences here: High dose regions and re-
gions of lower dose. In tumour tissue receiving generally high doses, the SF will
already be so low that in good approximation, the SF difference (even when high in
relative terms) will loose its importance since the absolute difference becomes irrele-
vant. The situation might be different when considering normal tissue that receives
generally lower doses in the majority of the volume. Here, the absolute differences
will be higher while the relative difference might be lower. Thus, one needs to keep
in mind that a relative SF difference of e.g. 20% might be irrelevant for tumour
tissue but can be significant in normal tissue. The effect from lower doses is even
more pronounced in the presented analysis since normal tissue was assigned higher
α/β compared with the tumour, resulting in a higher SF for a given dose.
The direct interpretation of the absolute and relative SF numbers (especially for
normal tissues) and linking the quantity of SF to experience on treatment outcome,
might not be common practice. Though dose itself is only linked to the outcome via
models, clinical practice is often based on prescription doses and dose constraints
as outlined in section 2.2.2.2. The derived concept of the total biological dose
bEQD (section 3.1.3) describes the total dose that, when applied in the LQM, re-
sults in the mathematically correct SF as given by the effect accumulation approach.
The concept of bEQD therefore enables the direct comparison of the derived biolog-
ically consistent workflow to current clinical practice of conventional dose accumu-
lation and common dose constraints.
Effect accumulation and bEQD are biologically equivalent. It should be noted that
the correction of the SF in the bEQD concept (compared to the use of Da), as
outlined in this thesis, is due to an increase in the overall dose, while the same
dose per fraction as for the conventional dose accumulation approach d = D/n is
used (to facilitate direct comparison on the same basis of d). Thus, it needs to be
considered in the calculation of the SF using bEQD - SF(bEQD) - that the number
of fractions is increased in the process: nbEQD = bEQD/d > n = Da/d. However,
the calculation of SF(bEQD) is unnecessarily complicated since the straight forward
effect accumulation approach SF(di) can be used instead.
Nevertheless, it might be advantageous for clinical practice to know the biologically
consistent mean dose per fraction, instead of the total biological dose bEQD. Fol-
lowing from the above, the biologically consistent dose per fraction is not given by
bEQD/n but needs to be derived differently since nbEQD is not necessarily given
by an integer number and the delivery of a fraction of a dose is not feasible or well
defined in clinical practice. Analogously to the bEQD approach, the biologically
equivalent dose per fraction db can be derived from SF(di) = SF(db) where
SF(db) uses equation 2.13 with the constant fraction dose db. The result of solving
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Figure 5.1. – Concept comparison: a) Example of the application of the different described
approaches for a scenario where the n = 3 delivered fractions are: d1 = 1Gy, d2 = 2Gy, d3 = 3Gy.
SF(di): effect accumulation approach yielding the correct SF. SF(d): dose accumulation approach
with d = di = 2Gy, resulting in systematically lower SF. SF(db): using the biological fraction
dose in the LQM, n = 3, correct SF. SF(bEQD,nbEQD = 3.25): correct application of the bEQD
concept, the correct survival fraction is achieved by delivering an extra dose on top of the three
fractions, d = 2Gy, correct SF. SF(bEQD,n = 3): wrong application of the bEQD method
by assuming a constant fraction dose of d = bEQD/n, wrong SF. b) Comparison of the total
biological dose bEQD and the biologically equivalent fraction dose db (as the total dose n · db).
Though both result in the same SF (see a), the total dose magnitudes are different. Shown for
different magnitudes of fractional dose variation in % to the mean dose.
db is systematically larger than d, analogously to bEQD being larger than D. db
is the constant fractions dose, that when delivered in the same number of fractions
n as the original treatment, results in the correct SF. On the other hand, bEQD
is the total dose, that when delivered in the same mean dose per fraction d as the
delivered treatment, results again in the correct SF. For an example case, this is
visualized in figure 5.1, a).
In the interpretation of bEQD and db, its needs to be noted that the magnitudes
of bEQD and n · db are not the same (figure 5.1 b)). It was found that the latter
is generally lower but follows the same trends: higher impact for hypofractionation
and lower α/β values. bEQD can generally be interpreted as an increase in the total
number of fractions, as outlined above. For example, in case a dose difference of 3
Gy is found in the rectum-voxel, where the mean dose per fraction was 1.5 Gy, this
would mean that this spot received the biological equivalent of two more fractions
than what was obtained from conventional dose accumulation. The number nbEQD
effectively changes for each single voxel, since the variation of the individual di
is different in all voxels. Furthermore, nbEQD is not necessarily a whole number,
which is a limitation of this approach. On the other hand, the concept of db has
the advantage, that for all voxel, the same number of fractions is equal and the
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same as in the treatment plan. Only the fraction dose db is changed (along with
the total dose n · db). A direct comparison to the actual fractionation scheme
that was delivered is therefore possible. In conclusion, it might be advantageous
to consider db instead of bEQD. This concept should therefore be investigated in
future work. Since lower difference to the conventional dose accumulation are to be
expected than from bEQD, the same systematic deviation trend is still given and
the following conclusions can in principle be also applied for db.
In literature, the topic of effect accumulation has been investigated only very little
in three consecutive papers between 2004 to 2010. Zavgorogni [87] introduced the
concept of the equivalent constant dose (ECD) to investigate the impact of fractional
dose variations on the biologically effective dose (BED) (similar concept as the










α/β)2 + (nσd)2 (5.2)
with n the number of fractions, σd the dose standard deviation and the total dose
D. The ECD represents the total dose that provides the same SF as the given by
the fractional varying doses. In comparison to the here presented approaches, this
approach is identical to the above described concept of the biologically equivalent
fraction dose db and results in the same curves as shown for n · db in figure 5.1 b).
Zavgorodni reformulated the equation to include the dose standard deviation. At
the time, this was advantageous since no daily dose data was available. With the
now available daily doses from imaging and dose mapping, this detour in the com-
putation process is not necessary any more and db provides the same, but straight
forward calculation approach. Zavgorodni only estimated dose variation magnitudes
that were based on setup errors of the patient. Further investigations for a theoret-
ical patient were performed by Bortfeld et al. [7] two years later where the ECD
is used under the name of the normalized total dose (NTD) for varying fraction
doses. Investigations were again only based on dose variations estimated from setup
errors without the use of a voxel-wise daily dose estimation from imaging and reg-
istration. In their conclusion, the impact of the NTD only becomes important for
standard deviations above 10%. The concept and impact of daily dose variations
on a biological basis was only studied in this manner by one other group of authors
in 2010. De Xivry et al. [17] investigated the legitimacy of dose accumulation on
a biological background on the basis of the ECD from Zavgorodni. The concept
was tested for 10 head and neck (H&N) patients that underwent weekly computed
tomography (CT) scans and treated with helical Tomotherapy. A demons based
deformable image registration (DIR) was performed to map the daily forward cal-
culated doses to the planning CT. The results were investigated on the basis of
dose-volume histograms (DVHs). In their conclusion, they found no clinically rele-
vant difference between conventional accumulation and biological accumulation in
the DVH parameters. However, they state that ”Care must be taken if further clin-
ical practices require local rather than global surrogates to adapt treatment”. The
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reported magnitudes are generally lower than the here observed values. This is how-
ever to be expected because of two reasons: as described above, the db approach, in
comparison to bEQD results in generally lower deviations and secondly, within the
H&N region, lower motion amplitudes might be observed, as will also be shown for
the here investigated cohort.
The study presented here compliments the above described literature in multiple
ways: the concept of the bEQD was investigated for daily imaging data, which was
used by none of the above authors; the impact of hypofractionation was investigated;
the analysis was performed locally in addition to volume-based, also on the basis
of dose surface maps (DSMs); the uncertainties of bEQD and Da were investigated
and compared; the investigations focussed on another body site (pelvis) that reg-
ularly shows high motion amplitudes; and the impact on dose-toxicity correlation
was studied. All these individual aspects will be discussed in the next section while
in the following, the found magnitudes of total dose difference will be compared.
It was found that the SF fraction difference can be well described by the total dose
difference in magnitude and extent as shown by comparing figures 4.3 with 4.4 and
table 4.1. Thus, the focus in this thesis was put mainly to the total dose difference
for an easier interpretation of the results as well as comparison of total dose metrics
rather than SF values.
In summary, the effect accumulation approach is a straightforward solution to
facilitate correct accumulation of the cell survival fraction. Therefore, this should be
used instead of effect prediction after conventional dose accumulation. The derived
concept of the total biological dose bEQD provides the total dose that predicts
the same SF as effect accumulation. With this, bEQD facilitates the comparison
of a biologically consistent total treatment doses to the planned dose and dose con-
straints. bEQD is systematically higher than Da, implemented by an increase
in the number of fractions. This deviation makes bEQD especially important for
investigations in normal tissue. For a more clinically applicable approach, the
biologically equivalent dose per fraction db can be used, which conserves the
number of fractions but increases the dose per fractions to be biologically equivalent
to effect accumulation.
Magnitudes of bEQD-Da The theoretical analysis of a fictional voxel under-
going certain dose variations showed generally strong deviations when using the dose
or the effect based approaches for the SF and the total dose. The strongest impact-
ing factor on the difference was given by the daily dose variation magnitude. For
both the SF and the total dose, a dose variation magnitude below 12.5% standard
deviation resulted in very low impact of below 10% relative survival difference and
dose differences below 1 Gy. This is in accordance with the observations by Bortfeld
et al. [7] described above. On the other side, for high dose variation magnitudes,
e.g. 50%, the differences can reach 100% relative SF difference and up to 12.9 Gy
total dose difference. From this, it is to be expected that a strong deviation between
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the two accumulation approaches will only be seen in areas of high organ motion
amplitude located in dose gradient regions. In regions of either little organ motion
or areas of uniform irradiation, none or only small differences are to be expected.
However, the magnitude of SF and total dose difference can reach clinically signifi-
cant orders of magnitude.
The magnitude of SF difference and total dose difference in patient data show
the ranges expected from the theoretical analysis. In all cases, the systematic dif-
ference to the dose-based methods was confirmed. For the nine analysed patient
cases of the German Cancer Research Center (DKFZ) pelvis cohort, the
detected difference hotspots were around 4 Gy in five cases. These differences in-
creased to more than 8 Gy when changing to a strong hypofractionated treatment
scheme. Maximum difference for standard fractionation was at 4.9 Gy, at 6.8 Gy for
moderate hypofractionation and at 8.4 Gy for strong hypofractionation. Highest dif-
ferences were localized around the target volume in the dose gradient regions. The
differences depended most strongly on the location and magnitude of organ motion
and were therefore highly case specific. In comparison to theoretical values, even
higher magnitudes could be expected when organ motion in critical dose gradient
regions increases. As expected, in regions of low motion amplitude or uniform dose
fields (like in the Clinical Target Volume (CTV)), the differences remained marginal.
Most, though not all hot spots of total dose difference were located in the volumes
of the contoured OARs of bladder and rectum. In addition, high dose deviations
were observed between the three organ contours in the regions of the seminal vesi-
cles and neurovascular bundles. The impact on these structures should therefore be
investigated.
For the VoxTox DSM cohort with 251 patient cases and using the same rectum
α/β value of 3 Gy as in the DKFZ cohort, the maximum deviations were 2.5 Gy with
an average of 0.74 Gy and the highest mean dose difference for the entire area was
0.25 Gy with an average of 0.08 Gy. Thus, the observed deviations were generally
smaller than for the DKFZ cohort but in a comparable range for maximum values.
There are several reasons why this magnitude might be lower: i) By only looking
at the dose deviation for the rectum, it is possible that other volumes of high local
dose deviation (as found in bladder and other organs in the DKFZ cohort) were not
considered in the analysis. ii) The analysis of the dose difference for the DSMs was
not based on the use of DIR. The daily contours of the rectum were overlayed with-
out a voxel-wise mapping. In case that daily dose deviations occurred repetitively in
the same region of the rectum, shifts of the entire organ might have washed out this
effect in the analysis. It would be necessary to include DIR in the analysis process
to avoid this strong limitation. Furthermore, the contours on the daily images were
generated automatically, which induced another source of uncertainty. This was,
however, necessary to enable the analysis on the large amount of data. iii) The ob-
served statistical difference might have been induced by different clinical protocols.
The VoxTox cohort was treated with intensity-modulated radiotherapy (IMRT) in a
TomoTherpay unit, while the DKFZ cohort received standard step-and-shoot IMRT.
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It was found in literature that for TomoTherapy and step-and-shoot IMRT, different
degrees of healthy tissue sparing and tumour dose homogeneity could be achieved
(section 2.1.2). Furthermore, for the DKFZ cohort, image guidance was used for
setup error correction on the basis of the target position. For the VoxTox cohort,
daily imaging was used to control the status of the rectal volume and if changes were
too large, remedial action was taken. The different strategies might have had an
impact on the dose delivered to the rectum. In summary, it needs to be concluded
that the dose deviation magnitudes depend on the clinical strategy and data post-
processing. Both cohorts show, however, that the magnitudes can reach clinically
significant values in individual cases, on a local scale. Section 5.2 will further discuss
the outcome of the dose-volume-based results of both cohorts on a statistical basis.
The VoxTox H&N cohort showed cases of both lower and higher dose deviation
magnitudes than in the pelvic region. In the majority of volume, the detected devia-
tions were marginal. However, difference hotspots were detected with highly varying
magnitudes of up to 8 Gy locally. For the brainstem, all 6 cases showed deviations
above 1 Gy locally in large volumes (median of 17% volume). Deviations were much
more localized for the spinal cord with a median volume of 4% showing deviations
above 1 Gy. This is mainly due to the fact that most deviations were localized in
the peripheral region of the images. A reason for this might be uncertainties in the
DIR process. This is due to the fact that the daily mega voltage computed tomog-
raphy (MVCT) scans did not cover the same volume in all cases and were generally
shorter than the planning CT scan. This can enhance the uncertainties in the re-
gions were not all MVCTs overlapped. However, the magnitude of impact of these
uncertainties could not be quantified with the available methods (and can generally
only be estimated, see below for the discussion on DIR). Smaller dose variation
magnitudes might be based on overall smaller motion amplitudes than in the pelvic
region, though, as just concluded before, clinical strategies impact the magnitudes
as well. De Xivry et al. [17] performed ECD-based analysis for H&N cancer patients
and found highest difference up to 2.6 Gy. In comparison, the magnitudes found in
the here presented cohort were higher. De Xivry only analysed the data from weekly
CT scans in contrast to the daily MVCT scans of the here presented cohort, which
might be a reason for the different dose deviation amplitudes. The trend towards
lower magnitude compared to the pelvis data is however in accordance with the
presented findings.
Generally, the comparison to the cases from pelvis and H&N suggest that it is of
interest to perform further investigation with a higher number of cases and different
tumour sites, especially in regions that are expected to show high motion amplitudes
as for example in the thorax and abdomen. The results of the magnitudes from the-
ory further underline that difference between the two dose accumulation principles
depends strongly on the local circumstances and can therefore exceed the highest
here observed dose difference by a factor of two.
While the difference between the two dose accumulation strategies is based on the
magnitude of dose variation from day to day, this does not necessarily coincide with
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larger systematic differences to the planned dose. For example, the patient’s
bladder might have been larger during the planning CT than in any other fraction,
leading to a systematic difference to the planned dose with only little day to day
dose variations. This example is a likely explanation for the presented DVH of case
3) in figure 4.6 where there is very little difference between bEQD and Da for the
bladder but a higher difference to the planned dose. For the rectum, there was
likely a higher magnitude of day to day motion leading to the depicted deviation
hot spot and DVH difference although the total dose was lower than the planned
dose. More discussion on the DVHs will be given in section 5.2. For the VoxTox
cohort, the difference between the planned dose and the accumulated doses (Da and
bEQD) is very high. Generally, for the mean and the maximum dose deviations, the
difference to the planned dose exceeds those between the accumulation strategies
by far. Maximum difference to the plan was at 37 Gy and at 3.5 Gy for the mean
rectum surface dose. Figure 4.18 b) showed however that the difference between
both accumulation strategies has a visible impact on the overall difference to the
planned dose and figure 4.19 showed that the mean dose increase from using bEQD
instead of Da was up to 25% of the mean dose with a peak around 6%.
In summary, the magnitudes of observed total dose and relative SF deviation are in
accordance with theory and match between the three investigated patient cohorts
and with the limited literature reports. The highest deviations are found in dose
gradient regions that coincide with organ motion and therefore especially for
organs at risk surrounding the target. Theoretically, higher than observed
deviations are possible within realistic dose variation magnitudes. Though devi-
ations were in the same order of magnitude, statistical differences in the total dose
deviation magnitudes were observed between the investigated patient cohorts. This
shows an impact of the deviation magnitudes on the method of dose delivery, the
image-guidance strategy and the tumour site.
5.2 individual workflow aspects, uncertainties and results
This section discusses the individually investigated workflow details given by: Im-
plementation remarks on biological dose mapping; the impact of α/β; the impact
of the fractionation scheme; local vs. volumetric analysis (including the discussion
on dose-volume (DV)-parameters); γ-analysis; DIR accuracy; interpolation; and the
dose-toxicity correlation.
Implementation of biologically consistent dose mapping In addition to
the discussion and conclusions given in section 3.1.1 that describes the concept of
biologically consistent dose mapping, the following should be consider for its imple-
mentation:
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Mean organ dose conservation: Depending on the location of growth and shrink-
age, deformation of tissue within one organ may not always be uniform, which is a
reason for the unknown quality of transformations on a voxel scale. It might be that
parts of the organ undergo greater volume changes than others [76]. It is also not
known where cells are lost or added, which is another source of uncertainty when
assigning dose values by the mapping process. This is a general problem beyond
the knowledge available from imaging. In many cases, organ dose is non-uniform
especially in the presence of steep dose gradients in normal tissues as delivered by
IMRT. As a conclusion, the mean organ dose before and after mapping may change
accordingly and should therefore not be used as a dose mapping constraint.
Uncertainties from DIR: DIR is most likely the largest source of uncertainty in
the dose mapping process. Instances where structures show uniform imaging inten-
sities, but lie in steep dose gradients, are especially susceptible to dose mapping
errors [74]. Errors in the mapped volume in the form V ′2 6= V1 (mapped volume and
reference volume), directly translate to dose errors in the overall structure. Volume
changes between the reference state and during therapy at the level of the individual
voxel can be estimated with the determinant of the Jacobian matrix of the deforma-
tion vector field (DVF) (see section 2.2.1.3). However, there is as yet no mechanism
by which to directly measure and validate the DIR process in a physical system to
calibrate in-silico modelling [68]. This is due to the anisotropic manner of deforma-
tion on a voxel scale discussed above not visible in imaging. For structures receiving
inhomogeneous dose levels, constraints demanding volume conservation in the form
V ′2 = V1 will therefore not necessarily ensure better results for the mapped dose
since errors might be hidden on the voxel scale. Dose accumulation should only be
performed in case the DVF from DIR are anatomically plausible (quantification of
this is still a topic of ongoing research). On the other hand, volume conservation
in the form V ′2 = V2 does not allow for dose accumulation in a common reference
frame.
Interpolation: Values assigned to a voxel are given by the value interpolated at
the grid centre point of that voxel in common implementations (e.g. Elastix [37]).
The principle of interpolation is explained in detail in section 2.2.1.4. Thus, dose is
a point value assigned to a volume and its accuracy in the mapping process depends
on the used interpolation method. For the above discussion, it therefore is the best
possible estimate of the interpolated dose to a voxel that needs to be conserved in the
dose mapping process to calculate the SF. As tissue shrinkage or growth is always
associated with cell transfer between neighbouring voxels in the mapping process
(in all discussed scenarios due to volume displacement in figure 3.2), voxels in the
reference frame (after mapping, T ′2) may be composed of cells receiving different dose
levels before mapping (T2), which is a general problem due to discretization. The
assigned dose to this voxel is interpolated. Only in the case of uniform irradiation
of the voxels included in the interpolation process, is the dose to individual cells en-
tirely conserved. However, in steep dose gradients, the shifted cells will be assigned
with a different dose within the newly composed voxel due to interpolation, also in
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dose conserving implementations. For a given dose gradient, this dose difference will
increase with decreasing resolution of the dose grid due to the discretization. If the
number of cells exchanged between voxels is small (i.e. small changes in cell number
or density), the shifted cells will travel only over a small distance and the dose alter-
ation actually received by these cells will be small as well. Furthermore, for a high
resolution of the dose grid, this small dose difference will also be assigned to the
shifted cells. Thus, in the limit of small changes of cell number or density and high
resolution of the dose grid, the above mentioned condition of a uniform irradiation is
asymptotically fulfilled on the scale of neighbouring voxels and combining these vox-
els, not only SF but also the absolute number of surviving cells will be maintained
after dose mapping. These assumptions appear to be valid for a standard fraction-
ated treatment at least for the case, when volume changes of the tumour or normal
tissue are not too large. Both dose and SF are subject to uncertainties when being
interpolated over a volume. Although SF could be mapped and interpolated as well,
SF changes nonlinearly over many orders of magnitude making it more susceptible
to discretization errors than dose interpolation and the use of simple interpolation
techniques such as trilinear interpolation may also be questioned. Therefore, it is
dose that should be mapped according to the DVF and not the SF directly. This
is not based on biological considerations but on minimizing the uncertainty in the
overall workflow.
In summary, in the process of dose mapping, mean organ dose as well as volume
conservation should not be used as constraints for DIR.
Discretization and interpolation induces uncertainties in the mapping process which
will be lower by mapping the voxel dose rather then the voxel-wise SF.
The impact of α/β In the following, the impact of α/β on the SF and bEQD is
discussed generally since results in theoretical analysis (section 4.1) and in patient
data (section 4.2.1) are in good agreement. In short summary: The lower the α/β,
the stronger the difference in relative survival and in the total dose between the dose
and the effect-based approaches. Furthermore, assigning smaller values for α and β,
while the ratio α/β remains the same, results in generally lower relative differences.
Lower α/β generally means that β increases with respect to α. Therefore, the β-
term is weighted higher in comparison to calculations based on higher α/β. The
difference between the dose and effect accumulation approach is manifested in the
β-term alone, explaining the observed higher differences for lower α/β.
As presented with the basics of the LQM (section 2.2.2.1), the smaller the tissue
α/β the higher the SF for a given dose. Smaller α/β are associated with slow
proliferating tissues which in turns means that damage to the cell can be repaired
more efficiently before the next cell cycle begins and the damaged cell might undergo
mitotic cell death. On the other hand, late radiation damage might occur. For the
evaluation of the SF from either dose or effect accumulation, this means that for
smaller α/β, the absolute SF difference between both methods is naturally higher
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than for larger α/β since the overall SF is higher. As can be seen in figure 4.1, the
SF for high α/β values is already so small that differences are hardly visible on the
given scale. This, however, changes when looking at the relative SF difference. Here,
it was shown that for lower α/β, the relative difference is higher for high α/β. As
discussed above, high relative differences are more important in medium and low
dose regions, while for high dose regions, as in the CTV, a high relative difference is
most likely related to very small absolute difference based on the overall SF scale.
For the computation of the SF, α was set to a constant value of 0.1 Gy and change
in the α/β value was achieved by changing β only. This is reasonable for the given
analysis since only the β-related quadratic dose term is affected in the comparison
between the effect and the dose accumulation approach and is therefore of higher
importance. The same approach is followed for example by Afsharpour et al. [1].
Changing α while keeping the same α/β of course means that β was changed by
the same factor. However, as was presented in LQM background in figure 2.9, the
same α/β with underlying smaller α and β results in lower cell kill (higher SF).
Therefore, the same as above applies that the absolute SF difference is higher, but
the relative difference is smaller.
For the comparison of bEQD with Da, only the assigned α/β value is of interest.
It was found that the difference between both total doses scales in the same way
with α/β as the relative SF difference: the lower α/β, the higher the difference.
Within the bEQD formula (eq. 3.10), Da is directly factorized with α/β, so that a
lower α/β leads to a smaller weighting. This trend is in accordance with the above
discussed observation that the SF difference is more pronounced due to the stronger
weighting of the β-term, which is essentially the same since α was kept constant.
Due to the impact of α/β on bEQD, uncertainties in the assigned value propagate
to bEQD itself. Lowering the α/β for the rectum for case 3) from 3 Gy−1 to 2 Gy−1
increased the local dose difference by 1.2 Gy. It was found that an increase from 3
to 4 Gy−1 had a lower impact than the reduction from 3 to 2 Gy−1, of only −0.7 Gy.
Only an increase to 5 Gy−1 resulted in a similar change in total dose difference of
−1.2 Gy. Thus, tissues with low α/β are prone to higher uncertainties inherited
from the α/β uncertainty. The uncertainty scales with the dose variation magnitude
as well so that areas of high bEQD −Da difference are affected more. The impact
was much lower for the CTV where the overall total dose differences were smaller.
The impact of around 1Gy to the total dose deviation in high deviation areas is
generally lower than the difference between bEQD and Da.
In summary, late responding organs that show a low α/β value are at risk for a
stronger underestimation of the achieved biological effect and total biological dose.
The uncertainties of the α/β values induce an uncertainty of bEQD. The impact
on the bEQD uncertainty is higher for tissues with a lower α/β. The magnitude
of uncertainty of bEQD can therefore be lowered by improving the accuracy in the
α/β-estimation. This magnitude is lower than the difference between bEQD and
Da but need to be considered in the overall uncertainty of bEQD.
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Thought experiment: The influence of dose variations on the prediction
of the α/β-value Very broadly summarized, there are two ways to predict the
α/β-value of a tissue. Either it is based on clonogenic assays, as already described
before in section 2.2.2.1; or it is based on patient-data, which means it is an endpoint-
related α/β-value based on dose-to-outcome data from patients. This would involve
the following steps: Dose volume parameters of the dose distribution are calculated
that are normally linked to the normal tissue complication probability (NTCP) cal-
culated for this tissue and for a certain endpoint (for example the equivalent uniform
dose (EUD)), see section 2.2.2.2. Then the NTCP curve is generated based on the
chosen model and the treatment outcome data. This needs to be done for different
fractionation schemes. For each fractionation scheme, the D50 is calculated from
the obtained NTCP curve (D50: the dose that results in a 50% complication proba-
bility). These D50 values are then plotted against the dose they are linked to, which
gives the so called Douglas-Fowler plot. The slope of the resulting curve gives the
α/β-ratio.
It is beyond the scope of this thesis to predict any α/β-value from reported outcome
due to the lack of data based on the only very recently acquired patient datasets.
In the following, a thought experiment is presented on how the effect accumulation
approach might impact the α/β prediction.
Assuming a certain biological effect E as an endpoint is observed clinically, this
can either be assign to the dose- or the effect-accumulation-based survival fraction.
Starting from the above equation setting Ed/α = Edi/α in order to convert from










For this, a constant α for both approaches was assumed. The α-term is not affected
by dose variations since it only links to the total dose of the treatment (equation
3.10).





















α/βd 6 α/βdi (5.6)
Thus, conventional dose accumulation would predict a systematically lower α/β-
value than effect accumulation. This is shown in figure 5.2 for a fictional voxel
analysis for different dose variation magnitudes given as the dose standard devia-
tion. It can be seen that for standard deviations below 20% the impact remains
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Figure 5.2. – The impact of dose variations on α/β prediction based on the same fictional voxel
analysis as presented in section 4.1, according to eq. 5.4. Standard deviation (std) with respect of
the mean dose.
below 5%. However, for higher dose variations, the impact quickly increases to 20%
for 50% standard deviation of dose variation.
Assuming that the variation of the fractional dose can be described by a mean dose
value with a dose variation factor given by a probability distribution, then it can be
written as
∑
i di = d
∑



















Therefore, the impact of the dose variations over therapy on the α/β-value is inde-
pendent of the mean treatment dose and only depends on the magnitude of dose
variations.
The impact of the fractionation scheme The difference between the two ac-
cumulation methods scales with the total delivered dose. It is therefore higher the
more fractions are accumulated and the higher the dose per fraction. The latter
leads to an increased risk of total effect underestimation in normal tissue for hy-
pofractionation, based on the higher prescription dose and potentially steeper dose
gradients. A higher dose per fraction increases the difference in the dose accumula-
tion methods since the difference is given in the β-term that is quadratic to dose.
Though the total treatment dose is higher for standard fractionation compared with
hypofractionation, it was found that a higher dose per fraction given for the lat-
ter case is dominating the effect of deviation between bEQD and Da, leading to
higher difference amplitudes for hypofractionated treatment. In rescaling the dose
to moderate hypofractionation with 3.0 Gy per fraction (21 fractions) and strong
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hypofractionation with 6.8 Gy per fraction (5 fractions) it was found that the dif-
ference magnitude increased strongly in the majority of cases, again with highest
difference in dose gradient regions in OARs. Going to moderate hypofractionation,
highest differences increased to 6.8 Gy (compared to 4.9 Gy in 34 fractions). For
strong hypofractionation, three cases already showed a total dose difference above
8 Gy which is already 24% of the tumour prescription dose but within the normal
tissue. This is in agreement with the theoretical predictions.
One should note that the comparison of the total dose difference for different frac-
tionation schemes is not only influenced by the choice of the treatment dose, but also
by the “choice” of the fractions that are taken into account in the presented analysis.
It might be that by reducing the number of fractions, this might exclude or include
fractions of high motion amplitude present in the analysis with more fractions. This
will impact the outcome of the observed deviations and can explain the lower dose
difference found for hypofractionation observed for 3 out of the 9 cases. To best
simulate the hypofractionated treatments, fractions 1-21 and 1-5 were chosen, re-
spectively. However, hypofractionation might lead to an earlier decrease in tumour
volume and thus a different pattern of organ deformation than for the presented
analysis.
It should also be noted that scaling of the dose was chosen over setting up new hy-
pofractionated treatment plans to ensure a more direct comparison of the total dose
difference. Scaling was performed on the already deformed doses di. Therefore, the
observed difference did not depend on the treatment plan optimization or the DIR
but solely on the fractionation scheme and analysed fractions. It was found that
by creating new treatment plans, resulting differences can change a lot in hotspot
magnitude and location based on different beam weights that might or might not
traverse areas of higher or lower motion amplitude.
The LQM is only recommended for use in standard fractionation dose regimes.
Therefore, for the high dose regions, its validity might be questioned. However,
other models like the linear-quadratic-cubic (LQC) model imply even higher uncer-
tainties in the additional tissue dependent parameter γ and with 6.8 Gy per fraction,
the high dose regions are still within the applicable range from a number of sugges-
tions [34]. Therefore, uncertainties might not be decreased with the use of these
models. However, in case a cubic parameter is included, this would only enhance
the observed trend by further increasing the weight of individual dose variations.
In summary, differences between bEQD and Da are higher, the higher the dose
per fraction, since the effects from daily dose variations are enhanced. Therefore,
hypofractionated treatment schemes are expected to show heavily increased dif-
ferences between bEQD and Da. Difference magnitudes above 8 Gy difference were
observed for strong hypofractionation (about 25% of the tumour prescription dose)
in normal tissue.
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Local vs. volumetric analysis The difference magnitudes found locally are in a
clinically significant range. However, the only small differences visible in the DVHs
of bEQD and Da for standard fractionation indicate that when clinical decision
or dose-response modelling is solely linked to few distinct DVH-parameters, there
will likely be no change in outcome when using one or the other dose accumulation
strategy. This is in accordance with conclusions by de Xivry et al. [17]. Impact
was however strongly increased in hypofractionated cases with generally higher dose
deviations also visible in DV-parameters and here, the difference between the two
accumulation strategies might have clinical impact.
With respect to the local differences that can be seen in the three-dimensional (3D)-
data slices, this highlights the limitation of the use of dose-to-volume-based simpli-
fication of the 3D dose information and is a serious over-simplification of the spatial
dose distribution in finding correlation of dose to toxicity. Especially based on this
rather local than global occurrence of total dose difference, the impact in using
bEQD rather than Da has a higher importance for serial type organs like spinal
cord or rectum. Generally, the computation of dose-volume parameters is more
meaningful for parallel-type organs for which the volume that receives a certain
dose is of interest. The here investigated organs of rectum and bladder show a more
serial-type nature. Therefore, the found hot spots in deviation are more important
than what is visible in the DVHs.
For the derived dose-volume metrics, the difference between the two accumulation
methods was generally low on average, although systematic as expected, especially in
the comparison with the difference to the planned dose, which was generally higher
by at least one order of magnitude. The difference to the planned dose showed me-
dian values very close to 0 for all metrics. This is mostly due to the fact that the
results differed in both positive and negative direction. Conclusions on dose vari-
ations should therefore only be taken when looking at the range of results, rather
than a mean or median value.
The Quantitative Analyses of Normal Tissue Effects in the Clinic (QUAN-
TEC) recommendations for dose constraints were evaluated for the DKFZ pelvis
cohort in the three investigated fractionation schemes. It needs to be noted that
the recommended constraints for rectum [51] and bladder [75] are only given for
standard fractionation. The here used constraints were converted using the EQD2
approach with the according α/β values for rectum and bladder, but are not to
be considered clinically approved recommended constraints. As can be seen in the
results, due to the fact that the α/β values for bladder and rectum were higher
than that of the prostate, the highest dose regimes calculated from conversion for
the OAR VxGy are not even delivered to the patient in the CTV so that these val-
ues were not reached. Furthermore, especially for the volume of the bladder but as
well for the rectum, the QUANTEC reports clearly state that the application of DV
constraints is highly problematic since they are based on static planning CTs and
highly susceptible to changes in volume, while volume changes in the bladder occur
in every fraction. Similar caution must be taken for the constraints for the rectum.
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The results showed for the majority of cases, that the constraints were still fulfilled
for the accumulated doses (bEQD and Da) but for some exception, violations of the
constraints were found. This underlines the importance of using dose accumulation
in general, especially for treatment adaptation in individual cases. However, the
violations were already observed for Da. bEQD only resulted in a small additional
deviation but to no case were constraints were fulfilled by Da but not bEQD.
The differences in the DV-metrics for bEQD and Da were visibly increased for hy-
pofractionation, in both median and range. In the case of strong hypofractionation,
an outlier was observed with 7% difference in V21Gy for the rectum and 4% in V23Gy
for the bladder. Violations of according appropriate constraints for hypofractiona-
tion might therefore occur. This indicates that the bEQD might probably not be
relevant in a statistical manner but can have high impact for individual cases. This
will be further discussed for the VoxTox cohort below.
For the DKFZ cohort, the dose metrics of bladder and rectal wall were compared
to those of the entire organ. The results for the organ walls were generally shifted
to smaller values (either closer to 0 or higher in negative numbers). Especially the
bladder volumes that received certain dose values tend to shift towards negative val-
ues in contrast to the whole bladder. This indicates that the largest dose difference
to the planned dose and between the accumulation methods is located within the or-
gan volume. However, the differences between results of the respective investigated
volumes remained small in all cases. The more labour intense contouring of the
organ walls can however improve the accuracy of the investigated DV-parameters.
For the VoxTox DSM cohort, it was found that the higher the threshold for the
dose width computation, the more negative the median difference to the planned
dose. At 30 Gy threshold, the difference is close to 0 and shifts towards -3 (relative
lateral extend) at 70 Gy. In comparison to the difference to the planned dose, the
difference between both accumulation strategies remains marginal, but still show-
ing the expected systematic difference. As discussed before, not using DIR to map
the dose on a voxel-basis might have washed out local dose deviation hot spots so
that observed dose variations magnitudes were decreased wrongly. The magnitude
of difference from accumulated to planned dose metrics is generally very high for
the dose width and the EUD. The EUD showed to be systematically lower for the
accumulated than the planned dose in the vast majority of cases. As was described
before, the mean dose was systematically higher for all cases. This is however no
contradiction but is simply based on the volume-effect parameter in the EUD calcu-
lation (see section 2.2.2.2). With a = 11.11, a rather serial type nature is assumed
for the rectum, thus, enhancing the impact of local dose hot spots. Based on this
observation, apparently the dose distribution showed high dose gradients and hot
spots for the planned dose, while this effect was washed out for Da and bEQD since
dose hot spot location varied from day to day. The wash out effect then impacts
the result of the EUD calculation with the chosen a to a high extent leading to the
observed lower than planned EUD. This underlines the previous assumption that
Da and bEQD were generally washed out either truthfully or to an increased extent
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based on not using DIR. EUD for bEQD and Da thus showed to be very similar.
The DV-parameters for the spinal cord observed in the VoxTox H&N cohort
showed no impact from the dose accumulation methods. Generally, higher devia-
tion were observed for the brainstem than for other organs, though, as discussed
above, the origin of the difference hot spots in the peripheral image regions cannot
be linked to dose variations without doubt. This will be discussed below for the
DIR accuracy.
In summary, due to the local impact of the bEQD, deviations of bEQD to Da
showed only marginal impact in conventional DV-metrics in standard fractionation.
The difference between the accumulation methods in conventional DV-analysis
only becomes clinically relevant for hypofracionation. With regard to the
observed local deviation hotspots of several Gy, this underlines the limitations of
DV-analysis. bEQD should especially be investigated for serial-type organs which
are affected most by local dose hot spots. Statistically, the difference between both
accumulation methods is low compared to the difference in planned dose but can be
high for individual cases. DV-metrics for organ walls showed to be lower than those
for the whole organs to a small degree.
γ-analysis The result from the γ-analysis underline once more the importance
of local dose analysis. The γ-value varied strongly, even within one organ. It was
also found to be important to differentiate between regions that received lower than
planned dose from those that received higher doses in the γ-analysis since otherwise
the γ-passing rates would be much lower than reasonable. However, it should be
noted that this is only true for the normal tissue regions since in tumour tissue,
underdosage instead of overdosage is critical. Within the CTV, areas of negative γ
value are thus of interest, nevertheless, these regions generally showed values close
to 0 and are therefore within the limits of acceptable γ-criterion.
It was found that the difference hot spots between bEQD and Da often correlated
to regions of already failed γ-criterion, thus, further increasing the γ-value but not
necessarily increasing the γ-failing rate. The equivalent is given for γ 6 −1. This
explains the only low impact of the accumulation strategy on the overall passing
rates. It is therefore of higher importance to consider the actual magnitude of γ
in the failed regions, rather than the passing-rate alone. When only passing- and
failing-rates are considered, while the magnitude of the γ-value is neglected, a region
of γ > 1 will be treated in the same manner independent of the fact that it shows
values close to 1 or far beyond. Here, it was found that the γ-value can be strongly
increased in failure regions and that based on this analysis, clinical decisions on Da
and bEQD, respectively, might have a different outcome. Therefore, for γ-analysis,
the bEQD approach should be considered.
For the analysis a criterion of 3% / 3 mm was chosen. For stricter criteria such as
2% / 2 mm or 1% / 1 mm, a similar trend is expected with even stronger influence
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of bEQD, since bEQD impacts locally, which is an aspect that could be investigated
in future work.
In summary, analysis of the absolute magnitude of the γ-value is proposed rather
than conventionally reported γ-passing rates. bEQD increased the local γ-value
in regions of already failed γ-criterion further and might therefore lead to
different clinical conclusions than Da. γ-passing rates were lowered in all cases by
1% on average, with a maximum of 3%.
DIR accuracy Propagation of DIR uncertainties to the conventionally accumu-
lated dose has been a popular field of research due to its increasing importance for
new emerging methods but there is not yet a standardized quality assurance proce-
dure available (section 2.2.1.3). Investigations of dose uncertainties from DIR
in literature are for example based on deformable phantoms using 3D dosimetry
gel [83] [32], numerical phantoms [56], different approaches of statistical error sam-
pling procedures [54][73] or by comparison of registration strategies [74]. All these
approaches require the implementation of specially designed soft- or hardware so-
lutions that are not publicly available at this point. Literature rarely reports on
the quantitative magnitude of dose errors propagated from DIR but only certain
dose criteria or algorithm performance, mostly due to a missing ground truth to
compare to. Nassef et al. [56] investigated conventional dose accumulation in 24
prostate cancer patients and found mean differences of Da to the planned dose of
6.9 Gy for the bladder and 2.0 Gy for the rectal wall. They investigated the dose
uncertainty from DIR by using a numerical phantom and the same DIR as for the
patients. They found a mean DIR uncertainty of 2.7 Gy in the bladder and 1.2 Gy
in the rectal wall. The statistical error sampling procedures investigated by Murphy
et al. [54] showed dose error hot spots around 1 - 1.5 Gy, especially in dose gradi-
ent regions. The use of biomechanical models is proposed by a range of authors to
improve the anatomical plausibility of the registration results, especially in regions
of homogeneous imaging values. This was for example tested recently in depth by
Zachiu et al. [85] who concluded that especially in regions of homogeneous imaging
values, biomechnanical models and additional quality assurance criteria can improve
the registration outcome.
It is beyond the scope of this work to perform an in depth analysis of the DIR accu-
racy. As can be seen from the reports in literature and the results within this thesis
discussed below, uncertainties will strongly depend on the choice of the underlying
DIR algorithm and the used parametrizations and constraints. Within this work,
commercially approved DIR software implemented in the RayStation was used. Or-
gan contours were additionally used to guide the DIR to improve registration quality
in terms of anatomically realistic deformations. Nevertheless, image registration is
arguably the biggest source of uncertainty and has been a controversial topic for
dose accumulation [68]. This, however, holds true for both Da and bEQD.
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The impact of the DIR on Da and bEQD was investigated in two ways in this work:
by a worst-case estimation and by comparing the outcome of different DIR algo-
rithms.
The worst case dose mapping error analysis was performed to solely focus
on the difference in the impact of dose mapping errors between both accumulation
strategies, independent of the choice of the DIR algorithm. This is, however, a
worst case estimation and should be regarded as such. Especially at organ bound-
aries, often located in the gradient regions around the target, smaller errors in the
mapped doses than estimated here are expected when using the contour information
in the DIR process. The observed worst case magnitudes of error in total dose were
generally higher or equal to those found for the difference between the accumula-
tion strategies and reached up to 5 Gy for Da and up to 9 Gy for bEQD. Thus,
the magnitude of error induced by using conventional dose accumulation instead of
effect-based accumulation strategies, is in the same range as the highly investigated
impact of DIR uncertainties. Quality assurance of the DIR for dose accumulation
(both bEQD and Da) is urgently needed to reduce uncertainties in both workflows.
Higher error magnitudes were found for ∆bEQD than for ∆Da. Highest uncertain-
ties were located in the dose gradient regions in both cases, due to the nature of the
error estimation based on neighbouring voxel doses. The increased uncertainty for
bEQD is due to the fact that the individual errors of the fractions are taken into
account, in the same way that bEQD is systematically higher than Da by consider
the individual fraction doses in the accumulation. This interesting aspect will be
further discussed in section 5.3 for the overall uncertainty budgets of bEQD com-
pared with Da.
For the second part of the analysis, a comparison of DIR algorithms was per-
formed: the Raystation-based registration was compared in the total dose outcome
with results from a simple demons and b-splines algorithm within the plastimatch
software (without landmark or contour guidance). Substantial difference in the re-
sults were observed. It was also found that anatomically plausible deformations
could not be guaranteed, especially for the b-splines registration. The demons al-
gorithm seemed to be more robust in the investigated cases. Large deformations of
the bladder, that induced very strong deformations in b-splines resulted in the fact
that especially in the bladder regions, high dose differences occurred. While this
might not be a problem for registration of CT images, since the area of interest is
not affected and might be represented in a qualitatively satisfying manner, it will
cause large deviations in the calculation of the accumulated dose (Da and especially
bEQD) and might therefore wrongly indicate high bladder doses after accumulation.
For the demons algorithm, the dose difference in the accumulation methods were
generally the lowest, also in comparison with the RayStation registration. This
suggests low degrees of deformation and without quality control, it cannot be as-
sured that the organ deformations were correctly backprojected in this case. The
b-spline and demons algorithms seem to present two extreme cases of very large
and very low deformation results, while the results from the RayStation are in be-
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tween both. For the presented cases, it was assumed that the RayStation algorithm
gives the most accurate representation of deformation in this comparison since it
was additionally guided by organ contours. The results underline that DIR without
geometry guidance is not sufficient in the pelvic region. Nevertheless, the quality of
the RayStation DIR results are not known. In contrast to the b-splines and demons
results, the DVFs could not be investigated. The former show high degrees of grid
folding and anatomically unrealistic deformations for both plastimatch implementa-
tions which suggest that the results are not valid for dose accumulation and that
deformation grids need to be investigated generally. The comparison of the b-splines-
and the demons-based results for the mapped dose showed high differences even for
fractions that seemed similarly acceptable for the CT deformation in both cases.
This underlines that a simple qualitative inspection of the deformed CTs is not a
valid quality assurance measure for the mapped doses. For the RayStation registra-
tion, if possible, quality assurance on the DVF should be performed (but exporting
of these was not possible), for example by using the Jacobian determinant matrix
that indicates grid folding and the degree of volume change of voxels (see section
2.2.1.3). It should be noted that measures of the spatial overlap of the resulting
structures (e.g. Dice-coefficient) should not be used for the RayStation registration,
since this was part of the DIR optimization process within the algorithm and is
therefore an inappropriate choice as a quality measure.
DIR was also used for the registration of the VoxTox H&N cases. High dose
differences were found especially in the peripheral regions of the registered images.
This might have been caused by the varying positions of the daily MVCT scans, that
did not overlap entirely in all cases causing ill-posed problems for the DIR algorithm
by mapping different anatomies. Cropping of the mapped doses in the areas that
did not overlap in all fractions was considered. However, it was concluded to rather
report on the dose deviations in the whole volume. This was because for clinical ap-
plications, a conservative approach would be preferred when dealing with potential
overdosage of critical structures. Thus, if it cannot be ruled out for sure that the
observed differences were caused by erroneous DIR, but might have been the result
of actual biological overdosage due to fractional dose variations, the results of the
biologically accumulated dose should still be considered.
In summary, DIR induces uncertainties in Da and bEQD that are in the
same range as the systematic deviation between the two. bEQD inherits
higher magnitudes of uncertainty than Da. Quantitative quality assurance of DIR
for dose accumulation is, thus, urgently needed but as of yet not available. For
the pelvic region, DIR guidance with anatomical features is necessary to obtain
anatomically plausible deformations or new advances from biomechanical modelling
should be investigated.
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Interpolation As discussed and concluded in detail in section 3.1.1, it is the dose
to a volume of homogeneous dose (the smallest of which is a voxel due to discretiza-
tion) that needs to be conserved in the mapping process in order to be biologically
consistent and with this conserve the obtained biological effect of the fraction in
the mapping process. Interpolation in this work is based on standard trilinear in-
terpolation techniques. It can be shown mathematically that trilinear interpolation
is equivalent to a volume-weighted average of the contributing voxel fractions. In-
terpolated dose is, thus, weighted by the number of contributing cells. As outlined
before, interpolation induces deviations of the dose assigned to a cell in case different
dose levels are summarized over a certain volume (discussed in section 3.1.1). This
is especially the case in regions of strong dose gradients. This is however a general
problem induced by discretization. Already on the level of a voxel, cells might have
received different dose levels but are being assigned the spatial dose average of the
volume of the voxel. In the mapping process, even if dose-conserved mapping is
applied, the dose a cell is assigned with will be different after mapping due to the
fact that interpolation will take into account the dose of the neighbour voxels as
well. Therefore, the change in assigned dose in the mapping process due to inter-
polation does not necessarily induce a greater deviation to the true delivered dose
to the cell than is already given by discretization alone. This is also given for cells
that might have been shifted to another neighbouring voxel in the mapping process.
For an accurate assessment of this problematic, it would be necessary to model the
dose distribution on the level of the individual cells and quantify the induced devia-
tion from discretization and interpolation. As concluded before, within the limits of
small volume changes and high grid resolution (or low gradients), the uncertainties
induced by interpolation and discretization are assumed to be small.
Discussed before was the difference between a dose- or energy-conserving interpola-
tion. This must not be confused with a dose- or energy-based interpolation.
The interpolation method in this work (trilinear interpolation) is based on dose, a
form of direct dose mapping (DDM). A problem in using this approach arises as
well for the ill-posed problem of volume changing structures. For volume growth,
mapping results in volume reduction and the doses from several voxels might be
overlapped into one voxel. This opens the question on how to implement the dose
mapping in case of overlap. Instead of DDM, another approach maps the energies
of the voxels. A good overview of both approaches is given by Li et al [44] and Milz
et al. [52]. The energy-based mapping of dose (called energy-mass transfer (EMT))
requires the estimation of the voxel mass from imaging gray values to derive the
deposited energy. Transferred energy and mass are being considered. In essence,
this approach is a mass-weighted average of the dose instead of the volume-weighted
average of DDM described above for trilinear interpolation. For the presented work,
EMT was not applied or investigated. This was due to two factors: in case physical
density is constant, as is the case for incompressible soft tissue, the change in both
mass and volume is directly proportional and the difference between both methods
becomes negligible. This is different in case of lung tissue, where density changes
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and EMT becomes more accurate than DDM. Another reason for not utilizing EMT
is the location of occurring volume change. In the pelvic region, volume change is
mainly driven by the filling states of both bladder and rectum. However, the dose
to the bladder and rectum content that changes in volume, is not of interest (in-
vestigated by comparing whole organ contours and organ walls). EMT might also
play a role on tissue surfaces to other structures with significantly different mass
density (e.g. bone or air). However, the structures of interest show very similar
mass densities, also at organ boundaries. Tumour shrinkage was not investigated
in this work, however, in case of strong volume changes of the tumour, it might be
worth considering EMT.
Besides trilinear interpolation, a sub-voxelization-based interpolation methods was
tested in this work, referred to as the Rosu-technique based on the underlying
publication by Rosu et al. [64]. The magnitude of difference between both inter-
polation strategies for the total doses of bEQD and Da reached several Gy, both
in negative and positive direction. The differences found for the investigated cases
were higher than what was reported by Rosu et al., which is surprising since higher
changes would have been expected for lung tissue due to the higher magnitude of
volume changes. Regions of high differences were mostly found within the bladder
which is were the strongest volume changes occurred. Furthermore, the differences
were higher when using the demons based registration which in turn showed lower
differences between the two accumulation strategies for the investigated case. This
might be a result of more washed out dose gradients in the b-splines registration
that are indicated by the larger area of total dose difference. Larger differences
would be expected in strong dose gradients and in the investigated case, the demons
algorithm seems to have produced a mapped dose with sharp gradients in contrast
to the b-splines registration result. Overall, it needs to be noted that the Rosu
implementation within the AVID workflow is as of yet not being used by other users
and the strong differences might indicate that another proof of the implementation
validity is necessary. In case the observed deviations are indeed a result of high
uncertainties induced by trilinear interpolation, then the impact is similarly high
as the impact of different dose accumulation strategies and should be taken into
account and investigated further. This would mean that the advanced method by
Rosu et al. should also be considered for use in the pelvic region and not only in
lung tissue.
In summary, dose-conserving dose mapping needs to be implemented in order
to facilitate a biologically consistent workflow and basis for accumulation.
The choice of the interpolation strategy shows a strong impact on the outcome of
bEQD and Da and especially the sub-voxelization method by Rosu et al.
should be investigated further.
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Dose-toxicity correlation For the preformed receiver operator characteristics
(ROC) analysis, only weak correlations of dose to toxicity were observed in all cases
except for rectal bleeding (RB) grade 2. This was found for all investigated total
doses (planned dose, Da and bEQD). It can be said for this specific dose-toxicity
correlation, that neither conventional nor biological dose accumulation showed to
be better predictors of toxicity than the planned dose. In clinical practice, dose
constraints are mostly given for the rectum in parameters that link a certain dose
to a volume. The fact that the found correlations are very weak in almost all cases
underlines that the simple use of these constraints might not be appropriate for the
rectum and more sophisticated dose-toxicity models including volume effects and or-
gan architecture should be investigated, especially for the locally affecting 4bEQD.
The performed dose-toxicity correlation was based on DSM, a method to investigate
the dose distribution on a local scale. The use of dose-width fits was used in or-
der to find summarizing descriptive dose metrics for the given distributions without
loosing all the spatial information of the DSM. Nevertheless, this method only takes
the central dose cluster into account and hot spots in the peripheral region might be
overlooked. It was found that especially in these peripheral regions, the difference
to the planned dose as well as between the accumulation strategies was the highest,
which therefore might have not been entirely included in the final correlation pro-
cess. EUD summarized the DSM as a weighted mean. Although, with a = 11.11 a
serial-type organ is assumed, which emphasizes the impact of local dose hot spots,
this metric reduced the investigated dose distribution to a single value. This value
should be interpreted carefully, also since a itself is an estimated empirical quantity
only. As was discussed above, accumulation was not based on a voxel-wise dose
mapping technique. This might have washed out the accumulated doses (Da and
bEQD), resulting in lower magnitudes of EUD as well as of bEQD−Da, since high
local dose variation amplitudes might not have been observed correctly.
The differences found between Da and bEQD to the planned dose, respectively, were
much higher than the difference between the accumulation strategies. Furthermore,
the impact on the single dose metrics was low. Therefore, only minor changes for
the dose-toxicity correlation is expected since this was only based on single metrics
and without an underlying model, as in NTCP modelling. This was accordingly
observed within the ROC analysis for the result of the area under the curve (AUC).
In many cases, the dose metrics obtained from the planned dose were higher than
those from Da. Since bEQD is systematically higher than Da, results from bEQD
were closer to that of the planned dose in many cases.
For most cases, surprisingly, the planned dose showed higher correlation than the
results from bEQD and Da. The difference was small in all cases between the three
investigated doses, though high differences to the planned dose were observed. Gen-
erally the outcome of the ROC analysis showed only very low correlation to outcome.
This indicates a low sensitivity of the correlation method to describe the relation
between dose and toxicity. It was however hypothesized that the accumulated dose
would be a better predictor than the planned dose since in principle, it should be
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closer to what was actually delivered to the patients. This was also published by
Shelley et al. [70] on a prior test cohort to the here used cases. There are two
reasons why this might not be the case: i) there might be a systematic deviation of
the accumulated dose (present for both Da and bEQD) to the true delivered dose.
The mapping process used in this workflow that does not utilize voxel-wise mapping
is a limitation that was discussed before and might have a systematic impact. Also
the automatic contouring of the rectum might have altered the outcome. ii) the cor-
relation of dose to toxicity might be more complex for the rectum, so that a simple
correlation of single dose metrics is not appropriately describing the dose-toxicity
relationship. For most endpoints, except for RB grade 2, the AUC was close to 0.6
which is set as the limit for a correlation assessment, which underlines hypothesis
ii). Thus, only for RB grade 2, and for dose widths fits between thresholds of 50-65
Gy, a correlation above an AUC of 0.7 was found, which indicates more strongly a
relationship of dose to toxicity in this regime.
Within the investigated cohort, patients were partially treated with standard frac-
tionation and partially with moderate hypofrationation. EQD2-based conversion
was performed to use both cohorts in the same analysis. Regarding the above
discussed results on hypofractionation, it should be investigated if the found correla-
tions differ when investigating both cohorts separately. Since the impact of bEQD is
strongly increased for hypofractionation, this leads to the hypothesis that difference
in AUC might be higher (comparing bEQD and Da) for the sub-cohort treated with
moderate hypofractionation.
In summary, the performed dose-toxicity correlation is only marginally impacted
by the use of bEQD. Generally, the performed ROC-analysis showed to have
only low descriptive power to describe dose-toxicity correlations of single
dose metrics: i) correlation results were generally low, only for RB grade 2, the mid
to high dose thresholds of the dose widths showed significant correlations above an
AUC of 0.6. ii) results were similar for the use of the planned dose, bEQD and Da,
despite high differences between bEQD and Da to the planned dose, respectively.
iii) the planned dose unexpectedly showed higher correlation than both Da and
bEQD in the majority of toxicity endpoints and dose metrics. Within this toxicity-
correlation analysis, it could not be shown, that Da or bEQD are better predictors
of toxicity than the planned dose. Based on the local impact of bEQD, more
advanced toxicity models should be investigated that take organ architecture
into account, especially for hypofractionation. This also questions the use of single
dose-volume constraints for rectal doses in clinics.
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5.3 conclusion:
should we accumulate effect instead of dose?
This section tries to answer two questions with regard to the above discussed aspects
and results: i) Is the use of the conventionally accumulated or the biological accu-
mulated dose still advantageous compared with the planned dose when considering
the uncertainty budget? ii) For which applications is biological dose accumulation
clinically favourable?
Figure 5.3. – Qualitative comparison
of the mathematical difference between
Da and bEQD: Da shows a system-
atic underestimation of the total dose
with respect to the total biological ef-
fect, thus, lower accuracy. In compar-
ison, bEQD shows lower precision due
to higher impact of uncertainties inher-
ited from DIR.
The uncertainty budget of bEQD and Da
The Linear Quadratic Model (LQM) to estimate
the biological effect from a radiotherapy (RT)
treatment is used in various clinical applications
(section 2.2.2.2). It describes a non-linear rela-
tionship of the biological effect to dose. Never-
theless, in current practice, the total delivered
dose of the treatment, obtained from simply us-
ing the planned dose or conventional dose accu-
mulation (Da), is used for clinical decisions on
treatment adaptation and correlation to the bio-
logical treatment outcome. To obtain the math-
ematically correct biological effect as defined by
the LQM as a (cell) survival fraction (SF), the
derived effect accumulation approach SF(di) has
to be used. The result of this calculation can
also be obtained by the use of the total biological
dose (bEQD) within the LQM. bEQD is there-
fore referred to as the total biological dose, as
it provides the mathematically correct survival
fraction. It was shown, that bEQD is systematically larger than Da. The compu-
tation of both Da and bEQD in patient data is prone to a number of uncertainties
that were described individually in section 5.2. This opens the question, whether
the difference between both approaches is clinically relevant when considering the
overall uncertainty budget.
Due to uncertainties in the computation of bEQD and Da, which cannot be quan-
tified (specifically deformable image registration (DIR) and α/β, as discussed in
section 5.2), their true value is not known in patient data. Within this section, the
accuracy and precision of Da and bEQD are therefore discussed in a qualitative
comparison with respect to an assumed true biological dose (bEQDtrue), to assess
the overall uncertainty budgets and relations between the approaches.
The mathematical difference between the bEQD and Da approaches is a systematic
deviation: the SF as calculated from Da is systematically larger than the mathe-
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matically correct value SF(di). Thus, Da is systematically too low in comparison
with bEQDtrue. Thus, bEQD increases the accuracy of biological effect prediction
by avoiding this systematic deviation, i.e. underestimation of the obtained total
biological effect. Figure 5.3 illustrates this principle.
Both bEQD and Da are as well prone to uncertainties of their own. Above all, the
uncertainties from DIR that propagate through to the mapped voxel doses represent
the bottleneck in the achievable precision of both accumulation approaches. The
presented results show the high impact of the registration uncertainties on both
dose accumulation strategies, though direct quantification is not possible (section
5.2). As discussed above, it was however found that bEQD as well as SF(di) are
prone to higher uncertainties inherited from DIR than Da. This is depicted in figure
5.3 which shows a wider spread for bEQD than for Da. Although the underlying
assumed dose error was equal (∆di), its propagation depends on the accumulation
strategy. As a result, the estimated uncertainties for bEQD were found to be up to
two times higher than those of Da. Therefore, in a first conclusion, the precision of
Da is higher than that of bEQD, while bEQD has a higher accuracy (figure 5.3).
Figure 5.4. – Qualitative compari-
son of the mathematical difference be-
tween Da and bEQD: ∆Da underesti-
mates the uncertainties from ∆di in the
same manner the total dose is underes-
timated with respect to the biological
effect, a higher uncertainty should be as-
sumed. bEQD shows an additional sys-
tematic uncertainty due to the assign-
ment of α/β, which is, however, lower
than the systematic difference to Da.
The systematic deviation between Da and
bEQD is based on the non-linear relation of the
SF to dose. This is also inherited by the uncer-
tainties ofDa in error propagation. Therefore, in
consequence, it needs to be concluded that ∆Da
also underestimates the influence of the individ-
ual dose errors ∆di in the same manner as Da
underestimates the total biological effect from
the individual di. This should be considered in
the assessment of Da accordingly. Thus, both
the precision and the accuracy of Da are low-
ered, which is illustrated in figure 5.4.
The assignment of the α/β-value to compute
bEQD represents a limitation to its accuracy
that is not present for Da. It was found that
this induced uncertainty in bEQD is smaller than
the potential registration uncertainty or the dif-
ference to Da. Nevertheless, due to its potential
magnitude of more than 1 Gy, it needs to be con-
sidered in the overall uncertainty budget. The
magnitude depends on the uncertainty in α/β
and is therefore organ specific and can be improved by better knowledge of the α/β
value. As for the uncertainty emerging from DIR, the uncertainty from α/β can
only be estimated since the true deviation is not known (section 5.2). In figure 5.4
this uncertainty is depicted as a systematic deviation since bEQD will for example
be systematically too low, in case the assigned α/β is higher than the true α/β of
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the tissue.
The uncertainty from interpolation is another source of uncertainty that impacts
both bEQD and Da. Due to the potentially high impact observed in the patient
data analysis using the Rosu implementation, this aspect should be investigated
further. As of now, it cannot be said whether the impact is systematic or random.
From the presented results, it can be seen that the magnitudes of the estimated un-
certainties of both Da and bEQD are in a similar range as the difference between the
two approaches. This underlines two aspects: first, the use of dose accumulation is
generally prone to high uncertainties from several sources that need to be quantified
and taken into account for both Da and bEQD; second, the biological inaccuracy
by the use of conventional dose accumulation has a similarly strong impact on the
overall uncertainty as other highly investigated sources such as DIR. In contrast to
the DIR uncertainty, it can, however, be easily avoided by use of bEQD.
For both investigated pelvis cohorts, the difference of the planned dose to Da and
bEQD, respectively, was higher than the found uncertainties. In the absence of
other not investigated sources of uncertainty within the accumulation process, it
can therefore still be assumed, that Da and bEQD are closer to bEQDtrue than the
planned dose. An illustration of this conclusion is depicted in figure 5.5. As shown,
Da is systematically below bEQDtrue, while the planned dose can deviate in either
direction. Depending on the direction of the difference to the planned dose, bEQD
is either closer to the planned dose (figure 5.5, cases 1) or shows a higher difference
(figure 5.5, cases 4-7) to the planned dose than Da.
Figure 5.5. – Qualitative comparison of the planned dose (Dp) with Da and bEQD for a schematic
number of examples. bEQD is always larger or equal to Da. On average, for a large cohort, Da
will be close to the assumed bEQDtrue, though systematically lower. The difference between
the accumulation strategies (bEQD and Da) is smaller in comparison with the difference to the
planned dose. However, the difference can be both high to the planned dose and/or between the
accumulation methods in individual cases.
For the investigated dose-volume (DV)-parameters as well as for reports from liter-
ature, the deviations of bEQD and Da from the planned dose often counterbalance
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when looking at entire patient cohorts. The systematic offset of bEQD compared
with Da resulted in a shift in the overall values that was small compared with the
range of difference to the planned dose within the entire cohort. A shift in median
values was, however, visible for hypofractionation. Moreover, individual outliers oc-
cur for both the difference to the planned dose as well as for the difference between
bEQD and Da. Figure 5.5 shows a qualitative example of this situation which can
be directly compared to the DV results in figure 4.11 and 4.21. This shows that
the use bEQD instead of the planned dose is important in individual cases while
statistically, its impact is lower.
Possible applications of bEQD To begin with, three potential areas where
bEQD and effect accumulation might have an impact on clinical decisions and out-
come were introduced: treatment adaptation, re-treatment and dose-response mod-
elling.
It was found that statistically, Da as well as bEQD are close to the planned dose
on average for large cohorts, especially when looking at dose-volume metrics. In-
dividual cases, however, showed high deviations. This is similar when looking at
three-dimensional (3D)-data: while hotspots occur, differences are small on average.
As was shown above, the magnitude of difference between bEQD and Da is low in
comparison to the difference to the planned dose, but again, high in individual cases.
The here performed dose-toxicity correlation did not show significant impact of nei-
ther Da nor bEQD compared with the planned dose and generally low correlation
for the majority of investigated endpoints and dose metrics. In combination, these
findings indicate that: i) The accumulated dose and especially bEQD should be con-
sidered for treatment adaptation and re-treatment. Although on average, the impact
is low, individual cases might benefit significantly. However, for standard fraction-
ation, this is only the case when local doses are investigated. For hyofractionation,
the impact is much larger and therefore also visible in DV-analysis. ii) The impact
on dose-response modelling is low when using simple dose metric-based approaches
as the one presented in this thesis. Since the impact of bEQD is low on average, no
clinical impact is to be expected. Thus, the use of bEQD is only relevant when in-
vestigating more sophisticated approaches in normal tissue complication probability
(NTCP) modelling that consider volume effects, organ architecture and interplay of
different dose-volume relations. It should for example be investigated if bEQD has
an impact when looking at functional sub-units (FSUs) of organs, especially those
with a serial-type nature. Moreover, dose-response modelling for hypofractionated
cohorts should be investigated.
bEQD should further be investigated for the accumulation of intrafractional doses,
since for example the interplay effect in gated treatments can cause high local dose
variations. This can occur both intrafractionally as well as between fractions. How-
ever, for this case, the energy-mass transfer (EMT)-based dose interpolation ap-
proach should be considered (see section 5.2).
Zavgorodni et al. [87] hypothesise that the similar approach of the equivalent con-
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stant dose (ECD) (section 5.1) might impact the choice of treatment margins. In-
deed, when using bEQD (or db which is equivalent to ECD), isodose lines will be
shifted due to the systematic offset to Da. Thus, when considering the bEQD con-
cept in for example probabilistic treatment optimization which considers possible
daily dose variation, the result and the choice of margins might be different.
132
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S U M M A RY
In this thesis, a biologically consistent way to perform dose accumulation in image-
guided radiotherapy (RT) was developed. It was shown that both the accuracy and
precision of the estimated total delivered dose are affected by biological mechanisms.
The first aim of this thesis therefore was the development of a workflow for dose ac-
cumulation that is in accordance with the commonly used Linear Quadratic Model
(LQM). It was shown how biological consistency needs to be addressed in two aspects
of the dose accumulation workflow (section 3.1): the dose mapping and dose accu-
mulation itself. The implementation of biological dose mapping was investigated
and discussed, showing that the recent claim for an energy conserving workflow im-
plies biological inconsistency which needs to be overcome by using a dose-conserving
approach. The methodology for biological dose accumulation was established. On
the basis of the daily deformed doses (on the background of biologically consistent
mapping), the described effect accumulation approach yields the mathematically
correct (cell) survival fraction (SF) according to the LQM. The conversion of this
approach to a total dose which yields the correct SF, can be performed by using the
derived total biological dose (bEQD) approach or the biological fraction dose db.
This enables comparison to the planned dose and commonly used dose constraints.
In comparison, it was shown that the conventional dose accumulation workflow im-
plies a systematic underestimation of the obtained biological effect.
The second aim of this thesis was the data-based conclusion on clinical relevance
and applicability of the derived biological dose accumulation approach with respect
to the current standard. In an in-depth analysis, the impact of all stages of the
dose accumulation workflow of bEQD in comparison with the conventional dose ac-
cumulation was investigated, concerning magnitude of difference and the occurring
uncertainties. This was addressed theoretically and by analysis of the data of three
patient cohorts. It was shown that using bEQD increases the accuracy of the dose
accumulation workflow with respect to the biological effect prediction by avoiding
the systematic inconsistency in the application of the LQM.
The quantitative results showed local hotspots with differences between bEQD and
Da with magnitudes around 4 Gy for standard and 8 Gy for hypofractionation. This
difference is largest for tissues with a low α/β value, in regions of large motion am-
plitudes and in hypofractionated treatments. Highest deviations were observed in
normal tissue in steep dose gradient regions. However, dose-volume based analysis
showed only very little dependency on the used dose accumulation strategy. This
means that clinical decision of dose-summarizing dose metrics and dose-toxicity cor-
relations based on these, will most likely not be affected. Local dose analysis is
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recommended to supplement dose-volume-based analysis.
The precision of dose accumulation needs to be improved by reducing the investi-
gated underlying uncertainties from α/β assignment, deformable image registration
(DIR) and interpolation. bEQD showed to be more sensitive to DIR uncertainties
than Da which underlines that these uncertainties are underestimated in conven-
tional dose accumulation in the same way that the total dose is underestimated. It
was shown that the difference bEQD −Da (thus the ”biological inaccuracy of Da)
is in the same range as the overall uncertainty budget from α/β assignment, DIR
and interpolation. This underlines the importance of biological dose accumulation
(comprehensive conclusion in section 5.3).
The analysis in the data from the three cohorts showed little impact in cohort-
averaged values for bEQD but individual cases of strong deviations toDa. Therefore,
the presented approaches should be considered especially for treatment adaptation,
to avoid overdosage of organ(s) at risk (OAR) in individual cases. No clinically rel-
evant impact on the performed dose-toxicity correlation for the rectum using single
dose metrics was observed of either bEQD nor Da, compared with the planned dose.
Based on the observed high difference to the planned dose and the systematic dif-
ference between bEQD and Da, dose-toxicity correlation should consider advanced
volume-effect models and organ architecture, to investigate the impact of biological
dose accumulation further, especially for hypofractionation (comprehensive conclu-
sion in section 5.3).
Dose accumulation is entering clinics and its use will further increase in the future.
This fact underlines the need for biological precision and accuracy. The presented
investigations provide a biologically consistent workflow and the results show the
necessity for its use in specific cases.
Physics vs. and biology: reasons that motivated the need for this thesis
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parameter fils for dir
Parameter files for deformable image registrations (DIR) using plastimatch in
this thesis to register the daily CT images to the planning CT images for the DKFZ















































































































150 APPENDIX B. APPENDIX B: ADDITIONAL DATA AND RESULTS
max_its=20
res=1 1 1
For the Elastix DIR used for the VoxTox H&N data, the following settings were
used:
• Similarity metric: mutual information using stochastic gradient descent
• Four resolution stages: (8,8,4); (4,4,2); (2,2,1); (1,1,1)
• affine transform followed by a cubic-bspline transform with a grid-point spac-




DV-metrics results complementing sections 4.2.3 and 4.2.4.
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Figure B.1. – Comparison of DV parameters for moderate hypofractionation as the difference
between DV(bEQD) and DV(Da) of the structures of interest of bladder(B), bladder wall (BW),
rectum (R), rectal wall (RW) and tumour (Clinical Target Volume (CTV) ) for various dose
metrics. The respective VxGy were converted for hypofractionation with n=21 fractions according
to the equivalent dose in 2 Gy fractions (EQD2) approach. with α/β = 5Gy for the bladder and
α/β = 3Gy for the rectum.
152
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Figure B.2. – Comparison of DV parameters for strong hypofractionation as the difference between
DV(bEQD) and DV(Da) of the structures of interest of bladder(B), bladder wall (BW), rectum (R),
rectal wall (RW) and tumour (CTV ) for various dose metrics. The respective VxGy were converted
for hypofractionation with n=5 fractions according to the EQD2 approach. with α/β = 5Gy for
the bladder and α/β = 3Gy for the rectum.
153
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Figure B.3. – Comparison of DV parameters for moderate hypofractionation (n=21) as the differ-
ence between either DV(bEQD) or DV(Da) to DV(Dplan), respectively. Shown for the structures
of interest of bladder(B), bladder wall (BW), rectum (R), rectal wall (RW) and tumour (CTV )
for various dose metrics. The respective VxGy were converted for hypofractionation with n=21




Figure B.4. – Comparison of DV parameters for strong hypofractionation (n=5) as the difference
between either DV(bEQD) or DV(Da) to DV(Dplan), respectively. Shown for the structures of
interest of bladder(B), bladder wall (BW), rectum (R), rectal wall (RW) and tumour (CTV ) for
various dose metrics. The respective VxGy were converted for hypofractionation with n=5 fractions
according to the EQD2 approach. with α/β = 5Gy for the bladder and α/β = 3Gy for the rectum.
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Figure B.5. – Vx% (volume receiving at least x% of the planned dose) comparison between planned
(Dp), accumulated (Da) and biological accumulation dose (bEQD) for rectum and bladder.
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[68] T. E. Schultheiss, W. A. Tomé, and C. G. Orton. Point/counterpoint: it is
not appropriate to ”deform” dose along with deformable image registration in
adaptive radiotherapy. Medical Physics, 39(11):6531–6533, 2012. 2, 40, 112,
121
[69] D. P. Shamonin, E. E. Bron, B. Lelieveldt, M. Smits, K. S., and M. Staring.
Fast parallel image registration on cpu and gpu for diagnostic classification of
alzheimer’s disease. Frontiers in Neuroinformatics, 7(50):1–15, 2014. 69
[70] L. E. A. Shelley, J. E. Scaife, M. Romanchikova, K. Harrison, J. R. Forman,
A. M. Bates, D. J. Noble, R. Jena, M. A. Parker, M. P. F. Sutcliffe, S. J.
Thomas, and N. G. Burnet. Delivered dose can be a better predictor of rectal
toxicity than planned. Radiotherapy and Oncology, 123(3):466–471, 2017. 1,
17, 18, 65, 66, 68, 95, 99, 127
[71] J.-J. Sonke, M. Azanr, and C. Rasch. Adaptive radiotherapy for anatomical
changes. Seminars in Radiation Oncology, 29(3):245–257, 2019. 1, 40
[72] S. J. Thomas, M. Romanchikova, K. Harrison, M. A. Parker, A. M. Bates, J. E.
Scaife, M. P. F. Sutcliffe, and N. G. Burnet. Recalculation of dose for each
fraction of treatment on tomotherapy. Br J Radiol, 89:20150770, 2016. 66, 69
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